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   hydrogen	  peroxide	  HCN	   	   hippocampal	  neuron	  hERG	   	   human	  ether-­‐a-­‐go-­‐go-­‐related	  gene	  HIF1α	   	   hypoxia-­‐induced	  factor	  1	  alpha	  HMG-­‐CoA	   3-­‐hydroxy-­‐3-­‐methyl-­‐glutaryl-­‐Coenzyme	  A	  HNF1	   	   hepatocyte	  nuclear	  factor	  1	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HRE	   	   hypoxia-­‐responsive	  element	  HUVEC	   	   human	  umbilical	  vein	  endothelial	  cells	  IAP	   	   inhibitor	  of	  apoptosis	  protein	  IDOL	   	   inducible	  degrader	  of	  the	  LDLR	  IGF-­‐1	   	   insulin-­‐like	  growth	  factor	  1	  IRE1	   	   inositol	  requiring-­‐1	  JNK	   	   c-­‐Jun	  N-­‐terminal	  kinase	  KCl	   	   potassium	  chloride	  LDH	   	   lactate	  dehydrogenase	  LDL	   	   low-­‐density	  lipoprotein	  LDL-­‐C	   	   low-­‐density	  lipoprotein	  cholesterol	  LDLR	   	   low-­‐density	  lipoprotein	  receptor	  LOAD	   	   late-­‐onset	  Alzheimer’s	  disease	  LRP1	   	   low-­‐density	  lipoprotein	  receptor-­‐related	  protein	  1	  LTP	   	   long-­‐term	  potentiation	  LXR	   	   liver	  X-­‐receptor	  MANF	   	   mesencephalic	  astrocyte-­‐derived	  neurotrophic	  factor	  MAPK	   	   mitogen-­‐activated	  protein	  kinase	  miRNA	   	   microRNA	  MMSE	   	   mini-­‐mental	  state	  examination	  MOMP	   	   mitochondrial	  outer	  membrane	  permeabilization	  MPTP	   	   mitochondrial	  permeability	  transition	  pore	  MS	   	   multiple	  sclerosis	  NARC-­‐1	   	   neural	  apoptosis-­‐regulated	  convertase	  1	  (aka	  PCSK9)	  NDD	   	   neurodegenerative	  disease	  NF-­‐κB	   	   nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B-­‐cells	  NGF	   	   nerve	  growth	  factor	  NMDA	   	   N-­‐methyl-­‐D-­‐aspartate	  Nrf2	   	   nuclear	  factor	  erythroid	  2	  (NF-­‐E2)	  related	  factor	  2	  (aka	  Nfe2l2)	  NT	   	   neurotrophin	   	  PARP-­‐1	   	   poly	  (ADP-­‐ribose)	  polymerase-­‐1	  	   	  PCSK9	   	   proprotein	  convertase	  subtilisin/kexin	  type	  9	  (aka	  NARC-­‐1)	  PD	   	   Parkinson’s	  disease	  PiB-­‐PET	  	   Pittsburgh	  Compound	  B	  -­‐	  positron	  emission	  tomography	  PI3K	   	   phosphoinositide	  3-­‐kinase	  PNS	   	   peripheral	  nervous	  system	  PPAR	   	   peroxisome	  proliferator-­‐activated	  receptor	  PSEN	   	   presinilin	  RAP	   	   lipoprotein	  receptor-­‐associated	  protein	  RNAi	   	   RNA	  interference	  ROS	   	   reactive	  oxygen	  species	  SEPP1	   	   selenoprotein	  P	  	  shRNA	   	   short-­‐hairpin	  RNA	  SIRT	   	   sirtuin	  SORL1	   	   sortilin-­‐related	  receptor,	  L(DLR	  class)	  A	  repeats	  containing	  (LR11,	  SorLA)	  SREBP	   	   sterol	  regulatory	  element	  binding	  protein	  T2DM	   	   type	  2	  diabetes	  mellitus	  TBI	   	   traumatic	  brain	  injury	  TDP-­‐43	   	   TAR	  DNA-­‐binding	  protein	  43	  TNFα	   	   tumor	  necrosis	  factor	  α	  TOR	   	   target	  of	  rapamycin	  UPR	   	   unfolded	  protein	  response	  VLDL	   	   very-­‐low-­‐density	  lipoprotein	  VLDLR	   	   very-­‐low-­‐density	  lipoprotein	  receptor	   	  WNT	   	   wingless-­‐type	  MMTV	  integration	  site	  family	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Abstract	  Aging-­‐related	   increase	  of	  neuronal	  stress	  may	  promote	   the	  development	  of	  sporadic	   late-­‐onset	  Alzheimer’s	  disease	   (LOAD)	  and	  other	   forms	  of	  dementia.	  Unlike	   in	   the	  minority	  of	  early-­‐onset	   Alzheimer’s	   disease	   (EOAD)	   cases	   that	   are	   primarily	   caused	   by	   rare	   genetic	  mutations,	  the	  most	  significant	  risk	  factors	  for	  LOAD	  are	  age,	  lifestyle	  factors	  and	  relatively	  common	  genetic	   risk	   variants.	   The	  primary	   risk	   gene	   variant	   for	   LOAD	   is	   the	   ε4	   allele	   of	  apolipoprotein	  E	  (ApoE),	  which	  is	  present	  in	  45%	  of	  LOAD	  patients	  and	  is	  known	  to	  affect	  cholesterol	   homeostasis,	   brain	   amyloid	   clearance	   and	   neuronal	   viability.	   Similarly,	  metabolic	   disorders,	   such	   as	   hypercholesterolemia	   and	   type	   2	   diabetes	  mellitus	   (T2DM),	  increase	  LOAD	  risk	  through	  similar	  pathways.	  	  	  Multifunctional	   lipoprotein	  receptors	  regulate	  brain	  development	  and	  neuronal	  plasticity;	  modulate	  cholesterol	  and	  metabolic	  homeostasis;	  and	  are	  implicated	  in	  LOAD	  pathogenesis.	  Interestingly,	   early	   LOAD	   pathology	   is	   characterized	   by	   alterations	   in	   brain	   lipoprotein	  receptor	   expression	   and	  neuronal	   hypometabolism.	   Lipoprotein	   receptors	   apolipoprotein	  receptor	   2	   (ApoER2)	   and	   very-­‐low	   density	   lipoprotein	   receptor	   (VLDLR)	   bind	   ApoE	   and	  mediate	  Reelin	  signaling	   in	  the	  brain,	  but	  also	   interact	  with	  proteins	  centrally	   involved	   in	  LOAD	  pathogenesis,	  such	  as	  amyloid	  precursor	  protein,	  Tau	  and	  clusterin/apolipoprotein	  J.	  The	   secreted	   protease	   proprotein	   convertase	   subtilisin/kexin	   type	   9	   (PCSK9)	   and	   the	  nutraceutical	   berberine	   modulate	   lipoprotein	   receptor	   levels	   in	   vivo.	   During	   the	   past	  decade,	  PCSK9	  inhibitors	  and	  berberine	  have	  surfaced	  as	  promising	  treatment	  options	  for	  hypercholesterolemia	   and	   T2DM,	   respectively.	   Additionally,	   PCSK9	   and	   berberine	   are	  implicated	   in	   pathways	   modulating	   neuronal	   viability,	   suggesting	   that	   they	   may	   hold	  therapeutic	   potential	   against	   neurodegenerative	   diseases.	   However,	   the	   effects	   of	   PCSK9	  and	   berberine	   on	   neuronal	   cell	   death	   and	   lipoprotein	   receptors	   are	   currently	   poorly	  understood.	  	  	  The	  objective	  of	  this	  study	  was	  to	  elucidate	  the	  role	  of	  PCSK9	  and	  berberine	  as	  modulators	  of	   lipoprotein	   receptors	   and	   cell	   death	   in	   neurons.	   The	   effects	   of	   PCSK9	   downregulation	  and	   berberine	   application	   on	   neuronal	   viability	  were	   studied	   in	  murine	   and	   rat	   primary	  neuron	   cultures	   in	   combination	   with	   lentiviral	   RNA	   interference,	   kinase	   inhibitors	   and	  various	   inducers	   of	   cellular	   stress	   and	   cell	   death.	   Cell	   viabilities	   were	   assessed	   by	  immunofluorescence,	  Western	  blotting,	  and	  cell	  toxicity	  and	  mitochondrial	  assays.	  	  The	  main	  conclusions	  of	  this	  study	  are:	  (1)	  reducing	  endogenous	  PCSK9	  levels	  genetically	  by	  lentiviral-­‐mediated	  RNA	  interference	  protects	  neurons	  against	  apoptotic	  cell	  death	  in	  an	  ApoER2-­‐dependent	   fashion.	   (2)	   A	   potential	   PCSK9	   inhibitor	   and	   a	   widely	   used	  nutraceutical	  berberine	  causes	  mitochondria-­‐	  and	  NMDA	  receptor-­‐dependent	  neuronal	  cell	  death	  at	  micromolar	  concentrations.	   (3)	  At	  subtoxic	  nanomolar	  concentrations,	  berberine	  sensitizes	   neurons	   to	   rotenone	   and	   glutamate	   toxicity	   calling	   for	   caution	   in	   berberine	  dosing	  and	  ubiquitous	  use.	  (4)	  Lipoprotein	  receptors	  and	  PCSK9	  are	  differentially	  regulated	  under	  neuronal	   stress.	  Neuronal	  VLDLR	  expression	   is	   increased	  by	   subtoxic	   stress,	  while	  berberine	  induced	  a	  biphasic	  effect	  on	  the	  stabilization	  of	  the	  transcription	  factors	  hypoxia-­‐inducible	   factor	   1α	   and	   β-­‐catenin.	   To	   conclude,	   ApoER2,	   VLDLR	   and	   their	   modulators	  PCSK9	   and	   berberine	   contribute	   to	   the	   regulation	   of	   neuronal	   cell	   death	   via	   multiple	  mechanisms,	  suggesting	  a	  potential	  role	   in	  neurodegenerative	  disease	  pathogenesis	  at	  the	  interface	  of	  metabolism	  and	  survival	  signaling.	  
	   1	  
1	  Introduction	  Alzheimer’s	   disease	   (AD)	   is	   the	   most	   common	   neurodegenerative	   disease	   (NDD)	   and	   is	  responsible	   for	   two	   thirds	   of	   age-­‐related	   dementia	   cases.	   Late-­‐onset	   AD	   (LOAD)	   is	  distinguishable	   from	   normal	   aging	   by	   distinct	   pathological	   hallmarks	   and	   accelerated	  cognitive	   decline.	   The	   earliest	   pathological	   changes	   in	   LOAD	   may	   be	   detected	   by	   brain	  imaging	  over	  a	  decade	  before	  the	  onset	  of	  first	  clinical	  symptoms;	  however,	  diagnostic	  and	  treatment	  options	  are	  currently	  limited.	  	  The	   estimated	   socio-­‐economical	   burden	   of	   AD	   is	   expected	   to	   double	   by	   2050	   due	   to	  demographic	  aging	  worldwide.	  The	  total	  annual	  societal	  costs	  of	  AD	  are	  expected	  to	  exceed	  250	  billion	  €	  by	  2030	  in	  Europe	  alone	  (Pouryamout	  et	  al.,	  2012).	  Less	  than	  5%	  of	  AD	  cases	  are	   caused	  by	   genetic	  mutations	   in	   the	   amyloid	  precursor	  protein	   (APP)	   and	  presinilin	  1	  and	   2	   (PSEN1/2)	   genes	   that	   result	   in	   an	   early-­‐onset	   form	   of	   AD	   (EOAD)	  with	   symptoms	  arising	  before	  the	  65th	  year	  of	  life.	  In	  contrast,	  LOAD	  represents	  over	  95%	  of	  AD	  cases,	  with	  age	   as	   the	  greatest	   risk	   factor	   (Chouraki	   and	  Seshadri,	   2014).	  The	   risk	   for	  LOAD	  doubles	  every	   5	   years	   after	   the	   age	   of	   65,	   reaching	   roughly	   40%	   by	   the	   age	   of	   80.	   However,	   the	  combined	  influence	  of	  lifestyle	  and	  genetic	  factors	  has	  a	  significant	  effect	  on	  LOAD	  risk	  and	  remains	  the	  focus	  of	  intense	  research	  globally.	  On	  the	  epidemiologic	  level,	  lifestyle	  choices,	  especially	  nutrition,	  exercise,	  and	  social	  activity	  are	  significant	  determinants	  of	   individual	  LOAD	   risk	   (Kivipelto	   et	   al.,	   2013).	   Also,	   the	   major	   metabolic	   diseases	   including	   type-­‐2	  diabetes	  mellitus,	   hypercholesterolemia,	   cardiovascular	   disease	   and	   stroke	   are	   known	   to	  increase	   LOAD	   risk	   on	   the	   population	   level	   (Solomon	   et	   al.,	   2014).	   As	   of	   today,	   only	  symptomatic	   treatment	   options	   are	   available	   for	   AD,	   but	   epidemiological	   and	   preclinical	  evidence	   support	   the	   idea	   that	   lifestyle	   interventions	   are	   a	   viable	   preventive	   strategy	  against	  cognitive	  decline	  and	  dementia	  (Ngandu	  et	  al.,	  2015).	  	  	  Differently	   from	   EOAD,	   where	   rare	   causative	   mutations	   in	   APP	   and	   PSEN1/2	   genes	  facilitate	  the	  disease	  process,	  numerous	  more	  common	  genetic	  variants	  are	  associated	  with	  LOAD	  risk.	  The	  ε4	  allele	  of	  apolipoprotein	  E	  (ApoE)	  is	  the	  greatest	  genetic	  risk	  variant	  for	  LOAD	  with	  45%	  of	  patients	  carrying	  the	  ε4	  risk	  allele	  (Chouraki	  and	  Seshadri,	  2014).	  ApoE	  is	   a	   protein	   component	   of	   high-­‐density	   lipoprotein	   (HDL)	   cholesterol	   and	   has	   important	  physiological	   functions	   as	   a	   cholesterol	   and	   lipid-­‐binding	   protein	   essential	   for	   neuronal	  cholesterol	  transport	  and	  signaling	  in	  the	  central	  nervous	  system	  (CNS)	  (Lane-­‐Donovan	  et	  al.,	  2014).	  ApoE4	  is	  shown	  to	  exhibit	  both	  loss-­‐of-­‐function	  and	  gain-­‐of-­‐function	  properties	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to	  increase	  AD	  risk	  (Kim	  et	  al.,	  2009a).	  In	  the	  brain,	  ApoE,	  along	  with	  Reelin,	  binds	  to	  and	  signals	  through	  lipoprotein	  receptors	  apolipoprotein	  E	  receptor	  2	  (ApoER2)	  and	  very-­‐low-­‐density	   lipoprotein	   receptor	   (VLDLR)	   to	   modulate	   neuronal	   plasticity	   and	   excitability,	  which	   are	   implicated	   in	   long-­‐term	   potentiation	   (LTP)	   at	   neuronal	   synapses,	   a	   crucial	  process	   facilitating	   memory	   formation	   (Valastro	   et	   al.,	   2001).	   Reelin	   is	   a	   large	   secreted	  extracellular	   matrix	   glycoprotein	   that	   signals	   through	   ApoER2	   and	   VLDLR	   to	   facilitate	  neuronal	  migration	  during	  development	  and	  promote	  neuronal	  viability	  in	  the	  adult	  brain	  (Trommsdorff	   et	   al.,	   1999;	  Hiesberger	  et	   al.,	   1999).	  Alterations	   in	   the	   levels	  of	   the	  Reelin	  signaling	   pathway	   components,	   including	   ApoER2,	   VLDLR	   and	   Dab1,	   are	   an	   early	  phenomenon	  in	  LOAD	  pathogenesis	  (Herring	  et	  al.,	  2012).	  Additionally,	  several	  lipoprotein-­‐related	   genes,	   such	   as	   clusterin	   and	   ATP-­‐binding	   cassette	   transporter	   7	   (ABCA7),	   have	  recently	  been	   identified	   as	  AD	   risk	   genes,	   indicating	   the	   importance	  of	   lipids,	   lipoprotein	  metabolism	  and	  lipoprotein	  receptors	  in	  LOAD	  (Chouraki	  and	  Seshadri,	  2014).	  	  Although	   our	   understanding	   of	   ApoE	   and	   lipoprotein	   receptor	   function	   has	   significantly	  been	  advanced	  in	  the	  last	  two	  decades,	  several	  aspects	  of	  lipoprotein	  receptor	  modulation	  and	  their	  role	  in	  neuronal	  viability	  remain	  incompletely	  understood.	  Recently,	  research	  on	  the	   endogenous	   downregulator	   of	   lipoprotein	   receptors	   proprotein	   convertase	  subtilisin/kexin	  type	  9	  (PCSK9)	  and	  the	  multifunctional	  nutraceutical	  berberine	  has	  fueled	  an	   interest	   in	   providing	   multi-­‐target	   approaches	   against	   LOAD-­‐associated	   risk	   diseases	  such	  as	  hypercholesterolemia	  and	  type	  2	  diabetes	  mellitus	  (Durairajan	  et	  al.,	  2012;	  Chen	  et	  al.,	   2014d).	   Interestingly,	   both	   PCSK9	   and	   berberine	   are	   also	   implicated	   in	   pathways	  associated	   with	   neuronal	   viability	   (Bae	   et	   al.,	   2013;	   Schulz	   et	   al.,	   2015).	   In	   the	   present	  study,	   downregulation	   of	   PCSK9	   via	   RNA	   interference	   (RNAi)	   and	   berberine	   application	  were	   used	   to	   elucidate	   their	   effects	   on	   lipoprotein	   receptors	   and	   neuronal	   cell	   death	   in	  primary	  neuron	  cultures.	  This	  Thesis	  provides	  an	  overview	  of	  the	  connections	  linking	  risk	  factors	  with	  pathogenesis	  of	  LOAD,	  and	  presents	  novel	  data	  on	   the	  effects	  of	  endogenous	  PCSK9	   downregulation	   and	   berberine	   application	   on	   neuronal	   cell	   death	   and	   the	  transcriptional	  and	  protein	  expression	  of	  lipoprotein	  receptors.	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2	  Review	  of	  the	  Literature	  
2.1	  Brain	  health	  The	   brain	   is	   the	  most	   complex	   organ	   of	   the	   human	   body.	   By	   some	   estimation,	   there	   are	  roughly	   100	   billion	   neurons	   in	   the	   brain,	   which	   receive	   an	   average	   of	   10,000	   neuronal	  contacts,	  or	  synapses,	  per	  cell,	  equaling	  1000	  trillion	  synaptic	  connections.	  To	  further	  add	  to	   the	   complexity,	   neuronal	   synapses	   remain	   in	   a	   constant	   state	   of	   flux	   and	   are	  continuously	   shaped	   by	   our	   individual	   development	   and	   experiences.	   Additionally,	   glial	  cells	  in	  the	  brain	  outnumber	  neurons	  10-­‐to-­‐1,	  and	  participate	  in	  supporting	  and	  modulating	  neuronal	   function.	  Neurons	  and	   their	  orchestrated	  networks	   are	   responsible	   for	   virtually	  all	  bodily	  tasks,	  from	  simple	  motor	  movements	  to	  complex	  cognitive	  tasks	  such	  as	  memory	  formation.	   As	   neurons	   have	   limited	   regenerative	   abilities,	   head	   trauma	   and	  neurodegenerative	   diseases	   (NDDs)	   affecting	   the	   central	   nervous	   system	   (CNS)	   and	  peripheral	  nervous	  system	  (PNS)	  have	  often	  serious	  and	  debilitating	  effects	  on	  life	  quality	  and	  overall	  health.	  Aging	  demographics	  worldwide	  pose	  serious	  concerns	  on	  the	  effects	  of	  increasing	  age-­‐related	  NDDs	  on	  the	  general	  quality	  of	  life	  and	  societal	  costs	  in	  the	  upcoming	  decades.	  	  The	   continued	   development	   of	   treatments	   against	   major	   life-­‐threatening	   diseases	   of	   the	  young	   and	   middle-­‐aged	   has	   successfully	   raised	   life	   expectancies	   worldwide.	   The	   life	  expectancy	  in	  Finland	  is	  currently	  83.8	  years	  for	  women	  and	  77.6	  years	  for	  men.	  In	  Finland,	  coronary	  heart	  disease	  (CHD),	  Alzheimer’s	  disease	  (AD),	  stroke	  and	  cancer	  are	  among	  the	  top	   causes	   of	   death	   (Westman	   et	   al.,	   2014);	   a	   statistic	   shared	   by	   many	   other	   Western	  countries.	   Age,	   lifestyle	   and	   genetic	   factors	   are	   common	   risk	   factors	   for	   all	   of	   the	  aforementioned	  diseases	  (Staimez	  et	  al.,	  2014;	  Kotze	  and	  van	  Rensburg,	  2012).	  	  Many	  consider	  the	  decline	  of	  cognitive	  function	  and	  the	  loss	  of	  independence	  in	  the	  form	  of	  dementia	  as	  one	  of	  the	  most	  feared	  aspects	  of	  aging.	  Although	  almost	  half	  of	  over	  85	  year-­‐olds	   suffer	   from	   AD-­‐related	   dementia,	   many	   elderly	   still	   remain	   with	   intact	   cognitive	  function.	  Why	  do	   some	   experience	   cognitive	   decline	   soon	   after	  midlife,	  while	   others	   stay	  mentally	  sharp	  through	  a	  century	  of	  life?	  This	  crucial	  question	  requires	  the	  understanding	  of	   aging	  mechanisms,	   and	   the	   effects	   of	   genetic,	   environmental	   and	   lifestyle	   factors	   that	  contribute	  to	  the	  individual	  resistance	  against	  cognitive	  decline.	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2.1.1	  Features	  and	  mechanisms	  of	  brain	  aging	  Neurons	  are	  some	  of	  the	  most	   long-­‐lived	  cells	  of	   the	  body.	  The	  brain,	   like	  other	  organs	  of	  the	  body,	  undergoes	  significant	  changes	  at	  the	  cellular	  and	  macroscopic	  levels	  during	  aging.	  A	  common	  feature	  of	  aging	  is	  vascular	  changes	  caused	  by	  the	  hardening	  of	  the	  arterial	  walls	  and	   the	   formation	   of	   atherosclerotic	   plaques,	   which	   result	   in	   decreased	   arterial	  circumference,	  reduced	  arterial	  wall	  elasticity	  and	  reduced	  blood	  flow.	  Reduced	  blood	  flow	  can	  promote	  the	  accumulation	  of	  waste	  products,	  and	  also	  reduce	  the	  oxygen	  and	  nutrient	  supply	  to	  tissues.	  Deprived	  nutrient	   intake	  and	  deficient	  waste	  clearance	  mechanisms	  can	  make	   neurons	   susceptible	   to	   hypometabolism	   and	   aggregation	   of	   misfolded	   and	  dysfunctional	   proteins	   (Dastur,	   1985;	   Yamamoto	   et	   al.,	   1980).	   Cells	   respond	   to	   the	  accumulation	   of	   misfolded	   proteins	   and	   protein	   aggregates	   by	   the	   activation	   of	   the	  unfolded	   protein	   response	   (UPR)	   that	   promotes	   cellular	   protein	   clearance	   and	   the	  expression	   of	   protein	   folding	   chaperones	   (Paz	   Gavilan	   et	   al.,	   2006).	   When	   the	   UPR	   is	  insufficient	  to	  halt	  protein	  aggregation,	  it	  may	  lead	  into	  the	  formation	  of	  protein	  aggregates	  and	  eventually,	  cell	  death.	  Accumulated	  protein	  aggregates	  and	  hypometabolism	  may	  also	  disturb	  other	  essential	  cellular	  functions	  including	  mitochondrial	  function	  and	  intracellular	  organelle	  transport,	  further	  promoting	  cell	  dysfunction	  (Shastry,	  2003).	  	  Cellular	   processes	   are	   largely	   dependent	   on	   the	   energy	   produced	   by	   mitochondrial	  respiration.	  Energy	  production	  in	  mitochondria	  yields	  reactive	  oxygen	  species	  (ROS),	  such	  as	   hydrogen	   peroxide	   (H2O2),	   which	   can	   damage	   the	   integrity	   of	   all	   cellular	   components	  including	  DNA,	  RNA,	  proteins,	  organelles	  and	  lipids	  by	  oxidation.	  Functional	  mitochondria	  normally	  produce	   low	   levels	  of	  ROS,	  which	  are	  counteracted	  by	  endogenous	  antioxidants,	  such	   as	   glutathione,	   which	   renders	   them	   harmless.	   During	   aging,	   disturbances	   in	  mitochondrial	   respiration	   can	   upset	   the	   relative	   balance	   between	   the	   production	   of	   ROS	  and	  antioxidants,	   and	  neurons	   can	  accumulate	  an	   increasing	  amount	  of	  ROS	  damage	  also	  known	  as	  oxidative	  stress	  (Melov,	  2000;	  Melov	  et	  al.,	  1998).	  Additionally,	  mitochondria	  are	  responsible	   for	   sequestering	   excess	   calcium	   (Ca2+),	   a	   function	   that	   may	   be	   disturbed	   by	  oxidative	  stress	  and	  increase	  susceptibility	  to	  cell	  death	  (Nicholls,	  2008).	  	  Increased	   cellular	   damage	   can	   activate	   cell	   death	   pathways	   and	   cause	   neuronal	   loss	   and	  defects	  in	  brain	  networks.	  Decreased	  neuronal	  connectivity	  also	  decreases	  the	  levels	  of	  pro-­‐survival	   target-­‐derived	  neurotrophic	   factors	   that	  support	  neuronal	   longevity	  and	  function	  (Acheson	   et	   al.,	   1995;	   Allendoerfer	   et	   al.,	   1994).	   As	   a	   result	   of	   neuronal	   and	   axonal	  degeneration,	  one	  notable	  macroscopic	  change	   is	  brain	  atrophy,	  or	  shrinking	  of	   the	  brain,	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especially	  in	  the	  areas	  of	  the	  prefrontal	  cortex	  and	  hippocampus.	  These	  areas	  are	  crucial	  for	  complex	   cognitive	   tasks	   such	   as	   memory,	   learning	   and	   planning.	   During	   aging,	   myelin	  content	   is	   also	   reduced	   within	   the	   brain.	   Oligodendrocytes,	   a	   type	   of	   glial	   cell,	   form	  cholesterol-­‐rich	   myelin	   sheaths	   around	   neuronal	   axons	   to	   promote	   efficient	   chemical	  neurotransmission	   by	   insulating	   the	   axonal	   plasma	   membrane	   from	   the	   extracellular	  milieu.	  The	  loss	  of	  neuronal	  cell	  bodies	  (grey	  matter)	  and	  myelin-­‐rich	  axonal	  tracks	  (white	  matter)	  both	  contribute	  to	  brain	  atrophy	  (Du	  et	  al.,	  2006;	  de	  Toledo-­‐Morrell	  et	  al.,	  2000).	  	  Another	   salient	   feature	   of	   aging	   is	   increased	   levels	   of	   inflammation.	   Microglial	   cells,	   the	  brain-­‐resident	  macrophages	  and	  components	  of	  the	  active	  immune	  system,	  protect	  the	  CNS	  from	   pathogens	   and	   clear	   protein	   aggregates	   and	   cell	   debris.	   Microglia	   also	   respond	   to	  stress	  markers	   secreted	   by	   neurons.	   Prolonged	   activation	   of	   the	   brain’s	   immune	   system	  may	   lead	   to	   chronic	   inflammation	   and	   hyperactivation	   of	   microglial	   cells.	   Hyperactive	  microglial	  cells	  may	  also	  target	  healthy	  tissue	  and	  release	  pro-­‐inflammatory	  cytokines	  and	  chemokines	   to	   further	   potentiate	   cellular	   damage	   and	   cause	   cell	   death,	   thus	   creating	   a	  malicious	  cycle	  (McGeer	  and	  McGeer,	  2004;	  Akiyama	  et	  al.,	  2000;	  Wenk	  et	  al.,	  2000).	  	  Taken	   together,	   aging-­‐related	   stress	   brings	   numerous	   challenges	   to	   neuronal	   physiology	  and	   function.	   Having	   to	   uphold	   their	   function	   for	   decades,	   neurons	   are	   nurtured	   and	  supported	   by	   glial	   cells,	   but	   they	   also	   possess	   intrinsic	   pathways	   to	   prevent	   untimely	  degeneration.	  Aging,	  in	  general,	  is	  a	  highly	  conserved	  process	  across	  organisms	  from	  simple	  worms,	   such	   as	  C.	   elegans,	   to	   humans,	   allowing	   the	  molecular	   dissection	   of	   aging-­‐related	  genes	  and	  processes	  in	  model	  organisms	  to	  be	  correlated	  with	  aging	  processes	  in	  humans	  (Kenyon,	   2010).	   In	   the	   most	   extreme	   human	   cases,	   mutations	   in	   prelaminin	   A	   cause	  progeria	   disease	   that	   is	   characterized	   by	   accelerated	   aging	   leading	   to	   death	   during	   the	  teenage	   years	   (Ghosh	   and	   Zhou,	   2014).	   The	   cells	   from	   progeria	   patients	   display	   severe	  mitochondrial	   dysfunction	   and	   DNA	   alterations,	   including	   chromatin	   remodelling	   and	  epigenetic	   changes	   (Ghosh	   and	   Zhou,	   2014).	   These	   cases	   have	   provided	   a	   unique	  perspective	   on	   the	   aging	   processes	   (Lopez-­‐Mejia	   et	   al.,	   2011).	   Additionally,	   recent	  developments	   in	   genetics	   and	   brain	   imaging	   techniques	   have	   revealed	   several	  evolutionarily	  conserved	  master	  regulators	  and	  processes	  that	  affect	  the	  rate	  of	  brain	  and	  organism-­‐level	   aging.	   These	   studies	   implicate	   1)	   mitochondrial	   function	   and	   oxidative	  stress,	  2)	   insulin/insulin-­‐like	  growth	   factor-­‐1	   (IGF-­‐1)	   signaling,	  3)	   autophagy	  and	  protein	  turnover,	   4)	   target	   of	   rapamycin	   (TOR)	   signaling	   and	   5)	   sirtuin	   function	   as	   central,	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interconnected	   pathways	   that	   determine	   neuronal	   longevity	   and	   organism-­‐level	   lifespan	  (summarized	  in	  Figure	  2.1)	  (Bishop	  et	  al.,	  2010;	  Gkikas	  et	  al.,	  2014;	  Stern,	  2012).	  
2.1.1.1	  Mitochondria	  Efficient	   mitochondrial	   function	   is	   crucial	   for	   healthy	   aging.	   Neurons	   are	   particularly	  sensitive	   to	   metabolic	   disturbances	   and	   mitochondrial	   dysfunction	   due	   to	   their	   large	  energetic	   needs	   (Nicholls,	   2008).	   Mitochondria	   transform	   nutrients	   into	   cellular	   energy,	  mainly	   adenosine	   triphosphate	   (ATP),	   through	   the	   glycolysis	   and	   oxidative	  phosphorylation	   of	   glucose	   through	   the	   mitochondrial	   complexes	   I-­‐V	   on	   the	   inner	  mitochondrial	   membrane.	   Small	   defects	   in	   mitochondrial	   function	   are	   associated	   with	  normal	   aging,	   but	   severe	   dysfunctions	   are	   characteristic	   of	   many	   NDDs,	   such	   as	   AD,	  amylotrophic	   lateral	   sclerosis	   (ALS)	   and	   Parkinson’s	   disease	   (PD)	   (Sullivan	   and	   Brown,	  2005;	   Melov,	   2000).	   Defects	   in	   the	   superoxide	   dismutase	   1	   (SOD1),	   an	   important	  antioxidant,	   and	   application	   of	   robust	   complex	   I	   inhibitors	   such	   as	   rotenone	   or	   paraquat	  can	  recapitulate	  the	  symptoms	  of	  ALS	  and	  PD	  in	  animals	  models,	  respectively	  (Rosen	  et	  al.,	  1993;	  Jackson-­‐Lewis	  et	  al.,	  2012).	  	  	  Mitochondria	  are	  also	  a	  master	  controller	  of	  cell	  death.	  Mitochondrial	  dysfunction	  and	  the	  loss	   of	  mitochondrial	   outer	  membrane	   integrity	   can	   release	   ROS	   and	   cell	   death-­‐inducing	  factors	   into	  the	  cytosol	  causing	  cellular	  damage	  and	  triggering	  cell	  death	  pathways	  (Budd	  and	   Nicholls,	   1996;	   Duchen,	   2004).	   However,	   low	   amounts	   of	   stress	   or	   mitochondrial	  complex	   inhibition	   can	   also	   activate	   stress	   resistance	   pathways	   and	   transcription	   factors	  such	  as	  Forkhead	  box	  protein	  (FOXO),	  which	  transcriptionally	  upregulate	  the	  production	  of	  ROS-­‐scavenging	  antioxidants	  and	  cell	  protective	  genes,	  such	  as	  brain-­‐derived	  neurotrophic	  factor	  (BDNF)	  (Rothman	  and	  Mattson,	  2013;	  Kumar	  et	  al.,	  2014).	  In	  neurons,	  this	  concept	  of	  pre-­‐conditioning	  can,	   in	  certain	  conditions,	   improve	  outcome	  against	  acute	  stress	  such	  as	  oxygen	   deprivation,	   or	   hypoxia,	   by	   upregulating	  mitochondrial	   biogenesis	   and	   protective	  gene	  responses.	  However,	  if	  the	  mitochondrial	  and	  cellular	  stress	  is	  prolonged	  or	  becomes	  more	   severe,	   countermeasures	   may	   not	   be	   sufficient	   to	   protect	   the	   cell	   and	   the	  accumulation	  of	  cellular	  damage	  may	  result	  in	  cell	  death	  (Tauskela	  et	  al.,	  2003;	  Kalogeris	  et	  al.,	  2014).	  	  
2.1.1.2	  Insulin/IGF-­‐1	  signaling	  Blood	  sugar	  levels	  are	  maintained	  relatively	  constant	  by	  insulin.	  The	  pancreatic	  β-­‐islet	  cells	  secrete	   insulin	   to	   increase	   glucose	   receptors	   on	   the	   cell	   surface	   and	   facilitate	   cellular	  glucose	  uptake	  to	  lower	  the	  levels	  of	  circulating	  blood	  glucose.	  Additionally,	  insulin	  affects	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cellular	   metabolism	   through	   modulation	   of	   numerous	   kinases	   and	   enzymes,	   decreasing	  catabolic	   pathways	   and	   promoting	   energy	   storage	   (Kleinridders	   et	   al.,	   2014).	   IGF-­‐1	   is	  similar	   in	   structure	   to	   insulin	  and	   is	  mainly	   secreted	  by	   the	   liver	   to	  promote	  growth	  and	  anabolic,	   synthesizing	   pathways.	   The	   loss	   of	   pancreatic	   β-­‐islet	   cells	   and	   insulin	  desensitization	   contribute	   to	   the	   development	   of	   both	   juvenile,	   type	   1,	   and	   adult,	   type	   2,	  diabetes	  mellitus	  (T2DM).	  In	  addition	  to	  being	  a	  risk	  factor	  for	  AD,	  neurological	  disorders	  are	  also	  associated	  with	  diabetes,	  as	  roughly	  10-­‐15%	  of	  diabetics	  also	  develop	  neuropathy,	  which	  primarily	  manifests	  in	  the	  sensory,	  sympathetic	  and	  motor	  neurons	  of	  the	  PNS	  (Ishii,	  1995).	  	  	  Interestingly,	  insulin/IGF-­‐1	  signaling	  has	  a	  dual	  role	  in	  regulating	  neuronal	  viability.	  In	  the	  CNS,	  low	  levels	  of	  insulin	  and	  IGF-­‐1	  are	  neuroprotective	  and	  promote	  memory	  and	  learning	  in	  mammals.	  In	  humans,	  specific	  polymorphisms	  of	  the	  IGF-­‐1	  receptor	  and	  its	  downstream	  FOXO3	   transcription	   factor	   variant	   are	   enriched	   in	   centenarians,	   humans	   reaching	   100	  years	   of	   age	   (Anselmi	   et	   al.,	   2009;	   Flachsbart	   et	   al.,	   2009;	  Willcox	   et	   al.,	   2008;	   Suh	   et	   al.,	  2008).	   These	   polymorphisms	   are	   shown	   to	   decrease	   the	   risk	   of	   cardiovascular	   disease	  (CVD)	   and	   T2DM,	   and	   increase	   longevity.	   Interestingly,	   IGF-­‐1	   pathway	   components	   are	  downregulated	  in	  AD	  patients,	  suggesting	  a	  compensatory	  mechanism	  or	  that	  brain	  insulin	  signaling	  deficiency	  is	  contributing	  to	  neuronal	  hypometabolism	  (Yang	  et	  al.,	  2005;	  Rivera	  et	   al.,	   2005).	   The	   latter	   view	   is	   supported	   by	   the	   efficacy	   of	   intranasal	   insulin	   therapy	   in	  enhancing	  cognition	  in	  patients	  with	  cognitive	  impairment	  (Freiherr	  et	  al.,	  2013).	  	  However,	   a	   reduction	   in	   the	   insulin/IGF-­‐1	   signaling	   pathway	   activity	   increases	   stress	  resistance	  and	   lifespan	   in	  worms	  (C.	  elegans)	  and	   fruit	   flies	   (Drosophila)	   (Lin	  et	  al.,	  2001;	  Broughton	  et	  al.,	  2005).	  Similarly,	  genetic	  knockout	  of	   the	  IGF-­‐1	  receptor	   in	  an	  AD	  mouse	  model	   protects	   against	   β-­‐amyloid	   (Aβ)	   toxicity	   and	   cognitive	   impairment,	   and	   extends	  lifespan	   (Freude	   et	   al.,	   2009).	  Mechanistically,	   insulin/IGF-­‐1	   signaling	   pathway	   reduction	  improves	   the	   clearance	   of	   damaged	   proteins	   and	   boosts	   neuroprotective	   and	  neuroregenerative	  kinase	  pathways	   (Willcox	  et	   al.,	   2008;	  Suh	  et	   al.,	   2008).	  Hence,	   insulin	  and	   IGF-­‐1	   are	   important	   regulators	   of	   neuronal	   longevity	   and	   determinants	   of	  neuroprotective	  pathways.	  
2.1.1.3	  Autophagy,	  TOR	  signaling	  and	  protein	  homeostasis	  Studies	   in	   yeast	   and	   mammals	   have	   shown	   that	   efficient	   protein	   and	   cellular	   organelle	  turnover	  and	  quality	  control	  promote	  longevity	  (Labunskyy	  et	  al.,	  2014).	  Protein	  misfolding	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and	   accumulation	   in	   the	   endoplasmic	   reticulum	   (ER)	   initiates	   UPR	   to	   promote	   the	  expression	   of	   chaperones	   and	   components	   of	   the	   ER-­‐associated	   degradation	   complex.	  Whereas	  chaperones	  assist	  in	  protein	  folding,	  ER-­‐associated	  degradation	  clears	  misfolded,	  aggregated	   or	   damaged	   proteins,	   a	   process	   that	   is	   reduced	   during	   aging	   (Naidoo	   et	   al.,	  2008;	  Paz	  Gavilan	   et	   al.,	   2006).	  Additionally,	   damaged	   cell	   organelles	   are	  dismantled	   and	  recycled	  by	   lysosomes,	  proteasomes	  and	  autophagy.	  The	  expression	  of	  autophagy-­‐related	  genes	   (ATG)	   is	   decreased	   during	   aging,	   making	   neurons	   more	   susceptible	   to	   protein	  aggregation	  and	  neurodegeneration	  (Komatsu	  et	  al.,	  2006a;	  Komatsu	  et	  al.,	  2006b).	  	  	  	  In	   Drosophila	   and	   mice,	   boosting	   autophagy	   and	   protein	   turnover	   by	   caloric	   restriction	  decreased	  insulin/IGF-­‐1	  signaling	  and	  the	  overexpression	  of	  ATG	  genes	  extends	  organism-­‐level	   lifespan	   (Simonsen	   et	   al.,	   2008;	   Hara	   et	   al.,	   2006).	   In	   contrast	   to	   autophagy,	   TOR	  kinase	   pathway	   regulates	   protein	   homeostasis	   by	   inhibiting	   autophagy	   and	   increasing	  protein	   production	   through	   enhanced	   translation	   (Harrison	   et	   al.,	   2009;	   Bonawitz	   et	   al.,	  2007).	  Blocking	  TOR	  pathway	  with	  rapamycin	  increases	  lifespan	  and	  reduces	  the	  formation	  of	   toxic	  protein	  aggregates	   through	   increased	  autophagy	   in	  organisms	  ranging	   from	  yeast	  to	  mice	  (Harrison	  et	  al.,	  2009;	  Bonawitz	  et	  al.,	  2007).	  The	  accumulation	  of	  distinct	  protein	  aggregates	   is	   also	   a	   defining	   hallmark	   of	  many	  NDDs,	   such	   as	   AD,	   ALS,	   PD,	   Huntington’s	  disease	   and	   frontotemporal	   dementia	   (FTD).	   The	   prevalence	   of	   protein	   aggregates	   in	  neurons	   is	   significantly	   higher	   in	   comparison	   to	   other	   tissues,	   which	  may	   reflect	   on	   the	  exceptional	   longevity	   of	   neurons	   and,	   on	   the	   other	   hand,	   a	   potential	   bottleneck	   for	  increasing	  both	  neuronal	  longevity	  and	  human	  lifespan.	  
2.1.1.4	  Caloric	  restriction	  and	  sirtuins	  Caloric	  restriction	  increases	  lifespan	  in	  a	  wide	  range	  of	  organisms	  (Mair	  and	  Dillin,	  2008).	  Caloric	  restriction	  is	  defined	  as	  a	  reduction	  in	  calorie	  intake	  by	  roughly	  one	  third,	  without	  subjecting	  the	  study	  subject	  to	  malnutrition	  (Witte	  et	  al.,	  2009).	  Caloric	  restriction	  protects	  against	  age	  and	  disease-­‐related	  brain	  pathology	  and	  cognitive	  decline	  in	  mice	  (Halagappa	  et	  al.,	   2007).	   On	   the	   cellular	   level,	   caloric	   restriction	   improves	   mitochondrial	   function,	  upregulates	  autophagy,	  decreases	  protein	  translation	  and	  increases	  protein	  turnover,	  thus	  activating	   several	   cell	   protective	   pathways	   and	   increasing	   lifespan	   (Bishop	   et	   al.,	   2010).	  These	   effects	   have	   been	   linked	   to	   the	   function	   of	   nicotinamide	   adenine	   dinucleotide	  (NAD+)-­‐dependent	   deacetylases	   called	   sirtuins	   (SIRT)	   and	   adenosine	   monophosphate	  (AMP)	   kinase	   (AMPK)	   (Martin-­‐Montalvo	   and	   de	   Cabo,	   2013;	   Cohen	   et	   al.,	   2004).	   Both	  sirtuins	  and	  AMPK	  are	  directly	   linked	  to	  metabolic	  status	  by	  responding	  to	  an	   increase	   in	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NAD+	   and	  AMP	   levels,	   respectively,	  which	   act	   as	   cellular	   sensors	   for	   energy	   expenditure	  (Canto	  et	  al.,	  2009).	  	  	  Sirtuins	  and	  AMPK	  modulate	  mitochondrial	  biogenesis	  and	  are	  associated	  with	  cell	  repair	  pathways	   (Canto	   et	   al.,	   2009;	   Martin-­‐Montalvo	   and	   de	   Cabo,	   2013;	   Milne	   et	   al.,	   2007).	  Although	   their	   function	   is	   context-­‐dependent,	   increased	   sirtuin	   1	   (SIRT1)	   in	   rat	   cortical	  neurons	  may,	   for	   example,	   protect	   from	  Aβ	   toxicity	   in	   vitro	   (Sun	   et	   al.,	   2014;	   Chen	   et	   al.,	  2005).	  In	  contrast,	  transfecting	  SIRT2,	  SIRT3	  and	  SIRT6	  into	  rat	  cerebellar	  granule	  neurons	  (CGN)	   can	   induce	   apoptosis	   in	   otherwise	   healthy	   neurons	   (Pfister	   et	   al.,	   2008).	   Although	  long-­‐term	  caloric	  restriction	  may	  be	  difficult	  to	  uphold	  in	  practice,	  adapting	  a	  healthy	  diet	  with	   a	  modest	   calorie	   deficiency	   can	   prevent	   obesity	   and	   associated	  metabolic	   disorders	  (Witte	  et	  al.,	  2009).	  The	  recently	  concluded	  multidomain	  intervention	  trial	  of	  diet,	  exercise,	  cognitive	   training	   and	   vascular	   risk	   monitoring	   to	   prevent	   cognitive	   decline	   in	   at-­‐risk	  elderly	  people	  (FINGER	  trial)	  in	  Finland	  suggests	  that	  a	  multidomain	  approach	  can	  improve	  or	  maintain	  cognitive	  function	  in	  the	  elderly.	  	  As	   is	   true	   for	  most	   biological	   systems,	   the	   aforementioned	  pathways	   converge	   at	   several	  points,	   providing	   intricate	   control	   of	   cell	   metabolism	   and	   viability.	   The	   contribution	   of	  different	   signaling	   pathways	   to	   cellular	   viability	   and	   longevity	   are	   summarized	   in	   Figure	  2.1.	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Figure	   2.1:	   Summary	   of	   the	   central	   pathways	   and	   cellular	   organelles	   implicated	   in	   the	   aging	  
process.	  Aging	  related	  cellular	  stress	  can	  be	  partially	  counteracted	  by	  protective	  gene	  responses	  
and	   by	   boosting	   the	   clearance	   of	   damaged	   organelles	   and	  misfolded	   or	   aggregated	   proteins.	  
Blunt-­‐headed	  lines	  indicate	  inhibition,	  whereas	  arrowheads	  indicate	  activation.	  
2.1.2	  Determinants	  of	  individual	  brain	  aging	  and	  cognitive	  reserve	  The	  term	  cognitive	  reserve,	  discussed	  in	  the	  works	  of	  Dr.	  Yaakov	  Stern	  (Stern,	  2003;	  Stern,	  2012),	   accounts	   for	   the	   differences	   between	   individuals	   in	   their	   susceptibility	   to	   display	  symptoms	  of	   age-­‐related	   changes	   in	  brain	   function	   and	  pathophysiology.	  Epidemiological	  studies	   suggest	   that	   in	   addition	   to	   genetic	   and	   developmental	   factors,	   life	   decisions	  regarding	   education,	   occupation	   and	   social	   activity	   have	   an	   effect	   on	   cognitive	   reserve	  (Stern,	  2012).	  These	  differences	  are	  not	  determined	  by	  simple	  differences	  in	  physical	  brain	  shape	  or	  size,	  but	  by	   the	   individual	  differences	   in	   the	  organization	  of	   the	   functional	  brain	  networks	  and	  their	  utilization	  (Barulli	  and	  Stern,	  2013).	  	  Brain	   atrophy	   and	   neuronal	   network	   dysfunction	   occur	   in	   normal	   aging,	   but	   these	  processes	   are	   accelerated	   in	   AD.	   Technologies	   such	   as	   functional	   brain	   imaging	   have	  allowed	  us	  to	  distinguish	  between	  the	  physical	  and	  cognitive	  aspects	  of	  aging.	  The	  original	  concept	  of	  cognitive	  reserve	  proposed	  that	  larger	  brains	  with	  more	  neurons	  would	  be	  more	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resilient	   to	   dementia,	   but	   in	   fact,	   the	   interconnectedness	   and	   the	   pre-­‐existing	   cognitive	  processing	   pathways	   seem	   to	   play	   a	   major	   role	   in	   compensating	   for	   age-­‐	   and	   disease-­‐related	   cognitive	   decline	   (Stern	   et	   al.,	   2005;	   Brickman	   et	   al.,	   2011;	   Steffener	   and	   Stern,	  2012).	   This	   implies	   that	   with	   increased	   interconnectedness,	   brain	   networks	   are	   more	  resilient	  to	  local	  disturbances	  due	  to	  existing	  alternative	  and	  parallel	  pathways	  (Stern	  et	  al.,	  2005).	  	  Seemingly	   contradictory	   to	   the	   concept	   of	   cognitive	   reserve,	   in	   individuals	   with	   a	   high	  cognitive	  reserve,	  the	  rate	  of	  decline	  in	  AD	  after	  the	  onset	  of	  cognitive	  symptoms	  is	  faster	  due	  to	  the	  higher	  threshold	  against	  the	  pathological	  changes	  (Stern	  et	  al.,	  1999;	  Stern	  et	  al.,	  1995).	  This	  is	  likely	  due	  to	  the	  higher	  symptom	  threshold,	  since	  the	  pathology	  may	  be	  more	  advanced	  when	  first	  symptoms	  arise	  (Stern,	  2012).	  In	  patients	  with	  low	  cognitive	  reserve,	  less	  pathology	  and	  neurodegeneration	  is	  required	  to	  manifest	  as	  cognitive	  impairment	  (A;	  Figure	  2.2)	  (Stern	  et	  al.,	  1999;	  Stern	  et	  al.,	  1995).	  As	  a	  consequence,	  in	  clinical	  trial	  design	  for	  drugs	  affecting	  the	  cognition,	  factors	  affecting	  cognitive	  reserve	  should	  be	  accounted	  for	  to	  ensure	  proper	  control	  between	  pathology	  and	  cognitive	  impairment	  (Figure	  2.2)	  (Stern,	  2012).	  
	  
Figure	  2.2:	  Difference	  between	  the	  onset	  of	  cognitive	  impairment	  in	  people	  with	  low	  cognitive	  
reserve	  (A)	  and	  high	  cognitive	  reserve	  (B).	  People	  with	  higher	  cognitive	  reserve	  will	  retain	  their	  
cognitive	   performance	   against	   aging-­‐	   and	   disease-­‐related	   brain	   degeneration	   for	   longer.	  
However,	  the	  rate	  of	  decline	  will	  be	  faster	  after	  the	  onset	  of	  symptomatic	  cognitive	  impairment.	  
Figure	  adapted	  from	  the	  works	  of	  Yaakov	  et	  al.	  (Stern	  et	  al.,	  1999;	  Stern,	  2012).	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  Epidemiological	   evidence	   suggests	   that	   cognitive	   reserve	   is	   increased	   by	   education,	   high	  occupational	  attainment	  and	  engaging	   in	  daily	  social	  activities.	   In	  epidemiological	  studies,	  people	  with	  fewer	  than	  8	  years	  of	  basic	  education	  and	  low	  lifetime	  occupational	  attainment	  (unskilled,	  semiskilled	  work)	  had	  2.2	  and	  2.25-­‐fold	  increased	  risk	  of	  AD	  (Stern	  et	  al.,	  1994).	  Similarly,	  in	  another	  study	  engaging	  in	  frequent	  daily	  social	  or	  leisure	  activities	  significantly	  lowered	  AD	  risk	  by	  more	   than	  a	   third	  (Scarmeas	  et	  al.,	  2001).	  These	  studies	   indicate	   that	  higher	  education,	  occupations	  requiring	  the	  management	  of	  complex	  problems	  and	  active	  social	  life	  may	  strengthen	  brain	  connections	  and	  improve	  the	  utilization	  of	  alternative	  brain	  networks	  and	  thus	  increasing	  cognitive	  reserve	  (Scarmeas	  et	  al.,	  2001).	  	  In	  addition	  to	  increasing	  cognitive	  reserve	  by	  choices	  relating	  to	  education,	  occupation	  and	  social	  activity,	  aerobic	  exercise	  and	  healthy	  diet	  can	  also	  promote	  brain	  health.	  A	  systematic	  review	  of	  fifteen	  longitudinal	  studies	  with	  over	  5-­‐year	  follow	  up	  times	  reveals	  that	  physical	  activity	   has	   a	   positive	   long-­‐term	   influence	   against	   obesity,	   cardiovascular	   disease	   (CVD),	  T2DM,	  AD	  and	  dementia	  (Reiner	  et	  al.,	  2013).	  In	  these	  studies,	  energy	  expenditure	  of	  1000	  to	  3000	  kcal	   per	  week	  was	   required	   for	  health	  promoting	   and	  disease-­‐preventing	   effects	  (Rodriguez	  et	  al.,	  1994;	  Lee	  and	  Paffenbarger,	  1998).	  As	  a	  benchmark,	  an	  average	  man	  (75	  kg)	  will	  burn	  roughly	  600	  kcal	  by	  jogging	  for	  one	  hour	  at	  a	  moderate	  speed	  (8	  km	  per	  hour).	  Hence,	   exercising	  at	   least	   three	   times	  weekly	   is	   a	   generally	   accepted	   generic	   guideline	   to	  upkeep	  health	  (Warburton	  et	  al.,	  2006).	  	  	  Lastly,	   the	   quantity	   and	   quality	   of	   diet	   has	   a	   significant	   effect	   on	   brain	   health.	   A	   typical	  Western	  diet	  consists	  of	  processed	  foods	  heavy	  with	  saturated	  fats	  and	  simple	  sugars	  and	  is	  deleterious	   to	   brain	   health.	   Lowering	   the	   calorie	   intake	   and	   replacing	   red	   meats	   and	  processed	  foods	  with	  white	  meat,	  fish,	  vegetables	  and	  unsaturated	  omega-­‐3	  fatty	  acids	  can	  help	   to	   reverse	   the	   detrimental	   effects	   of	   the	   Western	   diet	   (Psaltopoulou	   et	   al.,	   2013;	  Holmes	   et	   al.,	   2008;	   Gardener	   et	   al.,	   2014).	   The	   role	   of	   diet	   in	   brain	   health	   and	   AD	   is	  explored	  in	  more	  depth	  in	  a	  later	  chapter	  2.2.4.3.	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2.2	  Alzheimer’s	  disease	  	  
2.2.1	  Neurodegenerative	  diseases	  Neurodegenerative	  diseases	  are	  a	  heterogenous	  group	  of	  diseases	   that	  affect	   the	   function	  and	  viability	  of	  specific	  neuronal	  populations.	  The	  symptoms	  are	  largely	  dependent	  on	  the	  affected	   region	   of	   the	   CNS	   or	   PNS.	   Hence,	   disturbances	   in	   motor	   neuron	   function	   and	  premotor	   regions	   will	   primarily	   result	   in	   movement	   disorders,	   whereas	   damage	   to	   the	  frontal	   or	   temporal	   lobes,	   including	   hippocampus,	   can	   affect	   decision-­‐making	   ability,	  complex	  cognitive	  task	  performance	  and	  personality	  (McGeer	  and	  McGeer,	  2004).	  	  	  Many	  NDDs	   are	   characterized	  by	   the	   accumulation	  of	   specific	   toxic	   protein	   aggregates	   in	  the	  brain	   (Wang	  et	   al.,	   2014;	  Takalo	   et	   al.,	   2013;	  Aguzzi	   and	  O'Connor,	   2010).	  Amyloid-­‐β	  (Aβ)	   is	   the	   primary	   constituent	   of	   senile	   plaques	   found	   in	   AD	   brains.	   Intracellular	  neurofibrillary	   tangles	   (NFT)	   composed	   of	   hyperphosphorylated	   Tau	   are	   found	   in	   the	  brains	  of	  many	  NDD	  patients,	  including	  AD,	  FTD	  and	  PD	  (Shastry,	  2003).	  In	  addition,	  brains	  of	   PD	   patients	   accumulate	   α-­‐synuclein	   aggregates	   (Spillantini	   et	   al.,	   1997),	   and	  Huntington’s	   disease	   patients	   accumulate	   huntingtin	   aggregates	   (Group.,	   1993).	  Aggregation	  of	  TAR	  DNA-­‐binding	  protein	  43	  (TDP-­‐43)	  is	  a	  hallmark	  of	  FTD	  and	  ALS	  (Zhang	  et	   al.,	   2011;	   Kabashi	   et	   al.,	   2010).	   In	   prion	   diseases,	   such	   as	   Creutzfeld-­‐Jacob	   disease,	  mutant	   prion	   proteins	   misfold	   and	   spread,	   causing	   severe	   neuronal	   dysfunction	   and	  neuronal	   cell	   death	   (Palmer	   et	   al.,	   1991;	   Merz	   et	   al.,	   1983).	   In	   dementias,	   however,	  pathologies	   are	   often	   mixed	   and	   “pure”	   forms	   of	   sporadic	   NDDs	   can	   often	   be	   only	  determined	  in	  post-­‐mortem	  studies	  (Foy	  et	  al.,	  2007).	  This	  is	  especially	  true	  with	  diseases	  such	  as	  AD	  and	  FTD,	  which	  affect	  similar	  brain	  regions	  (Foy	  et	  al.,	  2007).	  	  Roughly	   two	   thirds	   of	   dementia	   patients	   have	   AD,	   making	   it	   the	   most	   common	   NDD.	  Initially,	   AD	   manifests	   near	   the	   temporal	   lobe	   in	   the	   hippocampus	   and	   the	   entorhinal	  cortex,	   causing	   cognitive	   symptoms	   including	   behavioral	   changes,	   memory	   loss	   and	  impaired	   learning.	  One	  of	   the	  earliest	  signs	  of	  AD	  pathology,	   the	  cerebral	  accumulation	  of	  Aβ,	   is	   detectable	   by	   brain	   imaging	   even	   15-­‐20	   years	   before	   the	   onset	   of	   clinical	   AD	  symptoms	   (Pike	   et	   al.,	   2011;	  Villemagne	   et	   al.,	   2013;	   Lim	  et	   al.,	   2014).	  However,	   a	   single	  biomarker	  like	  Aβ	  has	  limited	  predictive	  power	  during	  the	  prodromal	  phases	  of	  AD,	  as	  high	  levels	   of	  Aβ	   can	   also	  be	  detected	   in	   some	   cognitively	  normal	   adults	   and	   elderly	   (Herholz	  and	  Ebmeier,	  2011).	  Hence,	  currently	  one	  of	  the	  greatest	  challenges	  in	  the	  development	  of	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AD	   treatments	   is	   to	   understand	   the	   disparity	   between	   the	   onset	   of	   first	   pathological	  changes	   and	   cognitive	   symptoms	   (Landau	   and	   Frosch,	   2014).	   Additionally,	   individual	  differences	  in	  cognitive	  performance	  and	  cognitive	  reserve	  add	  another	  level	  of	  complexity	  when	  attempting	  to	  correlate	  stages	  of	  pathology	  and	  clinical	  symptoms	  (Stern,	  2012).	  
2.2.2	  AD	  neuropathology	  and	  the	  amyloid	  cascade	  hypothesis	  Since	  the	  discovery	  of	  Aβ	  as	  a	  major	  constituent	  of	  the	  plaques	  found	  in	  AD	  brains	  (Glenner	  and	  Wong,	  1984),	  increased	  accumulation	  of	  cerebral	  Aβ	  has	  been	  suggested	  to	  be	  a	  major	  contributor	   to	   AD	   pathogenesis.	   John	   Hardy	   and	   David	   Allsop	   originally	   proposed	   the	  amyloid	  cascade	  hypothesis	  in	  1991	  (Hardy	  and	  Allsop,	  1991),	  which	  links	  the	  pathological	  events	   leading	   from	   the	   early	   events	   of	   cerebral	   Aβ	   accumulation	   to	   the	   late	   stages	   of	  widespread	   neurodegeneration	   and	   brain	   atrophy	   (Figure	   2.3A).	   The	   main	  pathophysiological	  hallmarks	  of	  AD	  are	  the	  cerebral	  accumulation	  of	  toxic	  Aβ	  peptides	  and	  hyperphosphorylated	  Tau	  that	  lead	  to	  the	  formation	  of	  Aβ	  plaques	  and	  NFTs,	  respectively	  (Figure	  2.3B)	  (Kang	  et	  al.,	  1987;	  Lichtenberg	  et	  al.,	  1988;	  Delacourte	  and	  Defossez,	  1986).	  The	  other	  major	  hallmarks	  of	  AD	  include	  synaptic	  loss,	  inflammation,	  astrogliosis	  and	  brain	  atrophy.	  These	  hallmarks	  and	  their	  progression	  are	  similar,	  although	  not	  identical,	  between	  the	   early-­‐	   and	   late-­‐onset	   forms	   of	   AD,	   EOAD	   and	   LOAD,	   respectively.	   A	  major	   difference	  between	   genetic	   EOAD	   and	   sporadic	   LOAD	   is	   suggested	   to	   be	   the	  mechanism	   behind	   Aβ	  accumulation.	   In	   EOAD,	   Aβ	   production	   is	   significantly	   increased	   due	   to	   increased	  amyloidogenic	  processing.	  In	  contrast,	  reduced	  Aβ	  clearance	  has	  been	  suggested	  to	  be	  the	  primary	  reason	  for	  the	  build	  up	  of	  toxic	  Aβ	  oligomers	  and	  plaques	  in	  LOAD	  (Panegyres	  and	  Chen,	   2013;	   Cho	   et	   al.,	   2013).	  However,	   it	   should	   be	   noted	   that	   significant	   heterogeneity	  and	  disease	  subtypes	  of	  AD	  can	  be	  associated	  with	  different	  etiologies.	  	  	  AD	   pathology	   often	   initiates	   from	   the	   hippocampus	   and	   entorhinal	   cortex,	   with	   the	  increased	  appearance	  of	  amyloid	  plaques	  and	  hyperphosphorylated	  Tau	  inclusions	  causing	  synaptic	   and	   network	   disturbances	   (mild-­‐AD).	   During	   disease	   progression,	   AD	   pathology	  spreads	   to	   the	   temporal	   and	   frontal	   cortex	   (moderate-­‐AD).	   At	   later	   stages,	   pathology	   is	  widespread	  and	  brain	  atrophy	  significant	  (severe-­‐AD)	  (Figure	  2.3A,C)	  (Braak	  et	  al.,	  1993).	  AD	  stages	  are	  categorized	  in	  several	  ways.	  Braak-­‐staging	  defines	  the	  stages	  of	  AD	  pathology	  according	   to	   the	   spread	   of	   NFT	   formed	   by	   hyperphosphorylated	   Tau	   across	   the	   brain	  (Figure	   2.3C)	   (Braak	   and	   Braak,	   1995).	   These	   stages	   are	   often	   correlated	   with	   the	   pre-­‐clinical	   stage	   of	  AD,	  mild-­‐cognitive-­‐impairment	   (MCI)	   and	   the	  mild,	  moderate	   and	   severe	  
	   15	  
stages	   of	   clinical	   AD.	   In	   AD,	   there	   is	   a	   strong	   correlation	   between	   synaptic	   loss	   and	  cognitive	  decline	  (Shankar	  and	  Walsh,	  2009;	  Naslund	  et	  al.,	  2000).	  
	  
Figure	  2.3:	  Alzheimer’s	  disease	  pathological	  hallmarks	  and	  typical	  pattern	  of	  AD	  progression.	  A:	  
A	  comparison	  between	  a	  healthy	  control	  and	  an	  AD	  brain	  shows	  a	  severe	  reduction	  in	  the	  white	  
and	  grey	  matter.	  B:	  Aβ	  plaques	  and	  NFT	  tangles	  in	  a	  histological	  section	  of	  AD	  brain	  visualized	  
by	  the	  Bielschowsky	  silver	  stain	  method.	  Adapted	  from	  (Mufson	  et	  al.,	  2012).	  C:	  AD	  progression	  
and	  the	  affected	  brain	  regions	  highlighted	  in	  red.	  	  Understanding	  Aβ	  metabolism	  is	  central	  to	  the	  amyloid	  cascade	  hypothesis.	  Aβ	  is	  produced	  by	   amyloidogenic	   processing	   from	   the	   amyloid	   precursor	   protein	   (APP),	   a	   ubiquitously	  expressed	   cell	   surface	   protein	   that	   participates	   in	   synaptic	   functions	   and	   cholesterol	  metabolism	   (Pramatarova	   et	   al.,	   2008;	   Wang	   et	   al.,	   2013).	   APP	   can	   be	   proteolytically	  processed	   by	   either	   the	   non-­‐amyloidogenic-­‐	   or	   amyloidogenic	   pathway.	   In	   the	   dominant	  non-­‐amyloidogenic	   α-­‐pathway,	   APP	   is	   processed	   by	   an	   α-­‐secretase,	   a	   disintegrin	   and	  metalloproteinase	   domain-­‐containing	   protein	   10	   (ADAM10),	   and	   a	   γ-­‐secretase	   complex	  (formed	  by	  PSEN1,	  PSEN2,	  nicastrin	  and	  anterior	  pharynx-­‐defective	  1)	  to	  yield	  the	  soluble	  ectodomain	   sAPPα	   and	   p3	   fragment	   (Lammich	   et	   al.,	   1999).	   In	   the	   amyloidogenic	   β-­‐pathway,	  sequential	  processing	  of	  APP	  by	  the	  β-­‐secretase,	  β-­‐site	  amyloid	  precursor	  protein-­‐cleaving	  enzyme	  1	   (BACE1),	  and	   the	  γ-­‐secretase	  generates	   the	  soluble	  ectodomain	  sAPPβ	  and	  Aβ	  (Sinha	  et	  al.,	  1999).	  The	  soluble	  sAPPα	  and	  sAPPβ	  fragments	  have	  neuroprotective	  and	   neurotoxic	   effects,	   respectively	   (Chasseigneaux	   and	   Allinquant,	   2012).	   The	   APP	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intracellular	  domain	   is	  released	  after	  γ-­‐cleavage	  and	  functions	  as	  a	  transcription	  factor	  to	  regulate	  APP	  expression	  (von	  Rotz	  et	  al.,	  2004;	  Kimberly	  et	  al.,	  2001).	  The	  major	  Aβ	  species	  are	  the	  40	  amino	  acid	  (aa)	  Aβ40	  and	  the	  more	  toxic	  and	  aggregation	  prone	  42	  aa	  Aβ42.	  Other	  minor	  species	  of	  Aβ	  peptides	  have	  also	  been	  described	  (Schieb	  et	  al.,	  2011).	  	  	  In	   normal	   conditions,	   the	   nonamyloidogenic	   pathway	   dominates	   and	   Aβ-­‐degrading	  enzymes,	   such	   as	   insulin-­‐degrading	   enzyme,	   neprilysin,	   cathepsin	   B,	   angiotensin-­‐converting	   enzymes	   and	   matrix	   metalloproteinases	   prevent	   Aβ	   accumulation	   by	  degradation	   (Miners	   et	   al.,	   2008).	   Increased	  generation	  or	  decreased	   clearance	  of	  Aβ	   can	  enhance	   the	   cerebral	   accumulation	   of	   Aβ.	   Increased	   Aβ	   levels	   favor	   the	   formation	   of	   Aβ	  dimers,	   trimers	   and	   oligomers,	   which	   have	   been	   shown	   to	   disturb	   neuronal	   functions	  through	  multiple	  pathways	  (Sakono	  and	  Zako,	  2010;	  Takahashi	  et	  al.,	  2004a).	  Aβ	  oligomers	  have	   the	   ability	   to	   suppress	   long-­‐term	   potentiation	   (LTP)	   and	   impair	   synaptic	   plasticity	  required	  for	  memory	  formation	  in	  various	  animal	  models	  of	  AD	  (Pozueta	  et	  al.,	  2013;	  Wang	  et	   al.,	   2002).	   Interestingly,	   neuronal	   activity	   increases	   local	   Aβ	   generation,	   potentially	  indicating	  a	  physiological	  negative	  feedback	  loop	  in	  synaptic	  modulation	  and	  prevention	  of	  synaptic	  hyperactivity	  (Kamenetz	  et	  al.,	  2003).	  Eventually,	   the	  aggregation	  of	  Aβ	  peptides	  results	   in	   the	   formation	  of	   insoluble	  amyloid	  plaques,	   first	  as	  diffuse	  plaques	  and	   later	  as	  compacted,	   senile	   plaques	   with	   β-­‐pleated,	   protease-­‐resistant	   cores	   (Duyckaerts	   et	   al.,	  2009).	  	  Aβ	   also	   induces	   organelle	   stress	   and	   activates	   an	   inflammatory	   response	   in	   microglia.	  Prolonged	   inflammation	   can	   potentiate	   neuronal	   injury	   and	   alter	   ionic	   homeostasis	   to	  further	  promote	  cellular	  and	  oxidative	  stress	  due	  to	  mitochondrial	  dysfunction	  (Barger	  and	  Harmon,	  1997;	  Akiyama	  et	  al.,	  2000).	  Aβ	  also	  accumulates	  on	  the	  blood	  vessel	  walls	  in	  the	  brain,	  where	  it	  can	  accumulate	  to	  form	  vascular	  amyloid	  deposits,	  further	  damaging	  brain	  cells	   through	  reduced	  blood	  flow,	  nutrients	   intake	  and	  waste	  clearance	  (Duyckaerts	  et	  al.,	  2009).	  	  Another	   important	   protein	   in	   AD	   pathophysiology	   is	   Tau.	   Tau	   is	   localized	   specifically	   to	  axonal	   microtubules	   where	   it	   stabilizes	  microtubules	   and	   supports	   axonal	   integrity.	   Tau	  binding	   is	   controlled	  by	  phosphorylation	  and	  dephosphorylation	  by	  a	  network	  of	  kinases	  that	  may	  become	  dysregulated	  with	  increasing	  cellular	  disturbances	  and	  Aβ	  levels.	   	  Tau	  is	  hyperphosphorylated	  by	  the	  increased	  function	  of	  kinases	  such	  as	  glycogen	  synthase	  kinase	  3β	  (GSK3β)	  and	  is	  detached	  from	  axonal	  microtubules	  (Hanger	  et	  al.,	  1992).	  The	  loss	  of	  Tau	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function	  due	  to	  hyperphosphorylation	  affects	  axonal	  integrity	  and	  impairs	  vesicle	  transport	  along	  axons	  (Iijima-­‐Ando	  et	  al.,	  2012;	  Dawson	  et	  al.,	  2010).	  	  	  Hyperphosphorylated	   Tau	   and	   Aβ	   can	   form	   insoluble	   intracellular	   inclusions	   and	  extracellular	   plaques,	   respectively	   (Bloom,	   2014).	   Aβ	   accumulation	   and	   Tau	  hyperphosphorylation	   also	   interfere	   with	   the	   metabolism	   and	   release	   of	   acetylcholine	  (ACh),	  a	  major	  neurotransmitter	  within	  the	  hippocampus	  and	  the	  cortex.	  Hence,	  neurons	  of	  the	   cholinergic	   networks,	   neurons	  utilizing	  ACh	   as	   a	   neurotransmitter,	   are	  most	   severely	  affected	   in	  AD	  (Terry	  and	  Katzman,	  1983).	  Neurotransmitter	  deficits	  are	  coupled	  with	  an	  imbalance	  in	  the	  activity	  of	  excitatory	  and	  inhibitory	  neurons,	  especially	  around	  diffuse	  and	  senile	  Aβ	  plaques,	  affecting	  brain	  network	  function	  (Verret	  et	  al.,	  2012;	  Palop	  et	  al.,	  2007).	  When	   a	   significant	   portion	   of	   neurons	   become	   dysfunctional	   or	   die,	   the	   clinical	  manifestations	  of	  AD	  symptoms	  appear.	  By	  some	  estimates,	  memory	  deficits	  manifest	  only	  when	  over	  50%	  of	  neurons	  of	   the	  entorhinal	  cortex	  are	  dead	  or	  dysfunctional,	  displaying	  the	  vast	  adaptive	  capability	  of	  the	  brain,	  but	  also	  presenting	  a	  challenge	  for	  early	  diagnosis	  and	  treatment	  of	  AD	  (Kerchner	  et	  al.,	  2012).	  
2.2.3	  AD	  progression,	  diagnosis	  and	  biomarkers	  Alzheimer’s	   disease	   can	  be	   separated	   into	   the	   following	   clinical	   stages:	   prodromal	  phase,	  mild	   cognitive	   impairment	   (MCI),	   mild-­‐AD,	   moderate-­‐AD	   and	   severe-­‐AD.	   Diagnosing	  patients	  into	  these	  different	  stages	  can	  be	  assessed	  by	  a	  combination	  of	  cognitive	  memory	  tests,	  brain	  imaging	  and	  cerebrospinal	  fluid	  (CSF)	  analysis	  (Meredith	  et	  al.,	  2013;	  Lu	  et	  al.,	  2014;	  Sui	  et	  al.,	  2014).	  The	  global	  deterioration	  scale	  is	  used	  to	  assess	  impairment	  severity	  and	   ranges	   from	   0	   (cognitively	   normal)	   to	   7	   (severe	   cognitive	   impairment)	   (Reisberg,	  2007).	   Several	   task-­‐based	   memory	   tests	   have	   been	   developed	   as	   diagnostic	   tools.	   A	  commonly	   used	   questionnaire-­‐based	   test	   is	   the	   mini-­‐mental	   state	   examination	   (MMSE),	  which	   tests	   language,	  memory	   and	  more	   complex	   tasks,	   such	   as	   copying	   a	   drawing.	   The	  advantages	  of	  MMSE	  are	  its	  versatility	  and	  ease	  of	  use,	  but	  on	  the	  other	  hand	  MMSE	  scores	  are	  skewed	  by	  age	  and	  education,	  and	  it	  lacks	  sensitivity	  in	  distinguishing	  between	  normal,	  MCI	  and	  mild-­‐AD	  patients	  (Reisberg,	  2007).	  	  Structural	   and	   functional	   brain	   imaging	   can	   be	   used	   to	   determine	   changes	   in	   brain	  structure	  and	  volume,	   level	  of	  Aβ	  accumulation	  and	  changes	   in	   functional	  brain	  networks	  (Weiner	  et	  al.,	  2013).	  Structural	  brain	  imaging	  with	  magnetic	  resonance	  imaging	  (MRI)	  can	  be	   used	   to	   determine	   brain	   atrophy,	   especially	   of	   the	   specific	   AD-­‐inflicted	   regions	   of	  
	   18	  
hippocampus	  and	  temporal	  cortex	  (Appel	  et	  al.,	  2009).	  The	  radioactive	  analog	  of	  thioflavin	  T,	  called	  Pittsburgh	  Compound	  B	  (PiB),	  binds	  to	  Aβ	  with	  high	  affinity	  when	  injected	  into	  a	  patient.	  Radioactive	  PiB	   can	   then	  be	  detected	  using	  positron	  emission	   tomography	   (PET)	  brain	   imaging	  to	  determine	  the	   levels	  of	  Aβ	  accumulation	  in	  the	  brain	  (Price	  et	  al.,	  2005).	  PiB-­‐PET	  imaging	  is	  the	  current	  golden	  standard	  in	  Aβ	  imaging	  (Perani,	  2014).	  Recently,	  also	  novel	  Tau	  markers	  have	  been	  utilized	   in	  PET	   imaging	  with	  promising	  results	   (Villemagne	  and	  Okamura,	  2014).	  	  	  	  Functional	   MRI	   (fMRI)	   and	   fludeoxyglucose-­‐PET	   imaging	   can	   reveal	   changes	   in	   the	  activation	  patterns	  of	  default	  neuronal	  networks	  at	  rest	  and	  during	  various	  cognitive	  tasks	  (Dennis	   and	   Thompson,	   2014).	   More	   invasive	   methods	   include	   the	   analysis	   of	   Aβ42	   and	  phosphorylated	   Tau	   from	   the	   CSF	   (Meredith	   et	   al.,	   2013).	   CSF	   Aβ42	   levels	   are	   known	   to	  decrease	   and	  phosphorylated	  Tau	   levels	   increase	  during	  AD	  progression	   (Meredith	   et	   al.,	  2013).	   The	   greatest	   benefit	   from	   the	   aforementioned	   diagnostic	   methods	   comes	   from	  longitudinal	  studies,	  where	  the	  relative	  changes	  within	  the	  parameters	  can	  be	  assessed	  at	  the	  individual	  level	  over	  several	  years,	  giving	  a	  more	  accurate	  prediction	  of	  AD	  disease	  risk	  or	   progression	   (Murray	   et	   al.,	   2015).	   The	   relative	   temporal	   progression	   of	   LOAD	   risk,	  accompanying	  biomarker	  and	  grey	  matter	  alterations	  are	  summarized	  in	  Figure	  2.4.	  	  
	  
Figure	  2.4:	  Summary	  of	  AD	  biomarkers	  and	  pathological	  progression.	  Notably,	  Aβ	  accumulation	  
precedes	   cognitive	   impairment,	   whereas	   Tau	   NFT	   development	   is	  more	   closely	   correlated	   to	  
symptom	  severity	  (Parihar	  and	  Hemnani,	  2004;	  Duyckaerts	  et	  al.,	  2009;	  Naslund	  et	  al.,	  2000).	  	  
	   19	  
Some	  of	  the	  limitations	  and	  drawbacks	  of	  brain	  imaging	  and	  CSF	  analysis	  are	  their	  high	  cost	  and	  discomfort	  associated	  with	  lumbar	  puncture	  needed	  to	  acquire	  a	  CSF	  sample.	  However,	  significant	   efforts	   have	   been	   made	   to	   establish	   more	   cost	   efficient	   and	   large-­‐scale	  diagnostic	  methods	  (Fiandaca	  et	  al.,	  2014).	  One	  of	  the	  optimal	  solutions	  would	  be	  obtaining	  a	   reliable	   AD	   diagnosis	   from	   blood	   samples.	   Recently,	   researchers	   from	   the	   Georgetown	  University	   Medical	   Center,	   Washington	   DC	   reported	   that	   a	   specific	   blood	   plasma	   lipid	  profile	   consisting	   of	   ten	   lipids	   was	   associated	   with	   the	   phenoconversion	   of	   cognitively	  normal	  adults	  to	  MCI	  or	  mild-­‐AD	  with	  90%	  accuracy	  (Mapstone	  et	  al.,	  2014).	  These	   lipids	  were	  primarily	   associated	  with	   cell	  membrane	   integrity.	  Another	  potential	   class	   of	   blood	  biomarkers	   is	   circulating	   microRNA	   (miRNA),	   which	   are	   small	   non-­‐coding	   RNA	   that	  regulate	  mRNA	   translation	   rate.	   In	  a	   small	   set	  of	  AD	  and	  control	  patients,	   several	  miRNA	  species	   in	   the	   blood	   and	  CSF	  were	   identified	   as	   potential	   biomarkers	   for	  AD	   (Kiko	   et	   al.,	  2014).	   In	   an	   AD	   mouse	   model,	   a	   battery	   of	   84	   miRNAs	   isolated	   from	   the	   plasma	   was	  changed	  in	  an	  age-­‐	  and	  AD	  pathology-­‐dependent	  manner	  (Garza-­‐Manero	  et	  al.,	  2015).	  	  	  In	   Australia,	   the	   Australian	   Imaging,	   Biomarkers	   and	   Lifestyle	   (AIBL)	   study	   of	   aging	  was	  recently	  completed	  (Ellis	  et	  al.,	  2009).	  Investigators	  involved	  with	  the	  AIBL	  study	  revealed	  a	   number	   of	   novel	   predictors	   of	   neocortical	   amyloid	   burden	   as	   well	   as	   blood-­‐based	   AD	  biomarkers	   (Burnham	   et	   al.,	   2014;	   Doecke	   et	   al.,	   2012).	   Similar	   coordinated	   efforts	  may	  provide	  a	  fast	  and	  predictable	  AD	  risk	  and	  diagnostic	  method	  in	  the	  near	  future	  to	  support	  the	  early	  intervention	  and	  prevention	  of	  AD.	  
2.2.4	  Risk	  factors	  for	  Alzheimer’s	  disease	  Sporadic	   LOAD	   develops	   over	   a	   long	   period	   of	   time,	   including	   a	   long	   asymptomatic	  prodromal	  period,	  making	  the	  prediction	  of	  individual	  LOAD	  risk	  tough	  to	  assess.	  However,	  current	  understanding	  of	  LOAD	  pathogenesis	  and	  risk	  factors	  introduces	  the	  possibility	  to	  reduce	  AD	  risk	  at	  the	  individual	  level	  with	  lifestyle	  choices	  and	  possibly	  on	  the	  population	  level	  by	  raising	  awareness	  and	  supporting	  healthy	  life	  choices.	  
2.2.4.1	  Age	  Age	   is	   the	   biggest	   risk	   factor	   for	   LOAD.	   After	   65	   years	   of	   age,	   the	   risk	   for	   LOAD	  doubles	  every	  5	  years	   thereafter,	   reaching	   roughly	  40%	  by	   the	  age	  of	  80	  (Bishop	  et	  al.,	  2010).	  As	  discussed	   in	   chapter	   2.1.1,	   increased	  ROS,	  mitochondrial	   defects,	   hardening	   of	   the	   vessel	  walls	  and	  inflammation	  are	  among	  some	  of	  the	  cellular	  effects	  of	  aging	  that	  may	  contribute	  to	  AD	  pathogenesis	  (Harris	  et	  al.,	  2014).	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2.2.4.2	  Genetic	  risk	  factors	  Early-­‐onset	  AD	  is	  caused	  by	  mutations	  of	  APP	  and	  APP-­‐cleaving	  γ-­‐secretase	  subunits	  PSEN1	  and	   PSEN2.	   The	   prevalence	   of	   these	   mutations	   is	   limited	   to	   a	   small	   number	   of	   families	  worldwide	   and	   account	   for	   less	   than	   5%	  of	   all	   AD	   cases	   (Haass	   et	   al.,	   1994;	   Goate	   et	   al.,	  1991;	  Sherrington	  et	   al.,	   1995).	  People	  with	  Down’s	   syndrome,	   a	  developmental	  disorder	  caused	  by	  the	  triplication	  of	  chromosome	  21,	  have	  an	  increased	  risk	  for	  AD	  since	  the	  APP	  gene	  is	  located	  in	  the	  triplicated	  chromosome	  (Margallo-­‐Lana	  et	  al.,	  2004;	  Korenberg	  et	  al.,	  1989).	  Also,	  Finnish	  and	  French	  families	  with	  a	  rare	  duplication	  of	  an	  area	  containing	  the	  APP	   gene	   also	   develop	   early-­‐onset	   dementia	   (Sleegers	   et	   al.,	   2006;	   Rovelet-­‐Lecrux	   et	   al.,	  2007).	  As	  evident	  from	  the	  known	  EOAD	  cases,	  increased	  APP	  gene	  load	  and	  Aβ	  generation	  support	  the	  central	  role	  of	  Aβ	  in	  AD	  pathogenesis.	  	  Sporadic	  LOAD	  makes	  up	  over	  95%	  of	  AD	  cases.	  More	  than	  700	  genes	  have	  been	  associated	  with	   AD	   in	   meta-­‐analysis	   of	   genome-­‐wide	   association	   studies	   (GWAS)	   (Chouraki	   and	  Seshadri,	   2014).	   The	  most	   prominent	   genetic	   risk	   factor	   variant	   for	   AD	   is	   ApoE4,	   which	  significantly	   affects	   Aβ	   metabolism	   and	   disturbs	   neuronal	   signaling	   (Deane	   et	   al.,	   2008;	  Chen	   et	   al.,	   2010).	   The	   three	   human	   ApoE	   alleles	   are	   ε2	   (ApoE2),	   ε3	   (ApoE3)	   and	   ε4	  (ApoE4),	  which	   differ	   from	   each	   other	   by	   single	   nucleotide	   polymorphisms	   at	   the	   amino	  acid	   (aa)	   positions	   112	   and	   158.	   ApoE2,	   with	   cysteines	   at	   positions	   112	   and	   158,	   has	   a	  prevalance	  of	  7%	  and	  has	  a	  protective	  effect	  against	  LOAD	  risk	   (Conejero-­‐Goldberg	  et	  al.,	  2014).	  ApoE3,	  with	  a	  cysteine	  at	  112	  and	  an	  arginine	  at	  158,	   is	  the	  most	  common	  variant	  with	  a	  neutral	  effect	  on	  LOAD	  risk.	  ApoE4,	  with	  arginines	  at	  both	  112	  and	  158,	  increases	  AD	  risk	   by	   over	   3-­‐fold	  when	   present	   in	   one	   allele	   and	   by	   roughly	   12-­‐fold	   if	   present	   in	   both	  alleles	   (Farrer	   et	   al.,	   1997).	   As	   a	   relatively	   common	   allele	   variant	   at	   15-­‐20%	   population	  level,	  ApoE4	  is	  the	  single	  greatest	  genetic	  LOAD	  risk	  factor	  (Chouraki	  and	  Seshadri,	  2014).	  	  	  Interestingly,	   low	   levels	   of	  ApoE,	   irrespective	   of	   allelic	   variation,	  were	   recently	   shown	   to	  increase	   LOAD	   risk	   deduced	   from	   a	   75,708	   participant	   sample	   size	   from	   the	   general	  population	   (Rasmussen	   et	   al.,	   2015).	   Apart	   from	   supplying	   neurons	  with	   cholesterol	   and	  lipids	   required	   for	  neuronal	   growth	  and	   repair,	  ApoE	  also	   transports	  Aβ	   out	   of	   the	  brain	  (Tokuda	   et	   al.,	   2000;	   Koistinaho	   et	   al.,	   2004;	   Kim	   et	   al.,	   2014).	   Both	   the	   increased	  production	  and	  reduced	  clearance	  of	  Aβ	   are	  major	  determinants	   for	  both	  early-­‐	  and	   late-­‐onset	   AD.	   The	   ApoE4	   allele	   is	   suspected	   to	   increase	   LOAD	   risk	   by	   loss-­‐of-­‐function	   of	   its	  physiological	   roles	   in	  Aβ	   clearance	  and	  LTP	   formation,	  and	  gain-­‐of-­‐function	  neurotoxicity	  through	  its	  toxic	  cleavage	  fragments	  (Tokuda	  et	  al.,	  2000;	  Koistinaho	  et	  al.,	  2004;	  Deane	  et	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al.,	   2008;	   Kim	   et	   al.,	   2009a;	   Herz,	   2009;	   Bachmeier	   et	   al.,	   2014;	   Kim	   et	   al.,	   2014).	  Additionally,	   lipoprotein	   receptors	   act	   as	   ApoE	   receptors	   in	   the	   brain	   and	   are	   centrally	  involved	  in	  Aβ	  homeostasis	  (Jaeger	  and	  Pietrzik,	  2008).	  The	  interactions	  between	  ApoE	  and	  lipoprotein	   receptors	   in	   relation	   to	   neuronal	   cell	   death	   and	   AD	   risk	   and	   pathogenesis	   is	  reviewed	  in	  Chapter	  2.4.	  	  The	   other	   top	   risk	   LOAD	   genes	   (Figure	   2.5)	   are	  mainly	   involved	   in	   lipoprotein	   signaling,	  APP/Aβ	   metabolism,	   inflammation	   and	   metabolic	   pathways,	   but	   many	   of	   their	   exact	  functions	   are	   still	   unknown	   (Chouraki	   and	   Seshadri,	   2014).	   Particularly	   lipoprotein	  metabolism,	   signaling	   and	   receptors	   are	   well	   represented	   by	   ApoE4,	  clusterin/apolipoprotein	   J	   (ApoJ),	   ABCA7	   and	   sortilin-­‐related	   receptor,	   L(DLR	   class)	   A	  repeats	   containing	   (SORL1	   [also	  known	  as	  LR11	  and	  SorLa]).	  Clusterin	   is	  associated	  with	  lipid	   and	   cholesterol	   homeostasis	   similar	   to	   ApoE,	   and	   is	   increased	   in	   ApoE4	   carriers,	  suggested	   to	   be	   a	   compensatory	  mechanism	   (Desikan	   et	   al.,	   2014;	  Bertrand	   et	   al.,	   1995).	  Rare	  loss-­‐of-­‐function	  variants	  of	  ABCA7,	  protein	  involved	  in	  loading	  ApoE	  and	  ApoA-­‐I	  with	  phospholipids	  and	  cholesterol,	  were	  recently	  shown	  to	  double	  AD	  risk	  in	  study	  groups	  from	  Iceland,	  Europe	  and	  United	  States	  (Steinberg	  et	  al.,	  2015).	  SORL1	  is	  a	  lipoprotein	  receptor-­‐related	  receptor	  and	  is	  involved	  in	  intracellular	  APP	  trafficking	  (Scherzer	  et	  al.,	  2004;	  Motoi	  et	  al.,	  1999;	  Ma	  et	  al.,	  2009).	  Another	  risk	  factor	  gene	  variant	  is	  TREM2,	  which	  is	  associated	  with	  microglial	   functions	   (Li	   et	   al.,	   2015;	   Jonsson	   et	   al.,	   2013).	   Many	   of	   LOAD	   risk	   gene	  variants	  are	  fairly	  common	  and	  have	  a	  marginal	  effect	  on	  disease	  risk	  in	  comparison	  to	  the	  ApoE4	  allele	  (Figure	  2.5)	  (Chouraki	  and	  Seshadri,	  2014).	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Figure	   2.5:	   The	   genetic	   causative	   genes	   for	   EOAD	   (top	   left;	   blue)	   and	   risk	   genes	   for	   LOAD	  
(bottom;	  green	  and	  red)	  (Chouraki	  and	  Seshadri,	  2014).	  
2.2.4.3	  Diet	  and	  exercise	  Western	  diet	  is	  often	  nutrient-­‐poor,	  consisting	  mainly	  of	  processed	  fats	  and	  simple	  sugars	  that	   can	   be	   detrimental	   to	   overall	   health	   and	   brain	   function.	   The	   lack	   of	   vital	   nutrients	  together	  with	   excess	   calories	   increases	   the	   susceptibility	   for	   the	   development	   of	   obesity	  and	   metabolic	   disorders	   (Holmes	   et	   al.,	   2008;	   Danaei	   et	   al.,	   2011).	   On	   the	   contrary,	  Mediterranean	   diet	   is	   shown	   by	   many	   studies	   to	   protect	   from	   a	   number	   of	   diseases,	  including	   stroke	   and	   dementia	   (Psaltopoulou	   et	   al.,	   2013).	   Mediterranean	   diet	   consists	  primarily	  of	  vegetables,	   soft,	  omega-­‐3	  rich	   fats	   such	  as	  olive	  oil	  and	  avocado,	  white	  meat,	  fish	  and	  seafood.	  Similarly,	   traditional	   Japanese	  cuisine	  consists	  mainly	  of	  vegetables,	   fish	  and	  seafood,	  is	  also	  reflected	  in	  the	  long	  life	  expectancy	  of	  the	  Japanese	  (Ozawa	  et	  al.,	  2013).	  Particularly,	  foods	  rich	  in	  antioxidants,	  such	  as	  berries,	  are	  shown	  to	  have	  health-­‐promoting	  effects	  (Hu	  et	  al.,	  2013).	  	  Lack	  of	  physical	  exercise	  decreases	  the	  quality	  of	   life	  and	  increases	  the	  risk	  for	  numerous	  diseases	   (Warburton	   et	   al.,	   2006;	   Reiner	   et	   al.,	   2013).	   In	   two	   separate	   studies	   following	  Harvard	   alumni	   and	   Hawaiian	   men	   with	   Japanese	   ancestry,	   it	   was	   found	   that	   weekly	  exercise	  exceeding	  1000	  kilocalories	   reduces	   the	   risk	  of	  CHD	  (Rodriguez	  et	  al.,	  1994;	  Lee	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and	  Paffenbarger,	  1998).	  With	  2000	  to	  3000	  kilocalorie	  expenditure,	  also	  the	  risk	  for	  stroke	  and	  other	  diseases	  were	   reduced	   (Donahue	  et	   al.,	   1988;	   Sesso	  et	   al.,	   2000).	   Interestingly,	  dietary	   restrictions,	   such	  as	  omission	  of	  proteins	   from	   the	  diet,	   can	  be	  protective	   against	  brain	   ischemia	   induced	   neural	   damage,	   highlighting	   the	   importance	   of	   diet	   in	   the	  prevention	  of	  neuronal	  injury	  (Varendi	  et	  al.,	  2014).	  	  	  Some	  studies	  implicate	  moderate	  alcohol	  consumption	  (1-­‐3	  drinks	  per	  day)	  with	  increased	  protection	   from	  cardiovascular	  disease	  and	  dementia	   in	   comparison	   to	  people	   abstaining	  from	   alcohol	   use	   altogether	   (Solfrizzi	   et	   al.,	   2009;	   Di	  Marco	   et	   al.,	   2014).	   Some	   alcoholic	  beverages,	  such	  as	  red	  wine,	  contain	  resveratrol	  and	  other	  antioxidants	  that	  are	  associated	  with	  neuroprotective	  functions	  (Pinder	  and	  Sandler,	  2004).	  However,	  prevalence	  of	  various	  cancers	   is	   increased	   with	   alcohol	   consumption,	   from	   as	   low	   as	   2-­‐3	   drinks	   per	   day,	  especially	   if	   combined	   with	   smoking	   (Wienecke	   et	   al.,	   2015;	   Zhang	   and	   Zhong,	   2015).	  Hence,	  a	  fine	  balance	  exists	  between	  health	  promoting	  and	  degrading	  effects	  of	  alcohol.	  
2.2.4.4	  Type	  2	  diabetes	  mellitus	  and	  brain	  insulin	  resistance	  Type	  2	  diabetes	  mellitus	  accounts	   for	  roughly	  90%	  of	  diabetes	  cases	   in	   the	  USA,	  affecting	  roughly	  8%	  (25.8	  million)	  of	  all	  Americans	  (Yarchoan	  and	  Arnold,	  2014).	  The	  coincidence	  of	  T2DM	  with	  AD	  is	  26.9%	  among	  people	  65	  years	  and	  older	  (Yarchoan	  and	  Arnold,	  2014).	  The	   links	   between	   the	   two	   diseases	   have	   been	   shown	   through	   multiple	   retrospective	  studies.	  The	  main	  mechanism	  is	  thought	  to	  be	  related	  to	  increased	  brain	  insulin	  resistance	  and	   its	   downstream	   effects	   on	   the	   suppression	   of	   neuronal	   survival	   signaling,	   increased	  amyloid	   and	  Tau	  pathology,	   and	   increased	   stress	   signaling	   (Yarchoan	   and	  Arnold,	   2014).	  Hyperglycemia	   can	   lower	   neuronal	   viability	   via	   increased	   oxidative	   stress	   and	   by	  facilitating	  the	  accumulation	  of	  advanced	  glycation	  end	  products	  in	  the	  vasculature	  and	  the	  brain	   in	  animal	  models	   (Deane	  et	  al.,	   2003;	  Klein	  and	  Waxman,	  2003;	  Singh	  et	  al.,	   2001).	  Interestingly,	   brain	   insulin	   resistance	   is	   increased	   in	   MCI	   patients	   who	   convert	   to	   AD	  (Morris	   et	   al.,	   2014).	   T2DM	   is	   treated	  with	   insulin	   and	   insulin-­‐sensitizing	   drugs	   such	   as	  metformin,	  which,	  however,	  was	  recently	  associated	  with	  increased	  dementia	  risk	  due	  to	  its	  side	   effects	   on	   vitamin-­‐B12	   absorption	   (Moore	   et	   al.,	   2013).	   Taken	   together,	   proper	  glycemic	  control	  is	  crucial	  for	  neuronal	  function.	  
2.2.4.5	  Hypercholesterolemia,	  atherosclerosis	  and	  cardiovascular	  disease	  Hypercholesterolemia	   is	   a	   known	   risk	   factor	   for	   AD	   (Umeda	   et	   al.,	   2012).	  Hypercholesterolemia	   is	   defined	   by	   increased	   plasma	   concentrations	   of	   circulating	   low-­‐density	   lipoprotein	  (LDL)	  cholesterol	  (LDL-­‐C)	  and	  total	  cholesterol.	  Hypercholesterolemia	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and	   hypertension	   promote	   susceptibility	   to	   atherosclerosis,	   the	   formation	   of	  atherosclerotic	  plaques	  and	  the	  hardening	  and	  thinning	  of	  the	  arterial	  walls	  (Libby,	  2002).	  Cardiovascular	  disease	  is	  prominent	  in	  Western	  countries,	  which	  is	  largely	  attributed	  to	  the	  Western	   diet	   and	   lack	   of	   exercise	   that	   promote	   obesity,	   atherosclerosis,	   high	   blood	  pressure	  and	  T2DM	  (Staimez	  et	  al.,	  2014;	  Kotze	  and	  van	  Rensburg,	  2012).	  The	  combination	  of	   excess	   LDL-­‐C	   and	   increased	   cellular	   stress	   results	   in	   the	   production	   of	   oxidized	   LDL,	  which	  may	  increase	  Aβ	  production	  and	  AD	  susceptibility	  in	  association	  with	  CVD	  (Murr	  et	  al.,	   2014;	  Dias	   et	   al.,	   2014b;	  Draczynska-­‐Lusiak	   et	   al.,	   1998).	   Increased	   cholesterol	   in	   the	  CNS	   and	   neuronal	   cell	   membranes	   also	   promotes	   Aβ	   generation,	   Aβ	   oligomer	   formation	  and	  abnormal	  Tau	  phosphorylation,	  thus	  contributing	  to	  LOAD	  pathogenesis	  (Umeda	  et	  al.,	  2012;	  Dias	  et	  al.,	  2014b).	  	  
2.2.4.6	  Brain	  ischemia	  and	  traumatic	  brain	  injury	  Ischemia	  and	  traumatic	  brain	  injury	  (TBI)	  increase	  susceptibility	  to	  NDDs	  (Goldberg	  et	  al.,	  2012).	   Prevalence	   of	   CNS	   disorders	   including	   depression,	   schizophrenia,	   AD	   and	   PD,	   are	  significantly	   higher	   in	   occupations	   where	   head	   injuries	   are	   commonplace	   (McKee	   and	  Robinson,	   2014).	   Recently,	   the	   National	   Institute	   of	   Health	   allocated	   significant	   funds	  towards	  research	  in	  developing	  treatments	  against	  TBI	  largely	  due	  to	  an	  increasing	  number	  of	   professional	   athletes	   and	   war	   veterans	   that	   suffer	   from	   NDDs	   and	   associated	  psychological	   disorders	   (Otis	   et	   al.,	   2011;	   Makdissi	   et	   al.,	   2014).	   These	   professions	   are	  associated	  with	   increased	  prevalence	  of	  mild	  TBI,	   including	  microvascular	   injuries	  within	  the	  brain	  that	  are	  shown	  to	  increase	  Tau-­‐related	  local	  stress	  burden	  in	  afflicted	  brain	  areas	  (Yang	  et	  al.,	  2015).	  
2.2.4.7	  Smoking	  There	   is	   some	   evidence	   that	   nicotine,	   as	   a	   stimulant,	   may	   improve	   cognitive	   functions.	  However,	   the	   evidence	   for	   increased	   morbidity	   due	   to	   smoking	   is	   mostly	   undisputed.	  Smoking	  is	  known	  to	  decrease	  lifespan	  e.g.	  by	  contributing	  to	  the	  risk	  of	  numerous	  cancers	  and	  NDDs	  (Chang	  et	  al.,	  2014a).	  	  	  The	  risk	  factors	  and	  protective	  measures	  against	  LOAD	  are	  summarized	  in	  Figure	  2.6.	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Figure	  2.6:	  Summary	  of	  the	  risks	  and	  preventive	  measures	  against	  LOAD	  risk.	  	  
2.2.5	  AD	  therapeutics	  –	  current	  therapies	  and	  potential	  targets	  There	  are	  currently	  only	  symptomatic	  drug	  treatments	  available	  for	  AD.	  The	  two	  classes	  of	  drugs	  approved	  for	  the	  treatment	  of	  AD	  are	  acetylcholinesterase	  (AChE)	  inhibitors	  for	  mild-­‐to-­‐moderate	   AD,	   and	   NMDA	   receptor	   antagonist	   memantine	   for	   moderate-­‐to-­‐severe	   AD	  (Aisen	  et	  al.,	  2012).	  The	  FDA	  first	  approved	  these	  drugs	  for	  AD	  treatment	  in	  1993	  and	  2003,	  respectively	   (2003;	   1993).	   AChE	   inhibitors	   prevent	   the	   degradation	   of	   the	  neurotransmitter	  ACh	  and	  thus	  boost	  cholinergic	  signaling	  pathways	  and	  improve	  cognitive	  function.	   Recently,	   some	   anticholinergic	   drugs	   used	   to	   treat	   urinary	   incontinence	   were	  implicated	   in	   promoting	   AD	   progression,	   highlighting	   the	   importance	   of	   functional	  cholinergic	   networks	   to	   brain	   function	   (Torvinen-­‐Kiiskinen	   et	   al.,	   2014).	   NMDA	   receptor	  antagonist	  memantine,	   on	   the	   other	   hand,	   reduces	   glutamate	   excitotoxicity	   and	   neuronal	  cell	  death	  (Volbracht	  et	  al.,	  2006).	  Many	  AD	  patients	  benefit	  from	  the	  available	  medication,	  especially	  if	  started	  during	  the	  earlier	  phases	  of	  the	  disease.	  However,	  they	  have	  little	  or	  no	  effect	   on	   disease	   progression.	   Additionally,	   some	   patients	   have	   poor	   tolerance	   to	   the	  available	   drugs	   due	   to	   side	   effects	   (Assal	   and	   van	   der	  Meulen,	   2009;	   Seltzer	   et	   al.,	   2004;	  Wallin	  et	  al.,	  2004).	  	  	  The	  major	  obstacle	  in	  finding	  a	  cure	  for	  AD	  is	  the	  long	  prodromal	  phase	  associated	  with	  the	  disease.	  There	  are	  currently	  many	  AD	  drugs	  in	  clinical	  trials,	  with	  several	  antibodies	  against	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Aβ,	  Tau	  and	  β/γ-­‐secretases	  having	  reached	  phase	  III	  clinical	  trials.	  However,	  they	  have	  thus	  far	  failed	  to	  provide	  significant	  protection	  or	  improvement	  in	  cognitive	  measures,	  although	  the	   reduction	   in	   CSF	   Aβ	   levels	   has	   been	   prominent	   with	   Aβ	   antibodies	   (Salloway	   et	   al.,	  2014).	   It	   is	   postulated	   that	   Aβ-­‐based	   therapeutics	   might	   not	   be	   effective	   in	   mild-­‐to-­‐moderate	  AD	  patients,	  and	  that	  more	  MCI	  and	  cognitively	  normal	  at-­‐risk	  patients	  should	  be	  enrolled	  into	  AD	  clinical	  trials	  (Vellas	  et	  al.,	  2013).	  This	  poses	  another	  problem	  since	  not	  all	  MCI	   patients	   or	   at-­‐risk	   individuals	   convert	   to	   AD.	   New	   diagnostic	   markers,	   as	   discussed	  earlier,	  may	  provide	  better	  methods	   for	   selecting	   relevant	   study	  groups	   and	   increase	   the	  success	  of	  future	  clinical	  trials.	  	  	  The	   plasma	   lipid	   profiles	   characterized	   recently	   (Mapstone	   et	   al.,	   2014)	   suggest	   that	  markers	   of	   cell	   membrane	   integrity	   may	   act	   as	   both	   biomarkers	   as	   well	   as	   therapeutic	  targets	   in	   the	   future.	   Interestingly,	   a	   dietary	   supplement	   rich	   in	   precursors	   for	   the	  formation	   of	   plasma	  membrane	   and	   synapses	  was	   recently	   developed	   by	  Nutricia	   and	   is	  currently	  one	  of	   the	  most	   studied	  anti-­‐AD	  dietary	   supplements	   (van	  Wijk	   et	   al.,	   2014;	  de	  Waal	   et	   al.,	   2014).	   Statins,	   3-­‐hydroxy-­‐3-­‐methyl-­‐glutaryl-­‐CoA	   (HMG-­‐CoA)	   reductase	  inhibitors,	  prevent	  de	  novo	  production	  of	  cholesterol	  and	  are	  the	  most	  commonly	  used	  class	  of	   anti-­‐hypercholesterolemia	   drugs,	   but	   also	   have	   pleiotropic	   functions	   affecting	   APP	  metabolism	  (Malfitano	  et	  al.,	  2014).	  Statins	  are	  shown	  to	  have	  some	  potential	  to	  reduce	  the	  incidence	  of	  LOAD,	  however,	   the	  evidence	   is	   currently	   conflicting	   (Malfitano	  et	  al.,	  2014).	  Alternative	   approaches	   such	   as	   anti-­‐inflammatory	   drugs	   and	   neuroprotective	   factors	   are	  also	  being	  actively	  explored,	  but	  thus	  far	  there	  have	  not	  been	  any	  breakthroughs	  in	  clinical	  trials	  (Chen	  et	  al.,	  2011;	  Sood	  et	  al.,	  2014;	  Skerrett	  et	  al.,	  2014).	  	  	  Taken	   together,	   there	   is	   an	   immediate	   and	   critical	   need	   to	   develop	   novel	   AD	   diagnostic	  markers	  and	  disease-­‐modifying	  treatments	  to	  prevent	  neuronal	  cell	  death	  and	  dysfunction	  associated	  with	  AD	  pathology.	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2.3	  Neuronal	  cell	  death	  	  The	   loss	   of	   neurons	   and	   neuronal	   function	   is	   a	   unifying	   feature	   of	   NDDs.	   Neurons	   can	  undergo	  many	  different	  forms	  of	  cell	  death.	  The	  classical	  separation	  of	  cell	  death	  falls	  into	  controlled	   and	   uncontrolled	   cell	   death,	   termed	   apoptosis	   and	   necrosis,	   respectively.	   This	  separation	  is	  adequate	  in	  broad	  terms,	  but	  there	  are	  numerous	  subtypes	  of	  both,	  differing	  on	  the	  level	  of	  cellular	  energy	  needed	  and	  the	  involvement	  of	  different	  signaling	  pathways	  and	  cell	  organelles,	  such	  as	  autophagosomes	  in	  autophagic	  cell	  death	  (Uchiyama,	  2001).	  	  
2.3.1	  Types	  of	  cell	  death	  
2.3.1.1	  Apoptosis	  Apoptotic	  cell	  death	   is	  an	  active	  form	  of	  cell	  death,	  also	  known	  as	  programmed	  cell	  death	  type	  I.	  Cells	  undergoing	  apoptosis	  require	  energy	   in	  the	   form	  of	  ATP	  to	  produce	  proteins,	  such	   as	   caspases,	   that	   aid	   in	   dismantling	   cellular	   components	   in	   an	   orchestrated	   fashion.	  Apoptosis	   is	   prominent	   in	   physiological	   conditions	   during	   the	   embryonic	   and	   postnatal	  development	  when	   excess	   cells	   are	   produced	   and	   need	   to	   be	   subsequently	   eliminated	   to	  shape	  the	  mature	  organs,	  without	  subjecting	  the	  surrounding	  tissues	  to	  harm	  (Torchinsky	  and	  Toder,	  2004).	  Another	  physiological	  function	  of	  apoptosis	  is	  to	  dispose	  of	  damaged	  or	  unwanted	  cells,	  which	  is	  extremely	  crucial	  in	  the	  prevention	  of	  cancer	  and	  tumor	  formation	  (Czabotar	   et	   al.,	   2014).	   However,	   the	   tight	   control	   over	   the	   apoptotic	   processes	   can	   be	  disturbed	   due	   to	   inflammation,	  mutations	   or	   external	   stressors	   in	   a	   number	   of	   diseases,	  including	  cancers,	  NDDs,	  brain	  ischemia	  and	  autoimmune	  diseases	  (Hetts,	  1998).	  	  	  Apoptotic	  cells	  have	  distinct	  morphological	  hallmarks.	  Apoptotic	  cells	  exhibit	  cell	  shrinking,	  membrane	   blebbing	   and	   nuclear	   chromatin	   condensation	   and	   fragmentation.	   The	  phosphatidylserine	   lipid-­‐rich	   inner	   leaflet	   of	   the	   cell	  membrane	  also	  becomes	  exposed	   to	  the	   extracellular	   side	   (Susin	   et	   al.,	   2000;	   Kroemer	   et	   al.,	   1995).	   Cellular	   components	   are	  cleaved	   and	   degraded	   by	   caspases,	   calpains	   and	   other	   proteases.	   Apoptosis	   prevents	  extracellular	  stress	  and	   inflammation	  by	  the	  controlled	  packaging	  and	   lysis	  of	   the	  cellular	  structures	   and	   their	   subsequent	   release	   in	   intact	   vesicles.	   These	   apoptotic	   bodies	   are	  membrane-­‐surrounded	  vesicles	  that	  contain	  cleaved	  cell	  fragments	  and	  proteins	  (Kroemer	  et	  al.,	  1995;	  Hetts,	  1998).	  They	  are	  formed	  at	  the	  final	  stages	  of	  apoptosis	  and	  are	  taken	  up	  by	  macrophages	  and	  surrounding	  cells	  by	  phagocytosis	  for	  recycling	  or	  further	  processing	  (Krysko	  et	  al.,	  2006).	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Parallel	  molecular	  cascades	   that	   involve	  many	  cellular	  organelles	  exert	  strict	  control	  over	  apoptosis.	   The	   mitochondrion	   is	   a	   central	   organelle	   in	   apoptotic	   control.	   Pro-­‐	   and	   anti-­‐apoptotic	   proteins	   provide	   several	   layers	   of	   control	   before	   the	   initiation	   of	   proteolytic	  processes	   takes	  place	   (Susin	   et	   al.,	   2000).	  The	   relative	  balance	  of	   anti-­‐	   and	  pro-­‐apoptotic	  members	  of	   the	  B-­‐cell	   lymphoma	  2	  (Bcl-­‐2)	   family	  of	  proteins	  control	  mitochondrial	  outer	  membrane	   permeabilization	   (MOMP)	   by	   affecting	   the	   structure	   and	   opening	   of	   the	  mitochondrial	  permeability	  transition	  pore	  (MPTP).	  Increased	  MOMP	  due	  to	  MPTP	  opening	  leads	   to	   the	   release	   of	   pro-­‐apoptotic	   proteins	   such	   as	   cytochrome-­‐c	   (cyt-­‐c),	   apoptosis-­‐inducing	   factor	   (AIF)	  and	  apoptotic	  protease	  activating	   factor	  1	   (APAF1)	   into	   the	  cytosol,	  thus	  promoting	  apoptosis	  (Marino	  et	  al.,	  2014;	  Galluzzi	  et	  al.,	  2012;	  Marchetti	  et	  al.,	  1996).	  Apoptotic	  pathways	  are	  described	  in	  greater	  detail	  in	  the	  upcoming	  chapter	  (2.3.2).	  
2.3.1.2	  Necrosis	  Necrotic	   cell	   death	   often	   takes	   place	   following	   exposure	   to	   external	   factors	   that	   leads	   to	  uncontrolled	  cell	  death.	  Physical	  traumas,	  toxins	  or	  infection	  are	  typical	  causes	  of	  necrosis.	  The	  progression	  of	  necrotic	  cell	  death	  can	  vary	  depending	  on	  stimulus,	  but	  it	  often	  involves	  the	   disruption	   of	   the	   cell	   membrane,	   loss	   of	   organelle	   integrity	   and	   the	   swelling	   of	   the	  mitochondria	  (Vanden	  Berghe	  et	  al.,	  2010;	  Bizik	  et	  al.,	  2004).	  Bursting	  necrotic	  cells	  release	  their	   intracellular	   contents	   to	   evoke	   stress	   and	   inflammation	   in	   the	   surrounding	   tissues	  (Vanden	  Berghe	  et	  al.,	  2014).	  In	  the	  CNS,	  large	  areas	  of	  the	  brain	  may	  become	  necrotic	  after	  a	  stroke	  or	  hemorrhage,	  due	  to	  an	  increase	  in	  intracranial	  pressure	  further	  reducing	  blood	  flow	  and	  oxygen	  and	  glucose	  supply	  to	  the	  brain	  tissue	  (Li	  et	  al.,	  1998;	  Zhang	  et	  al.,	  1993).	  This	  is	  often	  referred	  to	  as	  the	  necrotic	  lesion	  core,	  whereas	  other	  cell	  death	  types,	  such	  as	  apoptosis	   and	   excitotoxic	   cell	   death	   are	   more	   common	   at	   the	   peripheral	   regions	   of	   the	  lesion	   (Touzani	   et	   al.,	   2001;	   Li	   et	   al.,	   1998).	   The	   size	   of	   the	   necrotic	   lesion	   is	   highly	  dependent	  on	  the	  duration	  of	   the	  trauma,	  how	  fast	   the	  affected	  area	  can	  be	  reoxygenated	  and	   the	   intracranial	   pressure	   alleviated	   (Alexander	   et	   al.,	   2010).	   In	   practice,	   treatment	  within	   the	   first	   four	   hours	   of	   stroke	   is	   associated	   with	   a	   significantly	   better	   prognosis	  (Muchada	  et	  al.,	  2014).	  
2.3.1.3	  Necroptosis	  Necroptosis	   is	  described	  as	  a	   form	  of	  programmed	  necrosis	   that	  exhibits	   features	  of	  both	  necrosis	   and	   apoptosis	   (Kaczmarek	   et	   al.,	   2013).	   Necroptosis	   can	   be	   induced	   by	   the	  inflammatory	  adipokine	  tumor	  necrosis	  factor	  alpha	  (TNFα)	  signaling	  and	  is	  dependent	  on	  the	   serine-­‐threonine	   kinase	   receptor-­‐interacting	   protein	   (Vanlangenakker	   et	   al.,	   2011;	  Wallach	  et	  al.,	  1997).	  Necroptosis	  consists	  of	  signaling	  and	  disintegration	  phases	  similar	  to	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apoptosis,	   whereas	   necrosis	   lacks	   this	   signaling	   phase	   (Vanden	   Berghe	   et	   al.,	   2010).	   In	  some	   apoptotic	   conditions,	   both	   exogenous	   and	   endogenous	   apoptosis	   inhibitors	   such	   as	  caspase	  inhibitors	  and	  Bcl-­‐2,	  respectively,	  can	  delay	  or	  prevent	  the	  onset	  of	  apoptosis	  and	  alternatively	  induce	  other	  modes	  of	  cell	  death	  including	  necroptosis	  or	  secondary	  necrosis	  (Vanden	  Berghe	  et	  al.,	  2010;	  Vanden	  Berghe	  et	  al.,	  2014).	   In	   the	  absence	  of	  phagocytosis,	  apoptotic	   cells	   can	   undergo	   secondary	   necrosis,	   releasing	   cellular	   contents	   similar	   to	  necrosis.	   This	   is	   particularly	   prominent	   in	   many	   in	   vitro	   models	   of	   cell	   death	   that	   lack	  phagocytosing	  cells	  (Emgard	  et	  al.,	  2002).	  	  
2.3.1.4	  Autophagic	  cell	  death	  Autophagy	   is	   a	   process	   of	   organizing	   intracellular	   constituents	   and	   organelles	   into	  autophagosomes,	   characterized	   by	   a	   double	   plasma	   membrane,	   which	   are	   subsequently	  fused	  with	   lysosomes	  to	  degrade	  the	  contents	  of	   the	  autophagosomes	  (Mizushima,	  2007).	  Autophagy	   is	  regulated	  by	  autophagy-­‐related	  genes	  (ATG)	  and	   inhibited	  by	  TOR-­‐signaling	  (Mizushima	   et	   al.,	   1998).	   By	   fusing	   the	   autophagosomes	   with	   the	   acidic	   lysosomes,	   the	  cargo	   is	  brought	   into	  contact	  with	  hydrolases	  and	  the	  constituents	  are	  broken	   into	  amino	  acids	   and	   lipids	   that	   may	   be	   utilized	   as	   an	   energy	   source	   or	   building	   blocks	   for	   protein	  synthesis.	   Autophagy	   is	   primarily	   an	   adaptive	   response	   to	   cellular	   starvation	   or	   cellular	  stressors.	  Autophagy	  can	  prolong	  the	  life	  of	  the	  cell	  by	  clearing	  and	  re-­‐utilizing	  damaged	  or	  underperforming	  organelles	   (Lin	  et	  al.,	  2014;	  Mizushima	  et	  al.,	  1998;	  Levine	  et	  al.,	  2011).	  However,	   the	   prevalence	   of	   autophagocytic	   vacuoles	   in	   dying	   cells	   suggests	   the	  involvement	  of	  autophagy	  in	  cell	  death	  (Wang	  et	  al.,	  2006).	  Autophagy	  is	  known	  to	  precede	  certain	   forms	   of	   apoptotic	   cell	   death;	   hence	   the	   distinction	   remains	   unclear	   whether	  autophagy	   itself	   can	   promote	   cell	   death	   (Shimizu	   et	   al.,	   2004).	   Nevertheless,	   the	  dysregulation	   of	   ATGs	   and	   autophagy	   is	   implicated	   in	  many	   NDDs	   such	   as	   PD,	   although	  dysfunctional	  rather	  than	  excessive	  autophagy	  is	  generally	  shown	  to	  be	  more	  detrimental	  for	  neurons	  (Debnath	  et	  al.,	  2005;	  Wang	  et	  al.,	  2006).	  
2.3.1.5	  Excitotoxic	  cell	  death	  Excitotoxic	   cell	   death	   involves	   an	   increase	   in	   cytosolic	   calcium	   (Ca2+)	   levels,	   either	   by	  currents	   flowing	   into	   the	   cell	   through	   receptors	   including	   the	   N-­‐methyl-­‐D-­‐aspartate	  (NMDA)	   receptor,	   α-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic	   acid	   (AMPA)	  receptor	   and	   kainate	   receptors,	   or	   through	   the	   release	   of	   Ca2+	   from	   intracellular	   stores	  (Galluzzi	   et	   al.,	   2012).	   Intracellular	   calcium	   concentrations	   are	   tightly	   controlled,	   with	   a	  roughly	   10000-­‐fold	   gradient	   maintained	   between	   extracellular	   and	   cytosolic	   Ca2+	  concentrations.	   	   Thus,	   even	   small	   local	   increases	   of	   cytosolic	   of	   Ca2+	   through	   channel	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opening	   can	   act	   as	   potent	   cellular	   signals,	   although	   prolonged	   or	   extensive	   rise	   in	  intracellular	   Ca2+	   can	   be	   detrimental	   to	   the	   cell.	   This	   may	   be	   mediated	   by	   an	   excess	   of	  extracellular	   glutamate	   from	   hyperactive	   synapses	   that	   increases	   glutamate	   receptor	  activity	  and	  promotes	  excitotoxicity	  (Nicholls,	  2004).	  Prolonged	  low	  levels	  of	  excitotoxicity	  due	  to	  an	  imbalance	  in	  glutamate	  receptor	  activation	  can	  also	  increase	  the	  susceptibility	  to	  further	   secondary	   insults	   by	   depleting	   the	   Ca2+	   buffering	   capacity	   of	   the	   cell	   rather	   than	  causing	   acute	   cell	   toxicity	   and	   death	   (Yadava	   and	   Nicholls,	   2007;	   Johnson-­‐Cadwell	   et	   al.,	  2007).	  	  	  ER	  is	  the	   largest	   intracellular	  Ca2+	  store	  (Kaufman	  and	  Malhotra,	  2014;	  Malli	  et	  al.,	  2005).	  Additionally,	   mitochondria	   and	   a	   host	   of	   Ca2+-­‐binding	   proteins	   such	   as	   calmodulin	  sequester	  excess	  cytosolic	  Ca2+	  (Stout	  et	  al.,	  1998).	  Disruption	  of	  organelle	  integrity	  and	  the	  release	   of	   Ca2+	   can	   hence	   cause	   excitotoxicity	   similar	   to	   channel-­‐mediated	   excitotoxicity	  (Ruiz	  et	  al.,	  2009;	  Van	  Moorhem	  et	  al.,	  2010;	  Foradori	  et	  al.,	  2007).	  Excitotoxic	   cell	  death	  has	  features	  resembling	  both	  apoptosis	  and	  necrosis,	  including	  mitochondrial	  swelling	  and	  drop	  in	  ATP	  levels,	  depending	  on	  the	  level	  and	  duration	  of	  the	  excitotoxic	  injury	  (Kroemer	  et	   al.,	   2009;	   Kroemer	   et	   al.,	   2005).	   Excitotoxicity	   is	   a	   prominent	   feature	   in	   AD	   and	   other	  NDDs.	   The	   regions	   surrounding	   Aβ	   plaques	   are	   particularly	   prone	   to	   network	   imbalance	  and	  are	  shown	  to	  exhibit	  increased	  levels	  of	  excitotoxicity	  (Ong	  et	  al.,	  2013;	  Harkany	  et	  al.,	  2000).	  
2.3.1.6	  Other	  forms	  of	  cell	  death	  Parthanatos	   is	   a	   form	   of	   poly	   (ADP-­‐ribose)	   polymerase-­‐1	   (PARP-­‐1)	   dependent	   cell	   death	  (Andrabi	  et	  al.,	  2008).	  Some	  features	  of	  parthanatos	  resemble	  apoptosis,	  except	  for	  the	  lack	  of	   apoptotic	  body	   formation,	   caspase	   activation	  and	   small	   scale	  DNA	   fragmentation.	  Cells	  lose	   their	   membrane	   integrity	   similar	   to	   necrosis,	   but	   they	   do	   not	   swell	   or	   include	   the	  autophagic	  vacuoles	  characteristic	  of	  autophagic	  cell	  death	  (Wang	  et	  al.,	  2011).	  Cell	  death	  is	  mediated	  by	  AIF,	  which	   is	  normally	  contained	   in	   the	  mitochondrial	   intermembrane	  space	  (Wang	  et	  al.,	  2011;	  Cregan	  et	  al.,	  2002).	  Upon	  parthanatos	   induction,	  AIF	   is	  released	  from	  mitochondria	   and	   translocates	   to	   the	   nucleus	   and	   cytoplasm	   to	   affect	   gene	   transcription	  and	  apoptosome	  formation,	  respectively,	  to	  facilitate	  cell	  death	  (Joza	  et	  al.,	  2009;	  Wang	  et	  al.,	  2004b).	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To	  summarize,	  cells	  can	  undergo	  many	  forms	  of	  cell	  death.	  In	  the	  aging	  brain,	  autophagy	  is	  decreased	   while	   the	   apoptotic	   and	   excitotoxic	   pathways	   become	   more	   active,	   thus	  promoting	  neuronal	  cell	  death	  (Kroemer	  et	  al.,	  2009;	  Galluzzi	  et	  al.,	  2012).	  	  
2.3.2	  Molecular	  control	  of	  neuronal	  cell	  death	  Renewal	  of	  mammalian	  CNS	  neurons	  is	  limited	  to	  several	  niches	  of	  stem	  cells	  in	  the	  dentate	  gyrus	   of	   the	   hippocampus	   and	   the	   subventricular	   zone	   of	   the	   lateral	   ventricles,	   which	  replenish	   the	   cells	   of	   the	   hippocampus	   and	   limbic	   system,	   respectively	   (Nogueira	   et	   al.,	  2014;	  Bottai	  et	  al.,	  2003).	  As	  a	  result,	  most	  neurons	  need	  to	  function	  efficiently	  for	  years	  or	  even	  decades.	  However,	  sheer	  high	  numbers	  of	  neurons	  do	  not	  ensure	  proper	  CNS	  function.	  The	   molecular	   machineries	   protecting	   neurons	   and	   preventing	   neuronal	   cell	   death	   are	  intertwined	   with	   plasticity	   signals	   such	   as	   neurotrophic	   factor	   signaling,	   energy	  metabolism	  and	  ion	  homeostasis	  (Nicholls	  and	  Budd,	  2000;	  Deigner	  et	  al.,	  2000;	  Schonfeld-­‐Dado	  and	  Segal,	  2009).	  On	  the	  other	  hand,	  cell	  death-­‐promoting	  pathways	  are	  also	  essential	  in	  the	  removal	  of	  damaged	  or	  cancerous	  cells.	  Hence,	  several	  layers	  of	  control	  mechanisms	  are	  needed	  to	  ultimately	  decide	  the	  fate	  of	  the	  cell.	  
2.3.2.1	  Intrinsic	  and	  extrinsic	  apoptotic	  pathways	  The	   two	  main	   apoptotic	   pathways	   are	   the	   intrinsic	   and	   extrinsic	   pathways.	   The	   intrinsic	  pathway	  is	  activated	  by	  a	  number	  of	  internal	  stress	  stimuli,	  such	  as	  excessive	  cytosolic	  Ca2+,	  hypoxia	  or	  trophic	  factor	  deprivation	  (Galluzzi	  et	  al.,	  2012;	  Ola	  et	  al.,	  2011).	  The	  activation	  of	  pro-­‐apoptotic	  Bcl-­‐2	  family	  proteins	  Bax	  and	  Bim	  inhibit	  their	  anti-­‐apoptotic	  counterparts	  Bcl-­‐2	   and	   Bcl-­‐XL	   and	   promote	   MOMP	   (Ola	   et	   al.,	   2011).	   AIF,	   cyt-­‐c	   and	   SMAC/Diablo	   are	  released	   from	   the	  mitochondria	   and	  promote	  DNA	   fragmentation,	   apoptosome	   formation	  and	  the	  activation	  of	  effector	  caspases	  (Samuel	  et	  al.,	  2006;	  Welsh	  et	  al.,	  2010).	  The	  effector	  caspases,	   mainly	   caspases	   3	   and	   9	   in	   neurons,	   are	   highly	   specific	   proteases	   targeting	  cysteine-­‐aspartyl	   protein	   residues	   and	   are	   activated	   by	   tetramer	   formation	   and	  autocleavage	  (Yuan	  and	  Yankner,	  2000).	  The	  widespread	  processing	  of	  proteins	  results	   in	  the	  inactivation	  of	  repair	  mechanisms,	  DNA	  cleavage,	  increased	  MOMP	  and	  the	  initiation	  of	  proteolytic	  cascades	  (Figure	  2.7)	  (Miura,	  2010;	  Ola	  et	  al.,	  2011).	  	  The	   extrinsic	   pathway	   is	   activated	   by	   an	   external	   ligand,	   such	   as	   proNGF,	   TNFα	   or	   Fas	  ligand,	  binding	  to	  a	  cell	  surface	  death	  receptor,	  such	  as	  p75,	  TNFα	  receptor	  or	  Fas	  receptor,	  respectively	   (Wallach	   et	   al.,	   1997).	   	   This	   activates	   the	   initiator	   caspases	   (6,	   8	   or	   10)	   by	  dimerization	   (Bredesen	  et	  al.,	  2006).	  The	   initiator	   caspases	  can	  activate	  effector	   caspases	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directly,	  but	  also	   indirectly	   through	  the	  activation	  of	  Bid	  by	   truncation	   into	   truncated	  Bid	  (tBid),	   which	   antagonizes	   Bcl-­‐2	   and	   promotes	   Bak	   oligomerization	   and	   cyt-­‐c	   release	  through	  MOMP	  formation	  (Wei	  et	  al.,	  2000;	  Marchetti	  et	  al.,	  1996).	  Hence,	  the	  extrinsic	  and	  intrinsic	   apoptotic	   pathways	   converge	   at	   the	   level	   of	   the	   mitochondria	   and	   effector	  caspases.	   Additionally,	   the	   c-­‐Jun	   N-­‐terminal	   kinase	   (JNK)	   pathway	   is	   activated	   by	  phosphorylation	  and	  supports	  the	  expression	  of	  pro-­‐death	  genes	  such	  as	  Bax	  (Dunn	  et	  al.,	  2002;	  Coffey	  et	  al.,	  2002).	  	  	  Mitogen-­‐activated	   protein	   kinases	   (MAPK),	   which	   include	   the	   JNK,	   extracellular	   signal-­‐regulated	   kinase	   1/2	   (ERK1/2),	   ERK5	   and	   p38	   kinases	   (Plotnikov	   et	   al.,	   2011)	   are	  regulators	  of	  apoptotic	  cascades.	  Each	  pathway	  is	  activated	  by	  external	  or	  internal	  signals,	  usually	   stress-­‐related,	   and	   the	   signal	   is	   relayed	   by	   the	   serial	   activation	   of	   MAPK	   kinase	  cascades,	   which	   control	   the	   activation	   of	   cytoplasmic	   and	   nuclear	   targets.	   Hundreds	   of	  potential	   targets	   include	   apoptotic	   modulators	   such	   as	   activating	   transcription	   factor	   2	  (ATF-­‐2)	   and	   c-­‐Jun	   (Plotnikov	   et	   al.,	   2011).	   Many	   cell	   death-­‐causing	   stimulus,	   such	   as	  nutrient	   deprivation,	   initially	   stimulate	   gene	   expression	   changes	   through	   MAPKs,	   which	  lead	  to	  imbalance	  of	  apoptotic	  modulators	  and	  the	  induction	  of	  preprogrammed	  cell	  death	  (Cao	  et	  al.,	  2004;	  Plotnikov	  et	  al.,	  2011;	  Yamagishi	  et	  al.,	  2005;	  Yuan	  and	  Yankner,	  2000).	  Adverse	   changes	   in	   MAPK	   cascades	   are	   implicated	   in	   many	   diseases	   including	   AD	   and	  diabetes,	  reflecting	  their	  importance	  in	  the	  control	  of	  many	  cellular	  functions	  (Plotnikov	  et	  al.,	  2011).	  
2.3.2.2	  Neuroprotective	  pathways	  During	   development,	   neurons	   are	   produced	   in	   excess.	   As	   neuronal	   networks	   begin	   to	  develop,	  neuronal	  pruning	   is	   largely	  driven	  by	   their	  dependence	  on	  neurotrophic	   factors.	  Target	   tissues	   guide	   axons	   and	   promote	   neuronal	   survival	   by	   secreting	   neurotrophic	  factors.	   Common	   neurotrophic	   factors	   in	   the	   CNS	   include	   nerve	   growth	   factor	   (NGF)	  (Angeletti	  et	  al.,	  1968),	  neurotrophin-­‐3	  (NT-­‐3)	  (Kalcheim	  et	  al.,	  1992),	  neurotrophin-­‐4	  (NT-­‐4)	   (Hallbook	   et	   al.,	   1991),	   brain-­‐derived	   neurotrophic	   factor	   (BDNF)	   (Hofer	   and	   Barde,	  1988),	   glial	   cell	   line-­‐derived	   neurotrophic	   factor	   (GDNF)	   (Lin	   et	   al.,	   1993),	   ciliary	  neurotrophic	   factor	   (CNTF)	   (Manthorpe	   et	   al.,	   1986),	   cerebral	   dopamine	   neurotrophic	  factor	   (CDNF)	   (Lindholm	   et	   al.,	   2007)	   and	  mesencephalic	   astrocyte-­‐derived	  neurotrophic	  factor	   (MANF)	   (Petrova	  et	   al.,	   2003;	  Lindholm	  et	   al.,	   2008).	  Neurotrophic	   factors	   interact	  with	  cell	  surface	  receptors,	  such	  as	  the	  Trk-­‐family	  receptors,	  to	   initiate	  signaling	  cascades	  that	  promote	  neuronal	  survival	  and	  promote	  the	  growth	  and	  differentiation	  of	  new	  neurons	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(Klein,	   1994).	   For	   instance,	   mature	   BDNF	   activates	   MAPK,	   phosphatidylinositol	   3-­‐kinase	  (PI3K)	   and	   phosphoinositide	   phospholipase	   C-­‐γ	   kinase	   to	   induce	   autophagy	   and	   prevent	  pro-­‐apoptotic	  pathways	  in	  cultured	  neurons	  (Chen	  et	  al.,	  2013).	  	  	  Neurotrophic	   factors	   have	   unique	   expression	   profiles	   and	   target	   cell	   populations.	   In	   PD,	  significant	   efforts	   have	   been	   made	   to	   develop	   neurotrophic	   factor	   based	   application	  systems	  to	  protect	  and/or	  restore	  striatal	  dopaminergic	  fibers	  (Allen	  et	  al.,	  2013;	  Sun	  et	  al.,	  2005).	   Interestingly,	   immature	   pro-­‐forms	   of	   neurotrophic	   factors,	   such	   as	   proNGF	   and	  proBDNF,	   can	   activate	   pro-­‐apoptotic	   signaling	   through	   binding	   to	   p75	   receptors	   and	   are	  shown	  to	  be	  increased	  in	  the	  brain	  during	  aging	  (Perovic	  et	  al.,	  2013).	  	  	  Neuroprotective	   pathways	   are	   largely	   dependent	   on	   the	   activation	   of	   the	   PI3K,	   which	  promotes	   the	   activation	   of	   Akt,	   induction	   of	   autophagy,	   inhibition	   of	   TOR	   signaling	   and	  inhibition	  of	  GSK3β,	  to	  name	  a	  few	  (Chen	  et	  al.,	  2013).	  PI3K	  pathway	  can	  be	  activated	  by	  a	  number	  of	   stimuli,	   including	  neurotrophic	   factors,	   local	  Ca2+	   currents	   through	  NMDA	  and	  AMPA	  receptors,	  activation	  of	  certain	  G-­‐protein	  coupled	  receptors	  (Pamenter	  et	  al.,	  2008;	  Xifro	  et	  al.,	  2005)	  and	   lipoprotein	  receptors	   (Bock	  et	  al.,	  2003).	   Importantly,	  PI3K	  and	   its	  downstream	   effectors	   promote	   the	   expression	   of	   anti-­‐apoptotic	   molecules	   to	   promote	  neuronal	  survival	  (Boggs	  et	  al.,	  1996;	  Hisatomi	  et	  al.,	  2009;	  Conejero-­‐Goldberg	  et	  al.,	  2014;	  Zhu	  et	  al.,	  2005;	  Repici	  et	  al.,	  2007).	  	  Several	  layers	  of	  pro-­‐survival	  protein	  classes	  exist	  within	  the	  apoptotic	  pathway	  cascades.	  Anti-­‐apoptotic	   Bcl-­‐2	   protein	   family	   members,	   including	   Bcl-­‐2	   and	   Bcl-­‐XL,	   protect	  mitochondrial	   outer	  membrane	   integrity	   and	   prevent	  MOMP	   by	   reducing	  MPTP	   opening	  (Shimizu	   et	   al.,	   2004;	   Czabotar	   et	   al.,	   2014;	   Shindler	   et	   al.,	   1997;	   Ola	   et	   al.,	   2011).	  Downstream	   from	   the	   mitochondria,	   the	   inhibitor	   of	   apoptosis	   (IAP)	   family	   of	   proteins,	  including	  cellular	  IAP	  (cIAP1/2),	  X-­‐linked	  IAP	  (XIAP),	  survivin	  and	  others,	  can	  act	  as	  direct	  endogenous	   caspase	   inhibitors	   (Vanlangenakker	   et	   al.,	   2011;	   Korhonen	   et	   al.,	   2004;	  Maycotte	  et	  al.,	  2008).	  Taken	  together,	  neuroprotective	  mechanisms	  are	  divided	  at	  various	  levels,	   at	   the	   cell	   surface,	   in	   the	   mitochondria	   and	   the	   nucleus,	   providing	   wholesome	  control	  over	  the	  cell	  fate	  (Figure	  2.7).	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Figure	  2.7:	  A	  simplified	  model	  of	  the	  protective	  and	  apoptotic	  pathways	  within	  the	  cell.	  Blunt-­‐
headed	  lines	  indicate	  inhibition,	  whereas	  arrowheads	  indicate	  activation.	  
2.3.3	  Neuronal	  cell	  death	  in	  AD	  The	  neuronal	  disruptions	  outlined	  by	  the	  amyloid	  cascade	  hypothesis	  (chapter	  2.2.2)	  elicit	  many	   of	   their	   functions	   through	   the	   dysregulation	   of	   pathways	   controlling	   neuronal	  survival.	   Particularly	   the	   toxic	   effects	   of	   Aβ	   accumulation,	   Tau	   hyperphosphorylation,	  neurotransmitter	  and	  synapse	  loss,	  and	  inflammation	  affect	  neuronal	  viability	  in	  AD.	  	  The	  accumulation	  of	  extra-­‐	  and	   intracellular	  Aβ	   is	   involved	   in	  membrane	  disruption,	  Ca2+	  homeostasis,	   glutamate/NMDA	   receptor	   signaling,	  mitochondrial	   effects	   and	   redox	   stress	  (Parihar	   and	   Hemnani,	   2004;	   Yuan	   and	   Yankner,	   2000).	   Aβ-­‐mediated	   Reelin	   signaling	  deficits	  and	  suppression	  of	  NMDA	  receptors	  can	  also	  mediate	  synaptic	  dysfunction	  (Chin	  et	  al.,	  2007;	  Cuchillo-­‐Ibanez	  et	  al.,	  2013;	  Herring	  et	  al.,	  2012;	  Weeber	  et	  al.,	  2002;	  Chen	  et	  al.,	  2010).	   Aβ	   is	   shown	   to	   activate	   GSK3β,	   in	   part	   through	   disrupting	   lipoprotein	   receptor	  signaling,	   thus	  promoting	  Tau	  hyperphosphorylation	  (Cuchillo-­‐Ibanez	  et	  al.,	  2013).	  Tau	   is	  essential	   for	   axonal	   structural	   stability	   and	   proper	   axonal	   trafficking	   of	   vesicles	   and	  organelles.	   Loss	   of	   Tau	   function	   through	   Tau	   hyperphosphorylation	   weakens	   axonal	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integrity	  by	  destabilizing	  axonal	  microtubules	  and	  can	  lead	  to	  axonal	  degeneration.	  	  Axonal	  degeneration	   can	   also	   lead	   to	   the	   loss	   of	   target-­‐derived	   neurotrophic	   factors	   and	  neurotransmitter	   deficits,	   thus	   reducing	   pro-­‐survival	   signaling	   (Allen	   et	   al.,	   2013;	  Chasseigneaux	   and	   Allinquant,	   2012;	   Foster	   et	   al.,	   2011;	   Rothman	   and	   Mattson,	   2013).	  Additionally,	  aggregated	  and	  misfolded	  phosphorylated	  Tau	  has	  toxic	  functions	  within	  the	  cell	   by	   reducing	   cellular	   metabolic	   activity	   and	   inducing	   caspase-­‐3	   dependent	   apoptosis	  (Zilkova	  et	  al.,	  2011;	  Helbecque	  et	  al.,	  2003).	  	  The	   aggregation	   of	   intracellular	   Aβ	   and	   hyperphosphorylated	   Tau	   induce	   the	   UPR	   to	  promote	   the	   clearance	   of	   misfolded	   and	   aggregated	   proteins	   (Narayan	   et	   al.,	   2012).	  However,	   prolonged	  UPR	   activation	   can	   induce	   ER	   stress	   and	  mitochondrial	   dysfunction.	  Interestingly,	   also	   high	   levels	   of	   oxidized	   LDL	   common	   in	   hyperlipidemia	   can	   induce	  neuronal	   ER	   stress	   (Murr	   et	   al.,	   2014;	  Draczynska-­‐Lusiak	   et	   al.,	   1998;	   Tang	   et	   al.,	   2012).	  Mitochondrial	  dysfunction	  and	  increased	  oxidative	  stress	  form	  a	  detrimental	  loop	  that	  can	  increase	   neuronal	   susceptibility	   to	   different	   forms	   of	   cell	   death	   (Iijima-­‐Ando	   et	   al.,	   2012;	  Sullivan	  and	  Brown,	  2005;	  Huang,	  2010).	  Oxidative	   stress	   and	  Aβ	  also	  activate	  microglia,	  which,	   once	   activated,	   secrete	   cytokines	   such	   as	   TNF	   that	   promote	   the	   extrinsic	   pro-­‐apoptotic	  pathway	  (McGeer	  and	  McGeer,	  2004).	  Taken	  together,	  apoptotic	  and	  excitotoxic	  pathways	  are	  activated	  in	  AD,	  promoting	  neuronal	  cell	  death	  (summarized	  in	  Figure	  2.8).	  
	  
Figure	  2.8:	  Summary	  of	  neuronal	  cell	  death-­‐promoting	  pathological	  changes	  in	  AD.	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2.4	  Physiological	  and	  pathophysiological	  roles	  of	  lipoprotein	  receptors	  Lipoprotein	   receptors	   are	   important	   regulators	   of	   biological	   functions	   ranging	   from	  cholesterol	   and	   lipid	   homeostasis,	   brain	   development,	   synaptic	   function,	   neuronal	   cell	  death	   and	   AD	   pathogenesis	   (Tamai	   et	   al.,	   2000;	   Rebeck,	   2009;	  Willnow,	   1999;	   Herz	   and	  Bock,	   2002;	   Beffert	   et	   al.,	   2004).	   The	   lipoprotein	   receptor	   family	   members	   are	   a	  heterogeneous	  group	  of	  type	  I	  membrane	  receptors	  that	  bind	  a	  variety	  of	  ligands	  at	  the	  cell	  surface,	   including	  apolipoproteins,	  Reelin	  and	  wingless-­‐type	  MMTV	  integration	  site	  family	  (Wnt)-­‐family	  members,	   to	   facilitate	   endocytotic	   and/or	   signaling	   functions	   depending	   on	  the	  receptor	  and	  ligand	  in	  question	  (Beffert	  et	  al.,	  2004;	  Lane-­‐Donovan	  et	  al.,	  2014).	  	  
2.4.1	  Properties	  of	  the	  lipoprotein	  receptor	  family	  members	  Lipoprotein	   receptors	   share	   common	   protein	   structures.	   Similar	   extracellular	   domains	  include	  epidermal	  growth	   factor	   (EGF)-­‐like	  domains,	  LDLR	  type	  A	   ligand-­‐binding	  repeats,	  β-­‐propeller	  and	  an	  O-­‐linked	  glycosylation	  domain	  (Figure	  2.9).	  The	  structures	  also	  share	  a	  single	  membrane-­‐spanning	   transmembrane	   anchor	  with	   varying	  degrees	   of	   homology.	   C-­‐terminal	   NPxY	   motifs	   in	   LDLR,	   VLDLR,	   ApoER2	   and	   LRP1	   facilitate	   interactions	   with	  intracellular	   ligands,	  endocytic	   trafficking	  routes	  and	  signal	   transduction	  (Gotthardt	  et	  al.,	  2000).	   The	   core	  members	   of	   the	   family	   include	   the	   LDLR	   (Yamamoto	   et	   al.,	   1984),	   LRP1	  (Herz	   et	   al.,	   1988),	   the	   very-­‐low-­‐density	   lipoprotein	   receptor	   (VLDLR)	   (Takahashi	   et	   al.,	  1992),	   megalin	   (LRP2)	   (Saito	   et	   al.,	   1994),	   apolipoprotein	   E	   receptor	   2	   (ApoER2/LRP8)	  (Novak	   et	   al.,	   1996;	   Kim	   et	   al.,	   1996)	   and	   	   LRP1b	   (Liu	   et	   al.,	   2000).	   Closely	   related	  lipoprotein	  receptors	  include	  LRP4	  (Tomita	  et	  al.,	  1998),	  LRP5	  (Hey	  et	  al.,	  1998;	  Kim	  et	  al.,	  1998)	   and	   LRP6	   (Brown	   et	   al.,	   1998).	   Additional	   members	   with	   structural	   similarities	  include	  sortilin-­‐related	  receptor	  (SORL1/SorLA/LR11)	  (Kanaki	  et	  al.,	  1998;	  Jacobsen	  et	  al.,	  1996),	  LDLR	  class	  A	  domain	  containing	  3	  (LRAD3)	  (Ranganathan	  et	  al.,	  2011)	  and	  LRP10	  (Brodeur	  et	  al.,	  2012).	  This	  literature	  review	  will	  primarily	  focus	  on	  the	  properties	  and	  the	  physiological	   and	   pathophysiological	   significance	   of	   the	   lipoprotein	   receptors	   LDLR,	  ApoER2,	   VLDLR,	   LRP1,	   LRP4,	   LRP5	   and	   LRP6	   (Figure	   2.9),	   introduced	   in	   the	   following	  chapters.	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Figure	   2.9:	   Domain	   structures	   of	   the	   core	   lipoprotein	   receptor	   family	   receptors	   LDLR,	   VLDLR,	  
ApoER2,	  LRP1	  and	  the	  structurally	  related	  protein	  family	  members	  LRP4,	  LRP5	  and	  LRP6.	  
2.4.1.1	  LDLR	  LDLR	   is	   the	   prototype	   member	   of	   the	   lipoprotein	   receptor	   family,	   which	   is	   a	   major	  controller	  of	   circulating	  LDL	  cholesterol	   levels.	  Loss-­‐of-­‐function	  mutations	  or	  deletions	  of	  the	   LDLR	   gene	   predispose	   humans	   to	   increased	   plasma	   cholesterol	   levels	   and	   familial	  hypercholesterolemia	   (Etxebarria	   et	   al.,	   2012).	   Mice	   lacking	   LDLR	   exhibit	   a	   similar	  phenotype	   to	   humans	   with	   loss-­‐of-­‐function	   mutations,	   with	   2-­‐fold	   increase	   in	   plasma	  cholesterol	   levels,	  and	  more	  specifically,	  a	  7-­‐	   to	  9-­‐fold	   increase	   in	   IDL	  and	  LDL	   levels	  and	  reduced	  VLDL	  and	  LDL	  clearance	  half-­‐lives	  (Ishibashi	  et	  al.,	  1993).	  	  Michael	   S.	   Brown	   and	   Joseph	   L.	   Goldstein	   (Brown	   and	   Goldstein,	   1974)	   discovered	   the	  familial	  hypercholesterolemia-­‐causing	  mutations	  of	  LDLR	  in	  1974,	  securing	  them	  the	  Nobel	  price	  in	  Physiology	  or	  Medicine	  in	  1985	  (Motulsky,	  1986).	  Since	  then,	  over	  1200	  different	  mutations	  distributed	  along	  the	  introns,	  the	  promoter	  region	  and	  the	  18	  exons	  of	  the	  LDLR	  gene	  have	  been	  described	  in	  humans	  (Leigh	  et	  al.,	  2008).	  In	  animal	  and	  cell	  models,	  these	  LDLR	  mutations	  are	  shown	  to	  alter	  the	  expression	  level	  of	  LDLR,	  or	  alternatively	  modulate	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the	   transport,	   LDL	   binding	   capability,	   clustering	   or	   recycling	   properties	   of	   the	   receptor	  (Etxebarria	  et	  al.,	  2012;	  Jeon	  and	  Blacklow,	  2005).	  	  	  The	   human	   LDLR	   gene	   encodes	   a	   860	   aa	   protein	   that	   is	   ubiquituously	   expressed,	   most	  prominently	  in	  the	  adrenal	  glands,	  liver,	  heart	  and	  muscle	  (Yamamoto	  et	  al.,	  1984;	  Herz	  and	  Bock,	  2002).	  Within	  the	  cell,	  LDLR	  locates	  primarily	  to	  the	  cell	  membrane,	  Golgi	  apparatus	  and	  endosomes.	  In	  addition	  to	  controlling	  circulating	  cholesterol	  levels,	  LDLR	  is	  implicated	  in	   pathogenic	   lipid	   clearance	   and	   reducing	   inflammation	   (Yao	   et	   al.,	   2010;	  Walley	   et	   al.,	  2014).	   Until	   recently,	   LDLR	  was	   thought	   to	   be	   largely	   dispensable	   in	   the	   CNS	   (Herz	   and	  Bock,	   2002).	  However,	  more	   recent	   studies	   indicate	   that	   LDLR	   overexpression	   can	   affect	  ApoE	  levels	  and	  facilitate	  Aβ	  clearance	  independently	  of	  ApoE	  in	  the	  mouse	  brain	  (Kim	  et	  al.,	  2009b).	  Hence,	  LDLR	  holds	  a	  potential	  role	  in	  Aβ	  metabolism	  in	  AD	  pathogenesis.	  
2.4.1.2	  ApoER2	  In	   contrast	   to	   LDLR,	   ApoER2	   functions	   primarily	   as	   a	   regulator	   of	   neuronal	   migration	  during	  development,	  modulator	  of	  synaptic	   function	  and	  as	  a	  receptor	   for	  selenoproteins,	  which	   are	   selenium-­‐rich	   proteins	   crucial	   for	   sperm	   development	   and	   neuronal	   viability	  (Beffert	   et	   al.,	   2005;	   D'Arcangelo,	   2005;	   Beffert	   et	   al.,	   2006a).	   In	   human	   cohorts,	   a	  nonconservative	   glutamine	   to	   arginine	   substitution	   at	   aa	   position	   952	   (R952Q)	   in	   the	  ApoER2	   gene	   is	   associated	   with	   an	   increased	   risk	   of	   familial	   and	   premature	  myocardial	  infarction	  and	  atherosclerosis	   (Shen	  et	   al.,	   2007;	  Waltmann	  et	   al.,	   2014).	   In	  mice	  models,	  ApoER2	   deletion	   causes	   brain	   development	   defects	   and	   male	   infertility	   (Masiulis	   et	   al.,	  2009;	   Andersen	   et	   al.,	   2003b).	   ApoER2	   deletion	   also	   predisposes	   mice	   to	   neuronal	  degeneration	  when	  fed	  a	  selenium-­‐deficient	  diet	  (Krol	  et	  al.,	  2012).	  	  	  ApoER2	  (aka	  LRP8)	  gene	  was	  first	  discovered	  in	  1996	  by	  the	  group	  of	  Tokuo	  Yamamoto	  in	  Tokyo	  (Kim	  et	  al.,	  1996).	  ApoER2	  expression	  is	  mainly	  restricted	  to	  the	  brain,	  placenta	  and	  testis	  (Kim	  et	  al.,	  1996),	  with	  lower	  expression	  levels	  reported	  in	  blood	  platelets	  (Riddell	  et	  al.,	   1999),	   endothelial	   cells	   (Korschineck	   et	   al.,	   2001)	   and	   macrophages	   (Baitsch	   et	   al.,	  2011).	   Within	   the	   CNS,	   ApoER2	   is	   detected	   in	   the	   cerebellum,	   cortical	   neurons,	  hippocampus,	   olfactory	   bulb	   and	   the	   choroid	   plexus	   of	   the	   blood	   brain	   barrier	   (BBB)	  (Hirota	   et	   al.,	   2014;	   Reddy	   et	   al.,	   2011).	   ApoER2	   expression	   is	   especially	   strong	   in	   the	  Purkinje	  cells	  of	  the	  cerebellum	  and	  the	  developing	  brain,	  where	  it	  acts	  as	  a	  Reelin	  signaling	  receptor	  (Burk	  et	  al.,	  2014).	   	  ApoER2	  has	  been	  reported	  to	  mostly	   localize	   to	  cholesterol-­‐
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rich	  lipid	  rafts	  of	  the	  plasma	  membrane	  in	  cells,	  reducing	  the	  internalization	  rate	  of	  ApoER2	  in	  comparison	  to	  the	  closely-­‐related	  VLDLR	  (Cuitino	  et	  al.,	  2005).	  	  	  The	  870	  aa	  ApoER2	  protein	  is	  encoded	  by	  the	  LRP8	  gene.	  ApoER2	  can	  undergo	  complicated	  patterns	  of	  alternative	  splicing	  of	  the	  exons	  5,	  7,	  9,	  16	  and	  19.	  Ligand	  binding	  repeats	  4-­‐6	  are	  encoded	  by	  exon	  5,	  which	  is	  invariably	  spliced	  from	  the	  mature	  form.	  Exon	  7	  codes	  for	  a	  ligand	  binding	  repeat	  8,	  exon	  9	  for	  an	  EGF-­‐B	  domain	  and	  16	  for	  an	  O-­‐linked	  glycosylation	  domain	  (Beffert	  et	  al.,	  2005;	  Brandes	  et	  al.,	  2001;	  Hibi	  et	  al.,	  2009;	  Sun	  and	  Soutar,	  1999;	  Wasser	   et	   al.,	   2014).	   Exon	   19	   encodes	   an	   ApoER2-­‐specific	   intracellular	   domain,	   which	  promotes	  binding	  to	  JNK	  interacting	  proteins	  JIP1/2,	  the	  synaptic	  scaffolding	  protein	  post-­‐synaptic	  density	  protein	  95	  (PSD-­‐95)	  (Helbecque	  et	  al.,	  2003;	  Stockinger	  et	  al.,	  2000)	  and	  plays	  a	  role	  in	  enhancing	  synaptic	  plasticity	  (Beffert	  et	  al.,	  2005;	  Petit-­‐Turcotte	  et	  al.,	  2005;	  Wasser	  et	  al.,	  2014;	  Weeber	  et	  al.,	  2002).	  	  
2.4.1.3	  VLDLR	  VLDLR	   is	   closely	   related	   to	   ApoER2	   in	   structure	   and	   function,	   but	   exhibits	   some	   crucial	  differences	  in	  its	  expression	  pattern,	  function	  and	  structure	  (Reddy	  et	  al.,	  2011).	  VLDLR	  is	  expressed	   widely	   around	   the	   body,	   but	   most	   prominently	   in	   the	   brain,	   heart,	   kidneys,	  muscle	   and	   adipose	   tissue	   in	   both	   humans	   and	   mice	   (Reddy	   et	   al.,	   2011).	   Systemically,	  VLDLR	  facilitates	   liver-­‐produced	  VLDL	   lipoprotein	  uptake	   into	  cells	   (Nguyen	  et	  al.,	  2013).	  In	   the	   brain,	   VLDLR	   is	   involved	   in	   cortical	   development	   as	   a	   canonical	   Reelin	   receptor	  together	  with	  ApoER2	  (Hiesberger	  et	  al.,	  1999;	  Larouche	  et	  al.,	  2008).	  	  Genetic	  VLDLR	  mutations	  in	  humans	  are	  associated	  with	  vascular	  dementia	  (Helbecque	  et	  al.,	   2001),	   dysequilibrium	   syndrome	   (Kizhakkedath	   et	   al.,	   2014)	   and	   age-­‐related	  macular	  degeneration	  (AMD)	  (Haines	  et	  al.,	  2006).	  Retinal	  damage	  associated	  with	  AMD	  is	   the	  top	  cause	  of	  blindness	   in	   the	  elderly	   (Haines	  et	  al.,	  2006).	  Mice	  deficient	   in	  VLDLR	  (VLDLR-­‐/-­‐)	  develop	   AMD	   characterized	   by	   inflammation	   and	   neovascularization.	   These	   mice	   exhibit	  increased	  vascular	  endothelial	  growth	  factor	  and	  fibroblast	  growth	  factor	  expression	  along	  with	   increased	   levels	   of	   proinflammatory	   cytokines	   IL-­‐18	   and	   intercellular	   adhesion	  molecule-­‐1	  prior	  to	  the	  neovascularization	  process	  (Li	  et	  al.,	  2007;	  Kyosseva	  et	  al.,	  2013;	  Hu	  et	  al.,	  2008;	  Chen	  et	  al.,	  2007).	  VLDLR	  is	  also	  shown	  to	  be	  upregulated	  during	  inflammation	  and	  ER	  stress	  in	  various	  other	  tissues	  including	  macrophages	  (Dombroski	  et	  al.,	  2010;	  Shen	  et	  al.,	  2012).	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VLDLR	  was	  first	  discovered	  in	  1992	  (Takahashi	  et	  al.,	  1992).	  The	  protein	  structure	  of	  VLDR	  is	  similar	  to	  both	  LDLR	  and	  ApoER2.	  VLDLR	  is	  expressed	  in	  four	  splicing	  variants	  that	  have	  functional	   effects	   due	   to	   the	   differential	   expression	   of	   the	   exons	   4	   and	   16,	   encoding	   for	  ligand-­‐binding	   repeat	  3	  and	   the	  O-­‐linked	  glycosylation	  domain,	   respectively:	  VLDLR-­‐I	  has	  all	   the	   exons,	   VLDLR-­‐II	   lacks	   exon	   16,	   VLDLR-­‐III	   lacks	   exon	   4	   and	   VLDLR-­‐IV	   lacks	   both	  exons	  4	  and	  16	  (Nakamura	  et	  al.,	  2001;	  Sakai	  et	  al.,	  2009).	  VLDLR	  processing	  and	  cleavage	  is	  particularly	  increased	  due	  to	  the	  lack	  of	  the	  O-­‐linked	  glycosylation	  domain	  (Nakamura	  et	  al.,	   2001).	   In	   the	   brain,	   exon	   4	   and	   16	   skipping	   are	  more	   frequent	   than	   in	   other	   tissues	  (Sakai	  et	  al.,	  2009).	  	  
2.4.1.4	  LRP1	  LRP1	   differs	   significantly	   in	   structure	   from	   LDLR.	   LRP1	   functions	   as	   primarily	   an	  endocytotic	   receptor	   by	   binding	   numerous	   ligands	   (Bu	   et	   al.,	   2006).	   LRP1	   also	   plays	   a	  significant	   role	   in	   AD	   pathogenesis.	   LRP1	   facilitates	   APP	   endocytosis	   and	   Aβ	   production,	  but	   also	  mediates	   the	   clearance	   of	   Aβ	   from	   the	   brain	   across	   the	   BBB	   (Kanekiyo	   and	   Bu,	  2014;	   Liu	   et	   al.,	   2007;	   Bachmeier	   et	   al.,	   2014;	   Deane	   et	   al.,	   2008).	   Additionally,	   LRP1	  functions	  as	  downregulator	  of	  Wnt-­‐signaling	  pathway	  and	  LRP1	  gene	  polymorphisms	  are	  associated	  with	  increased	  risk	  of	  CVD	  (Aledo	  et	  al.,	  2012).	  	  LRP1,	   previously	   known	   as	   alpha	   2-­‐macroglobulin-­‐proteinase	   receptor,	   was	   first	  discovered	  in	  1988	  (Herz	  et	  al.,	  1988)	  and	  cloned	  in	  1989	  from	  hepatocytes	  (Kristensen	  et	  al.,	  1990;	  Gliemann	  et	  al.,	  1989).	  LRP1	  is	  a	   large	  (∼600	  kDa)	  receptor	  expressed	  mainly	  in	  the	  liver,	  brain	  and	  lungs	  (Herz	  et	  al.,	  1988).	  LRP1	  protein	  consists	  of	  an	  85-­‐kDa	  membrane-­‐bound	  β-­‐subunit	   and	   a	   515-­‐kDa	   extracellular	  α-­‐subunit,	  which	   is	   cleaved	   by	   furin	   in	   the	  trans-­‐Golgi	   network	   and	   remains	   non-­‐covalently	   attached	   to	   the	   membrane-­‐bound	   β-­‐subunit	  (Van	  Leuven	  et	  al.,	  1994).	  LRP1	  contains	  4	  clusters	  of	  ligand-­‐binding	  repeats	  on	  the	  extracellular	  side	  and	  two	  NPxY	  motifs	  on	  the	  C-­‐terminal	  domain	  in	  contrast	  to	  LDLR	  (Van	  Leuven	  et	  al.,	  1994).	  
2.4.1.5	  LRP4	  LRP4	  is	  a	  critical	  lipoprotein	  receptor	  implicated	  in	  organ	  and	  bone	  development	  by	  acting	  as	  an	  antagonist	  of	  Wnt-­‐signaling	  (Li	  et	  al.,	  2010),	  and	   is	   involved	   in	   the	   formation	  of	   the	  neuromuscular	   junction	   (Kim	   et	   al.,	   2008).	   Loss-­‐of-­‐function	   mutations	   of	   LRP4	   are	  associated	   with	   Cenani-­‐Lenz	   syndrome,	   which	   is	   characterized	   by	   syndactyly	   and/or	  oligodactyly	   (malformations	   of	   the	   fingers)	   and	   kidney	   abnormalities	   (Li	   et	   al.,	   2010).	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LRP4-­‐deficient	   LRP4-­‐/-­‐	   mice	   die	   at	   birth	   due	   to	   defective	   neuromuscular	   junctions	   and	  organ	  abnormalities	  due	  to	  excessive	  Wnt-­‐signaling	  (Weatherbee	  et	  al.,	  2006;	  Gomez	  et	  al.,	  2014).	  	  LRP4	  was	  first	  discovered	  in	  1998	  with	  highest	  protein	  expression	  in	  the	  heart	  (Tomita	  et	  al.,	   1998).	   LRP4	   is	   also	   expressed	   in	   the	   brain	   and	   bones,	   and	   is	   involved	   in	   organ	  development	   and	   particularly	   in	   the	   initial	   steps	   of	   neuromuscular	   junction	   formation	  (Weatherbee	  et	  al.,	  2006).	  The	  structure	  of	  LRP4	   is	   related	   to	  LRP5	  and	  LRP6,	  with	  eight	  ligand	   binding	   repeats	   in	   its	   extracellular	   domain	   (Tomita	   et	   al.,	   1998).	   Similar	   to	   LRP1,	  LRP4	  antagonizes	  Wnt-­‐signaling	  (Asai	  et	  al.,	  2014;	  Johnson	  et	  al.,	  2006).	  Additionally,	  LRP4	  is	  expressed	  in	  the	  soma,	  dendrites	  and	  synapses	  of	  CNS	  neurons	  where	  it	  is	  shown	  to	  affect	  spine	  density,	  synaptic	  plasticity	  and	  neuronal	  viability	  (Gomez	  et	  al.,	  2014;	  Lu	  et	  al.,	  2007;	  Tian	  et	  al.,	  2006).	  	  
2.4.1.6	  LRP5	  and	  LRP6	  LRP5	   and	   LRP6	   function	   primarily	   as	   receptors	   for	  Wnt-­‐signaling	   (reviewed	   in	   detail	   in	  Chapter	  2.4.3.2).	  Gene	  mutations	  of	  LRP5	  cause	  skeletal	  system	  diseases	  in	  humans,	  such	  as	  osteoporosis-­‐pseudoglioma	   syndrome	   that	   is	   characterized	   by	   severe	   osteoporosis,	   bone	  fragility	  and,	  in	  some	  cases,	  mental	  retardation	  (Ai	  et	  al.,	  2005;	  Fan	  and	  Tang,	  2013).	  On	  the	  other	  hand,	  LRP6	  variants	  with	  exon	  3	  skipping,	  encoding	   for	   the	   first	  β-­‐propeller	  repeat,	  are	   associated	  with	   AD	   risk	   and	   are	   shown	   to	   cause	   synaptic	   abnormalities	   and	   amyloid	  pathology	   in	   AD	  mouse	  models	   (Liu	   et	   al.,	   2014a;	   Alarcon	   et	   al.,	   2013;	   De	   Ferrari	   et	   al.,	  2007).	  LRP5-­‐deficient	  mice	  exhibit	  increased	  plasma	  cholesterol	  levels	  and	  reduced	  glucose	  tolerance	  (Fujino	  et	  al.,	  2003).	  	  	  LRP5	  was	  first	  discovered	  in	  a	  genetic	  study	  associating	  it	  with	  type	  1	  diabetes.	  The	  protein	  structure	   of	   LRP5	   includes	   four	   EGF-­‐like	   domains	   and	   three	   LDLR	   repeats	   but	   lacks	   the	  NPxY	   domain	   (Hey	   et	   al.,	   1998).	   In	   humans,	   LRP5	   is	   mostly	   expressed	   in	   bones,	   with	  significant	   expression	   in	   the	   heart,	   placenta,	   lung,	   liver,	   kidney	   and	   pancreas	   (Dai	   et	   al.,	  2014;	  Hey	  et	  al.,	  1998).	  LRP6	  gene	  is	  structurally	  and	  functionally	  similar	  to	  LRP5,	  sharing	  71%	  gene	  identity	  and	  identical	  domain	  organization	  (Brown	  et	  al.,	  1998).	  In	  humans,	  LRP6	  is	  primarily	  expressed	  in	  the	  heart,	  brain,	  placenta,	  lung,	  kidney,	  pancreas,	  spleen,	  testis	  and	  ovary	  (Brown	  et	  al.,	  1998).	  In	  comparison,	  LRP6	  is	  more	  highly	  expressed	  in	  the	  brain	  and	  kidney,	  whereas	  LRP5	  has	  a	  more	  prominent	  expression	  in	  the	  liver,	  thymus,	  prostate	  and	  the	  small	  intestine	  (Brown	  et	  al.,	  1998).	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2.4.2	  Systemic	  roles	  of	  lipoprotein	  receptors	  	  
2.4.2.1	  Cholesterol	  homeostasis	  Lipoprotein	  receptors	  LDLR,	  VLDLR	  and	  LRP1	  bind	  and	  endocytose	  lipoprotein	  particles	  at	  the	   cell	   surface.	   Lipoprotein	   particles	   are	   made	   up	   of	   lipids	   and	   apolipoproteins,	   which	  supply	   tissues	   with	   essential	   lipid	   via	   the	   blood	   circulation	   and	   the	   lymphatic	   system	  (Wierzbicki	  et	  al.,	  2013).	  Lipids,	  which	  include	  triaglycerols,	  phospholipids	  and	  cholesterol,	  are	  essential	  for	  cells	  as	  precursors	  for	  hormones,	  sources	  of	  energy	  and	  components	  of	  the	  plasma	  membranes	  surrounding	  the	  cell	  and	  cell	  organelles.	  Lipoproteins	  are	  divided	  into	  five	   major	   classes:	   chylomicrons	   transport	   dietary	   lipids	   from	   intestines	   to	   tissues,	   very	  low-­‐density	   lipoproteins	   (VLDLs),	   intermediate	   density	   lipoproteins	   and	   low-­‐density	  lipoproteins	  (LDL)	  transport	  endogenous	   lipids	  from	  the	   liver	  to	  extrahepatic	  tissues,	  and	  HDL	   transport	   lipids	   from	   extrahepatic	   tissues	   to	   the	   liver.	   In	   layman	   terms,	   LDL-­‐C	   is	  usually	  referred	   to	  as	   “bad	  cholesterol”	  and	  HDL-­‐C	  as	   “good”	  cholesterol.	  Apolipoproteins	  surround	   lipids	   to	  make	   them	   soluble	   in	   the	   water-­‐based	   blood	   and	   lymph	   due	   to	   their	  detergent-­‐like	   properties.	   Systemically,	   the	   main	   apolipoproteins	   species	   are	   ApoA-­‐I,	  ApoB100,	  ApoC-­‐II	  and	  ApoE	  (Li	  et	  al.,	  1988).	  In	  the	  CNS,	  the	  main	  apolipoproteins	  species	  are	  ApoA-­‐I,	  ApoA-­‐IV,	  ApoD,	  ApoE	  and	  ApoJ	  (Harr	  et	  al.,	  1996;	  Hayashi,	  2011).	  ApoB100	  and	  ApoE	   are	   primarily	   associated	   with	   LDL	   and	   HDL,	   respectively,	   whereas	   the	   other	  lipoprotein	  species	  have	  a	  varying	  content	  of	  different	  apolipoproteins	  (Li	  et	  al.,	  1988).	  	  Lipoproteins	   are	   primarily	   taken	   into	   cells	   through	   the	   interaction	   between	   lipoprotein	  receptors	  and	  apolipoproteins.	  Lipoprotein	  particles	  are	  taken	  into	  cells	  by	  endocytosis,	  a	  process	  modulated	   by	   the	   cytoplasmic	   C-­‐terminal	   of	   the	   receptor	   and	   associated	   binding	  partners	  (Li	  et	  al.,	  2001b).	  The	  endocytosed	  lipoprotein-­‐receptor	  complexes	  can	  dissociate	  due	   to	   the	   low	   pH	  within	   early	   endosomes	   and	   the	   lipoprotein	   is	   trafficked	   into	   the	   late	  endosomes	   and	   lysosomes	   for	   degradation,	  while	   allowing	   the	   lipoprotein	   receptor	   to	   be	  recycled	   back	   to	   the	   cell	   surface	   (Figure	   2.10;	   I)	   (Beglova	   et	   al.,	   2004).	   Alternatively,	   the	  whole	   complex	  may	   be	   degraded,	   thus	   reducing	   the	   cell	   surface	   levels	   of	   the	   lipoprotein	  receptor	   (Figure	   2.10;	   II).	   PCSK9,	   for	   example,	   promotes	   the	   internalization	   and	  degradation	   of	   the	   LDLR	   in	   lysosomes,	   thus	   promoting	   reduced	   LDL-­‐C	   clearance	   and	  increased	  circulating	  levels	  of	  LDL-­‐C	  (Figure	  2.10;	  II)	  (Schmidt	  et	  al.,	  2008).	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Figure	  2.10:	  Endocytosis	  of	  lipoprotein	  particles	  by	  the	  LDLR.	  The	  lipoprotein-­‐receptor	  complex	  
may	  either	  dissociate	   (I)	  or	  be	  degraded	  as	  whole	   (II),	  depending	   largely	  on	  additional	   ligands	  
and	  intracellular	  binding	  partners.	  	  The	   systemic	   and	   CNS	   cholesterol	  metabolism	   are	   separated	   by	   the	   BBB	   (Lossinsky	   and	  Shivers,	   2004;	   Gosselet	   et	   al.,	   2009).	  Main	   sources	   of	   cholesterol	   include	   dietary	   sources	  and	  de	  novo	  production	  in	  the	  liver	  and	  glial	  cells	  in	  the	  CNS	  (Vaya	  and	  Schipper,	  2007).	  The	  brain	  is	  a	  cholesterol-­‐rich	  organ,	  bearing	  25%	  of	  total	  body	  cholesterol	  but	  only	  2%	  of	  total	  average	  bodyweight.	  Majority	  of	  CNS-­‐cholesterol	   is	  bound	   to	  myelin	  sheaths	   that	   insulate	  axons	   (Lutjohann,	   2006).	   Neurons	   require	   cholesterol	   and	   other	   lipids	   for	   the	   formation	  and	   maintenance	   of	   mature	   synapses	   (Mauch	   et	   al.,	   2001),	   and	   can	   undergo	   severe	  neurodegeneration	   in	   diseases	   such	   as	   Niemann-­‐Pick	   type	   C	   disease	   where	   cholesterol	  transport	   is	   disturbed	   (Naureckiene	   et	   al.,	   2000).	   Glial	   cells	   produce	   the	   majority	   of	  cholesterol	   and	   other	   lipids	   needed	   by	   neurons	   (Bjorkhem	   et	   al.,	   1998).	   In	   the	   CNS,	  cholesterol	   is	   mainly	   shuttled	   by	   ApoE	   and	   endocytosed	   by	   LDLR	   and	   LRP1	   (Li	   et	   al.,	  2001c).	   In	   addition	   to	   their	   role	   in	   mediating	   cholesterol	   transport,	   apolipoproteins	   can	  also	  hold	  signaling	  functions,	  as	  both	  ApoE	  and	  ApoJ	  variants	  are	  major	  genetic	  risk	  factors	  for	   AD	   (Mulder	   et	   al.,	   2014;	   Bertrand	   et	   al.,	   1995;	   Chouraki	   and	   Seshadri,	   2014).	   More	  importantly,	   the	   diversity	   and	   distinct	   expression	   patterns	   of	   lipoprotein	   receptor	   family	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members	   contribute	   to	   cholesterol	   metabolism	   and	   numerous	   signaling	   pathways	  associated	  with	  development	  and	  disease	  (Howell	  and	  Herz,	  2001;	  Tamai	  et	  al.,	  2000;	  Herz	  and	  Bock,	  2002;	  Schmidt	  et	  al.,	  2008).	  	  Intracellular	  cholesterol	  content	  is	  strictly	  controlled.	  Excessive	  cholesterol	  accumulation	  is	  inhibited	  through	  three	  primary	  measures	  following	  cholesterol	  intake:	  HMG-­‐CoA,	  the	  key	  enzyme	  in	  de	  novo	  production	  of	  cholesterol,	  is	  suppressed;	  cholesterol-­‐esterifying	  enzyme	  ACAT	  is	  activated	  to	  reduce	  free	  cholesterol;	  and	  lastly,	  LDLR	  expression	  is	  downregulated	  (Segatto	   et	   al.,	   2013).	   These	   measures	   are	   driven	   by	   sterol	   regulatory	   element-­‐binding	  proteins	   (SREBP)	   that	   act	   as	   transcriptional	   factors	   by	   reacting	   to	   changes	   in	   the	  cholesterol	   content	   of	   the	   ER	   membrane.	   Interestingly,	   in	   contrast	   to	   LDLR,	   VLDLR	  expression	   does	   not	   respond	   to	   changes	   in	   intracellular	   cholesterol	   due	   to	   inactive	   SRE-­‐elements	  within	   its	   gene	  promoter.	   Instead,	  VLDLR	  expression	   can	  be	  potentiated	  by	   the	  intake	   of	   VLDL,	   creating	   a	   positive-­‐feedback	   loop	   through	   ERK1/2	   pathway	   (Liu	   et	   al.,	  2009).	   Additionally,	   VLDLR	   can	   be	   upregulated	   by	   inflammation,	   ER	   stress	   and	   hypoxia,	  leading	   to	   increased	   VLDL-­‐mediated	   intracellular	   lipid	   accumulation	   in	   pathological	  conditions	  such	  as	  atherosclerosis	  and	  myocardiac	  infarction	  (Perman	  et	  al.,	  2011;	  Shen	  et	  al.,	  2012).	  
2.4.2.2	  Hypercholesterolemia,	  atherosclerosis	  and	  cardiovascular	  disease	  Hypercholesterolemia	   is	   a	   major	   risk	   factor	   for	   atherosclerosis	   and	   CVD	   (Umeda	   et	   al.,	  2012;	  Fantus	  et	   al.,	   2013).	  Familial	  hypercholesterolemia	   is	   caused	  by	  genetic	  variants	  of	  the	  LDLR,	  ApoB	  and	  PCSK9,	  an	  endogenous	  downregulator	  of	  LDLR	  (Futema	  et	  al.,	   2014;	  Abifadel	  et	  al.,	  2003).	  In	  familial	  hypercholesterolemia,	  high	  circulating	  LDL-­‐C	  is	  the	  result	  of	   reduced	   LDL-­‐C	   uptake	   due	   to	   poor	   binding	   affinity	   of	   defective	   ApoB	   or	   LDLR,	   or	  alternatively	  due	  to	  increased	  LDLR	  degradation	  by	  PCSK9	  gain-­‐of-­‐function	  mutants	  (Lye	  et	  al.,	  2013).	  Lipoprotein	  receptors	  LDLR,	  ApoER2	  and	  VLDLR	  are	  also	  down-­‐regulated	  by	  the	  ubiquitin-­‐proteasome	   pathway	   through	   the	   activation	   of	   inducible-­‐degrader	   of	   LDLR	  (IDOL)	  (Sorrentino	  and	  Zelcer,	  2012;	  Sorrentino	  et	  al.,	  2013;	  Lindholm	  et	  al.,	  2009;	  Zelcer	  et	  al.,	  2009;	  Hong	  et	  al.,	  2010)	  by	  the	  activation	  of	  nuclear	  liver	  X	  receptors	  (LXR)	  (Hong	  et	  al.,	  2014;	   Scotti	   et	   al.,	   2011;	   Zelcer	   et	   al.,	   2009).	   Interestingly,	   statins	   are	   shown	   to	  downregulate	  IDOL	  expression	  and	  thus	  prevent	  LDLR	  degradation	  in	  hepatocytes	  (Dong	  et	  al.,	  2011),	  whereas	  statins	  increase	  PCSK9	  expression	  (Dubuc	  et	  al.,	  2004).	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Hypercholesterolemia	   promotes	   the	   development	   of	   atherosclerotic	   plaques.	  Atherosclerosis	   is	   a	   disease	   of	   the	   arteries,	   where	   white	   blood	   cells,	   especially	  macrophages,	  infiltrate	  the	  arterial	  wall	  to	  consume	  a	  local	  buildup	  of	  lipids	  on	  an	  arterial	  wall	  (Bentzon	  et	  al.,	  2014).	  	  Due	  to	  excessive	  intracellular	  lipid	  accumulation,	  macrophages	  may	   transform	   into	   foam	   cells,	   inert	   cells	   rich	   in	   cholesterol	   and	   triacylglycerol	   deposits.	  After	  years	  of	  accumulation,	  extracellular	  lipid	  pools	  within	  an	  atherosclerotic	  plaque	  form	  on	   the	   arterial	   walls	   to	   restrict	   blood	   flow.	   These	   atherosclerotic	   plaques	   contain	  cholesterol-­‐rich	  lesion	  core	  made	  up	  of	  extracellular	  lipids,	   layers	  of	  calcifications	  and	  cell	  debris	  surrounded	  by	  active	  inflammation-­‐promoting	  white	  blood	  cells.	  Advanced	  plaques	  may	   result	   in	   a	  blocked	  artery,	   rupture	  of	   the	   artery,	   or	   a	   thrombosis,	   the	  detachment	  of	  local	  plaque	  and	  subsequent	  blockage	  of	  an	  artery	  downstream	  (Bentzon	  et	  al.,	  2014).	  	  	  In	   addition	   to	   managing	   physiological	   lipid	   transport	   between	   tissues	   and	   within	   cells,	  lipoprotein	  receptors	  play	  divergent	  roles	  in	  controlling	  the	  pathogenesis	  of	  atherosclerosis	  and	   detrimental	   lipid	   accumulation	   associated	   with	   hypoxia	   (Takahashi	   et	   al.,	   2004b).	  Lipoprotein	   receptors	   VLDLR	   and	   ApoER2	   are	   involved	   in	   the	   lipid	   accumulation	   and	  inflammation	   of	   macrophages.	   VLDLR	   is	   expressed	   in	   both	   aortic	   endothelial	   cells	   and	  macrophages	   (Takahashi	   et	   al.,	   2004b).	   ApoER2	   polymorphisms	   revealed	   in	   GWAS	   are	  implicated	  in	  atherosclerosis	  and	  myocardial	  infarction	  in	  humans	  (Waltmann	  et	  al.,	  2014).	  Loss-­‐of-­‐function	  mutations	  of	  ApoER2	  in	  mouse	  macrophages	  increase	  the	  susceptibility	  to	  oxidized	   LDL-­‐induced	   cell	   death	   and	   lipid	   accumulation.	   ApoER2-­‐deficient	   macrophages	  also	   display	   reduced	   Akt-­‐signaling,	   increased	   levels	   of	   p53	   and	   increased	   expression	   of	  peroxisome	   proliferator-­‐activated	   receptor	   γ	   (PPARγ)	   (Waltmann	   et	   al.,	   2014).	  Coincidentally,	   VLDLR	   is	   upregulated	   by	   both	   stress	   and	   PPARγ,	   bringing	   into	   question	  whether	   the	   decreased	   stress	   resistance	   is	   mediated	   by	   VLDLR	   dependent	   lipid-­‐accumulation	   in	   ApoER2-­‐deficient	  macrophages.	   In	   fact,	   elimination	   of	   VLDLR	   from	  mice	  and	   a	   cardiomyocyte	   cell	   line	   reduced	   lipid	   accumulation	   and	   cell	   death	   in	   response	   to	  ischemia	   and	   hypoxia,	   respectively	   (Perman	   et	   al.,	   2011).	   Finally,	   ApoER2	   expressed	   in	  platelets	   and	   endothelial	   cells	   modulate	   leukocyte-­‐endothelial	   cell	   adhesion,	   nitric	   oxide	  synthesis	  and	  thrombosis	  (van	  der	  Stoep	  et	  al.,	  2014;	  Pennings	  et	  al.,	  2007).	  	  
2.4.2.3	  Apidogenesis	  and	  inflammation	  Adipocytes,	   or	   fat	   cells,	   are	   formed	   from	  preadipocytes	   through	  apidogenesis.	  Adipocytes	  store	   energy	   in	   the	   form	   of	   triacylglycerols.	   Excessive	   adipogenesis	  may	   lead	   to	   obesity,	  which	  causes	  low	  systemic	  inflammation	  and	  ER	  stress	  within	  the	  liver	  and	  adipose	  tissue	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(Jo	  et	  al.,	  2013).	  Recently,	   it	  was	  shown	  that	  PCSK9	  modulates	   levels	  of	  VLDLR	  in	  adipose	  tissue	  in	  mice	  to	  affect	  triglyceride	  accumulation,	  highlighting	  its	  role	  in	  cellular	  cholesterol	  and	   lipid	  metabolism	   (Roubtsova	   et	   al.,	   2011).	   VLDLR-­‐/-­‐	  mice	   also	   tend	   to	   be	   leaner	  with	  less	   body	   fat,	   indicating	   a	   crucial	   role	   of	  VLDLR	   in	   adipogenesis	   (Goudriaan	   et	   al.,	   2001).	  Obesity	  can	  also	  increase	  VLDLR	  expression	  in	  the	  liver,	  which	  is	  normally	  absent	  from	  the	  liver,	   resulting	   in	   the	   development	   of	   hepatic	   steatosis	   (fatty	   liver)	   (Jo	   et	   al.,	   2013).	  Mechanistically,	   VLDLR	   expression	   is	   stimulated	   by	   ER	   stress	   through	   the	   ERK/ATF-­‐4	  pathway	  and	  promotes	  intracellular	  triglyceride	  accumulation	  (Dombroski	  et	  al.,	  2010;	  Jo	  et	  al.,	  2013;	  Yang	  et	  al.,	  2014;	  Wang	  et	  al.,	  2003).	  Mice	  deficient	   in	  VLDLR	  and	  ApoE	  display	  attenuated	  liver	  steatosis	  upon	  ER	  stress	  induction	  (Jo	  et	  al.,	  2013).	  	  Interestingly,	  VLDLR	  is	  also	  implicated	  in	  adaptive	  immune	  responses	  and	  inflammation.	  In	  mice	   lacking	   VLDLR,	   house	   dust	   mite-­‐challenge	   induces	   an	   increased	   inflammatory	  response	   as	   compared	   to	   wild-­‐type	   mouse.	   House	   dust	   mite-­‐challenge	   increased	   VLDLR	  expression	  in	  dendritic	  cells	  while	  55%	  of	  CD11c-­‐positive	  dendritic	  cells	  in	  allergic	  patients	  expressed	  VLDLR	  at	  basal	  conditions	  (Fredriksson	  et	  al.,	  2014).	  Taken	  together,	  LDLR	  and	  VLDLR	  differentially	  regulate	  processes	  associated	  lipid	  homeostasis	  in	  various	  tissues	  and	  in	  response	  to	  inflammation.	  
2.4.3	  Lipoprotein	  receptors	  in	  the	  CNS	  
2.4.3.1	  Reelin	  signaling	  pathway	  Reelin	  signaling	  pathway	  is	  needed	  for	  the	  proper	  development	  of	  the	  nervous	  system,	  as	  the	   Reelin-­‐knockout	   mice,	   Reeler	   mice,	   exhibit	   major	   malformations	   of	   the	   CNS	  (Trommsdorff	  et	  al.,	  1999).	  The	  canonical	  Reelin	  receptors	  VLDLR	  and	  ApoER2	  are	  crucial	  developmental	   receptors	   for	   proper	   cortical	   and	   cerebellar	   patterning.	   Reelin	   signaling	  involves	  a	  cascade	  of	  proteins	  (Figure	  2.11)	  (Kim	  et	  al.,	  1996;	  Novak	  et	  al.,	  1996).	  Reelin	  is	  a	  large	  400	  kDa	  secreted	  extracellular	  protein	  that	  is	  primarily	  produced	  by	  the	  Cajal-­‐Retzius	  cells	   in	   the	   cerebellum	  during	  development	   and	   throughout	   the	  brain	  by	   interneurons	   in	  adults	   (Herz	   and	   Chen,	   2006).	   Lipoprotein	   receptors	   VLDLR	   and	   ApoER2	   act	   as	   the	  canonical	   Reelin	   receptors	   in	   the	   brain.	   Mice	   that	   lack	   VLDLR	   and	   ApoER2,	   disabled	   1	  (Dab1)	   or	   Src-­‐family	   kinases	   (SFK)	   show	   a	   similar	   phenotype	   to	   the	   Reeler	   mouse,	  indicating	  that	  these	  components	  are	  essential	  for	  mediating	  Reelin	  signaling	  (Beffert	  et	  al.,	  2006a).	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Reelin	  functions	  by	  binding	  to	  the	  ligand	  binding	  repeats	  of	  VLDLR	  and	  ApoER2,	  facilitating	  clustering	   and	   the	   initiation	   of	   the	   intracellular	   Reelin	   signaling	   cascade.	   VLDLR	   and	  ApoER2	   have	   partially	   compensatory	   roles,	   although	   subtle	   differences	   can	   be	   seen	  between	   VLDLR	   and	   ApoER2	   knockout	   animals	   (Hack	   et	   al.,	   2007).	   Reelin	   signaling	  pathway	   involves	   tyrosine	   phosphorylation	   of	   Dab1	   that	   binds	   to	   the	   NPxY	  motif	   on	   the	  intracellular	  domain	  of	  VLDLR	  and	  ApoER2.	  Phosphorylated	  Dab1	  facilitates	  the	  activation	  of	   PI3K	   and	   SFK	   pathways	   affecting	   wide	   range	   of	   cellular	   functions	   (Figure	   2.10).	   SFK	  activation	  promotes	  phosphorylation	  of	  NR2B	  subunit	  of	  the	  NMDA	  receptor	  and	  promotes	  its	   redistribution	   to	   the	   plasma	  membrane	   (Groc	   et	   al.,	   2007).	   Increased	  NMDA	   receptor	  signaling	   at	   the	   synapse	   promote	   local	   influx	   of	   calcium	   and	   increased	   AMPA	   receptor	  incorporation	   to	   the	   synapse.	   Hence,	   Reelin	   promotes	   the	   formation	   of	   LTP,	   which	   is	  essential	  for	  learning	  and	  memory	  (Figure	  2.11)	  (Rogers	  and	  Weeber,	  2008).	  	  
	  
Figure	   2.11:	   Canonical	   Reelin	   signaling	   pathway.	   Green	   and	   red	   lines	   indicate	   protective	   and	  
neurodegenerative	   pathways,	   respectively.	   Blunt-­‐headed	   lines	   indicate	   inhibition,	   whereas	  
arrowheads	  indicate	  activation.	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Even	   with	   the	   structural	   similarity	   with	   LDLR	   and	   VLDLR,	   exon	   19	   in	   the	   intracellular	  domain	   of	   ApoER2	   and	   its	   primary	   association	   with	   lipid	   rafts	   are	   responsible	   for	   its	  specific	   neuronal	   functions	   (Stockinger	   et	   al.,	   2000;	   Andersen	   et	   al.,	   2003a;	   Duit	   et	   al.,	  2010).	   Downstream	   effect	   of	   ApoER2-­‐mediated	   Reelin-­‐signaling	   is	   inhibition	   of	   n-­‐cofilin,	  which	   acts	   as	   an	   actin-­‐depolymerizing	   enzyme.	  Hence,	   n-­‐cofilin	   inhibition	   stabilizes	   actin	  structures,	   modulating	   spine	   plasticity	   (Leeb	   et	   al.,	   2014;	   Chai	   et	   al.,	   2009a;	   Chai	   et	   al.,	  2009b).	   Interestingly,	   ApoER2	   splicing	   variant	   encoding	   exon	   19	   is	   increased	   during	  physical	   activity,	   while	   being	   downregulated	   during	   resting	   periods,	   suggesting	   a	  mechanism	  for	  a	  form	  of	  physical	  activity-­‐induced	  synaptic	  plasticity	  (Beffert	  et	  al.,	  2005).	  	  	  ApoER2	   levels	   are	   controlled	   by	   transcriptional,	   posttranslational	   modifications	   and	   by	  proteolytic	  cleavage	  similar	  to	  APP	  and	  Notch	  processing	  (May	  et	  al.,	  2003;	  Hoe	  et	  al.,	  2005;	  Hoe	   et	   al.,	   2006b).	   The	   O-­‐linked	   glycosylation	   domain	   modulates	   the	   processing	   of	   the	  mature	  receptor	  by	  extracellular	  cleavage	  by	  ADAM10	  and	  the	  subsequent	  intramembrane	  cleavage	  by	   γ-­‐secretase	   (May	  et	   al.,	   2003;	  Wasser	   et	   al.,	   2014).	  Both	  differentially	   spliced	  exon	  16	   coding	   for	   the	  O-­‐linked	   glycosylation	  domain	   and	   its	   hypoglycosylation	  promote	  ApoER2	  processing	  (Wasser	  et	  al.,	  2014).	  	  Differential	   binding	   of	   ligands	   such	   as	  ApoE	   and	  Reelin	   and	   interactions	  with	  membrane	  receptors	  such	  as	  APP	  affect	  ApoER2	  and	  VLDLR	  processing	  (Andersen	  et	  al.,	  2003a;	  Hoe	  et	  al.,	   2005;	   Hoe	   et	   al.,	   2006b;	   Larios	   et	   al.,	   2014).	   Both	   ApoE	   and	   Reelin	   promote	   the	  processing	  of	  ApoER2	  and	  VLDLR	  upon	  binding.	  Reelin	  downregulates	  VLDLR	  expression	  through	   IDOL	   (Do	   et	   al.,	   2013).	   ApoE	   binding	   competes	   with	   Reelin,	   hence	   modulating	  Reelin	   signaling	   (Herz	   and	   Chen,	   2006).	   VLDLR	   has	   a	   higher	   endocytic	   capacity	   and	   is	  recycled	  back	  to	  the	  cell	  surface	  more	  frequently	  than	  ApoER2	  (Duit	  et	  al.,	  2010).	  Altered	  ApoER2	  processing	   contributes	   to	   changes	   in	   spine	  density,	   synaptic	   formation	   and	   cued	  fear	  conditioning	  in	  vivo.	  Additionally,	  the	  change	  in	  the	  release	  of	  the	  ApoER2	  intracellular	  domain	  is	  proposed	  to	  alter	  the	  transcriptional	  control	  of	  ApoER2	  (Wasser	  et	  al.,	  2014).	  	  
2.4.3.2	  Wnt/beta-­‐catenin	  signaling	  pathway	  Wnt-­‐signaling	  affects	  cellular	  function	  associated	  with	  cell	  metabolism,	  growth,	  cancer	  and	  synapse	   maintenance	   in	   neurons	   through	   three	   distinct	   pathways:	   canonical	   Wnt/	   β-­‐catenin	   pathway,	   and	   the	   noncanonical	   planar	   cell	   polarity	   and	   Wnt/Ca2+	   pathways	  (Malaterre	  et	  al.,	  2007).	  Wnts	  are	  a	  family	  of	  secreted	  glycoproteins	  (Wnts1-­‐16	  in	  humans)	  that	  act	  as	  ligands	  for	  Wnt	  receptors.	  In	  the	  canonical	  Wnt	  signaling	  pathway,	  Wnts	  bind	  the	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receptor	   complex	   of	   Frizzled,	   LRP5/6	   and	   the	   scaffold	   protein	   Dishevelled	   to	   trigger	  intracellular	   signaling	   cascades	   (Malaterre	   et	   al.,	   2007).	   As	   a	   result,	   cytosolic	   β-­‐catenin	  levels	   are	   stabilized	   by	   disruption	   of	   a	   destruction	   complex	   that	   degrades	   β-­‐catenin.	  Increased	   levels	   of	   stabilized	   β-­‐catenin	   in	   the	   cytosol	   promote	   the	   translocation	   of	   β-­‐catenin	   into	   the	   nucleus	   and	   activate	   transcription	   factors	   such	   as	   Lef1	   (Pleasure,	   2001).	  The	   planar	   cell	   polarity	   non-­‐canonical	   Wnt-­‐signaling	   pathway	   involves	   the	   activation	   of	  GTPases,	  such	  as	  Ras,	  Rho,	  and	  JNK	  kinase	  to	  modulate	  the	  cytoskeleton.	  The	  non-­‐canonical	  Wnt/Ca2+	  pathway	  involves	  the	  activation	  of	  calcium/calmodulin-­‐dependent	  protein	  kinase	  II	  (CaMKII)	  and	  protein	  kinase	  C	  due	  to	  a	  release	  of	  Ca2+	   from	  ER	  intracellular	  Ca2+	  stores	  (Tamai	  et	  al.,	  2000).	  	  	  Lipoprotein	   receptors	   modulate	   the	   Wnt-­‐signaling	   pathway.	   LRP5	   and	   LRP6	   act	   as	   co-­‐receptors	  for	  Wnt	  ligands	  (Gong	  et	  al.,	  2001;	  Mao	  et	  al.,	  2001).	  LRP5	  is	  required	  for	  normal	  cholesterol	  homeostasis	  and	  glucose-­‐induced	  insulin	  secretion	  from	  pancreatic	  β-­‐islet	  cells	  (Fujino	   et	   al.,	   2003).	   LRP5/6	   are	   also	   implicated	   in	   organ	   development	   (Herz	   and	   Bock,	  2002).	  In	  contrast,	  LRP1,	  LRP4	  and	  VLDLR	  antagonize	  the	  Wnt-­‐signaling	  pathway	  (Borrell-­‐Pages	  et	  al.,	  2011;	  Zilberberg	  et	  al.,	  2004;	  Pinson	  et	  al.,	  2000;	  Chen	  et	  al.,	  2014c;	  Tamai	  et	  al.,	  2000).	  LRP1	  binds	  the	  Frizzled	  receptor	  and	  inhibits	  Wnt-­‐signal	  propagation	  (Zilberberg	  et	  al.,	  2004).	  VLDLR	  heterodimerizes	  with	  LRP6	  and	  inhibits	  Wnt-­‐signaling	  transduction	  (Lee	  et	  al.,	  2014b).	  LRP4	  functions	  as	  a	  receptor	  for	  Dickkopf	  1	  (Dkk1)	  (Lindy	  et	  al.,	  2014),	  which	  antagonizes	  the	  Wnt-­‐pathway	  and	  is	  elevated	  in	  brains	  of	  AD	  patients	  and	  animal	  models	  of	  AD	  (Tamai	  et	  al.,	  2000).	  Defects	  in	  LRP6	  and	  Wnt-­‐signaling	  were	  recently	  implicated	  in	  AD	  pathogenesis	  (Liu	  et	  al.,	  2014a;	  Alarcon	  et	  al.,	  2013;	  Purro	  et	  al.,	  2014).	  Aβ	  oligomers	  induce	  rapid	  expression	  of	  the	  Wnt	  antagonist	  Dkk1,	  which	  cause	  synapse	  disassembly	  in	  neurons	  (Purro	   et	   al.,	   2014).	   LRP6	   deficiency	   increases	   Aβ	   generation	   and	   leads	   to	   cognitive	  impairment,	  synaptic	  deficits	  and	  neuroinflammation	  in	  aged	  mice	  (Liu	  et	  al.,	  2014a).	  Taken	  together,	   lipoprotein	   receptors	   are	   important	   regulators	   of	   Wnt	   signaling	   and	   are	  implicated	  in	  a	  number	  of	  diseases	  including	  diabetes	  and	  AD.	  
2.4.3.3	  Interactions	  of	  lipoprotein	  receptors	  with	  APP	  As	   described	   in	   chapter	   2.3,	   APP	   processing	   is	   a	   sequential	   process	   involving	   the	   non-­‐amyloidogenic	  and	  amyloidogenic	  pathways	  that	  yield	  either	  the	  neuroprotective	  sAPPα	  or	  the	  toxic	  sAPPβ	  and	  Aβ	  fragments,	  respectively.	  Endosomal	  trafficking	  plays	  an	  important	  role	   in	   APP	  metabolism.	   Both	  β-­‐	   and	   γ-­‐secretases	   are	   enriched	   and	  most	   active	   in	   acidic	  endosomal	   compartments.	   Both	   histological	   data	   and	   AD	   patient-­‐derived	   fibroblast	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experiments	  suggest	  that	  early	  AD	  pathology	  is	  characterized	  by	  enlarged	  early	  endosomes	  and	   disturbed	   endocytic	   recycling,	  which	   is	   associated	  with	   increased	   interaction	   of	   APP	  with	  β-­‐	  and	  γ-­‐secretases	  resulting	  in	  elevated	  generation	  of	  Aβ	  (Cataldo	  et	  al.,	  2000;	  Cataldo	  et	  al.,	  2004).	  	  	  APP	  interacts	  with	  several	  lipoprotein	  receptors	  to	  affect	  the	  internalization	  and	  endocytic	  processing	  of	  APP.	  Studies	  on	  cell	  lines	  have	  revealed	  that	  LRP1-­‐APP	  interaction	  accelerates	  the	  internalization	  and	  processing	  of	  APP	  (von	  Einem	  et	  al.,	  2010).	  LRP1	  is	  also	  responsible	  for	   alpha	   2-­‐macroglobulin-­‐dependent	   Aβ	   clearance,	   with	   a	   greater	   affinity	   to	   Aβ40	   over	  Aβ42.	   In	   conditional	  mice	   knockout	  models,	   APP	   deletion	  was	   shown	   to	   upregulate	   LRP1	  levels,	  which	  in	  turn	  was	  associated	  with	  increased	  ApoE	  and	  cholesterol	  catabolism	  (Liu	  et	  al.,	  2007).	  The	  intracellular	  domain	  of	  APP	  was	  shown	  to	  downregulate	  LRP1	  expression	  by	  binding	  the	  LRP1	  promoter	  region	  together	  with	  Fe65	  and	  Tip60	  (Liu	  et	  al	  2007).	  	  ApoER2	  interaction	  with	  APP,	  on	  the	  other	  hand,	  enriches	  APP	  to	  lipid	  rafts	  (Fuentealba	  et	  al.,	   2007).	  The	  presence	  or	   the	   absence	  of	   ligands	  F-­‐spondin,	  ApoE	  and	  Reelin	  determine	  how	  ApoER2	  interaction	  with	  APP	  affects	  endocytosis	  and	  processing	  (Hoe	  et	  al.,	  2005;	  He	  et	   al.,	   2007).	   In	   the	  absence	  of	   ligands,	   lipid	   raft	   co-­‐localization	   increases	   cell	   surface	  Aβ-­‐processing.	  ApoE3	  binding	  targets	  ApoER2,	  APP	  and	  BACE1	  for	  endocytosis,	  and	  ApoER2	  is	  recycled	   back	   to	   the	   cell	   surface	   (He	   et	   al.,	   2007).	   ApoE4,	   however,	   delays	   this	   recycling	  process,	   potentially	   reducing	   both	   the	   cell	   surface	   levels	   of	   ApoER2	   and	   increasing	  amyloidogenic	   APP	   processing	   (Heeren	   et	   al.,	   2004;	   Rellin	   et	   al.,	   2008).	   Reelin	   binding	  promotes	   clustering	  and	  homodimerization	  of	  ApoER2	  and	  VLDLR,	   resulting	   in	   increased	  signal	  transduction,	  and	  potentially	  reduced	  APP	  association	  (Divekar	  et	  al.,	  2014).	  VLDLR	  can	   also	   interact	   with	   APP	   through	   the	   intracellular	   scaffold	   protein	   Fe65,	   and	   can	   thus	  increase	  the	  surface	  expression	  of	  both	  receptors	  (Dumanis	  et	  al.,	  2012).	  	  Of	   the	   other	   lipoprotein	   receptor	   family	   associated	   members,	   LRAD3	   promotes	  amyloidogenic	   processing,	  whereas	   LRP10	   and	   SorLA	   redistribute	   internalized	   APP	   from	  the	  endosomes	  to	  the	  Golgi	  apparatus,	  thus	  decreasing	  Aβ	  generation	  (Brodeur	  et	  al.,	  2012;	  Dodson	  et	  al.,	  2006;	  Ranganathan	  et	  al.,	  2011;	  Scherzer	  et	  al.,	  2004).	  	  
2.4.3.4	  Synaptic	  effects	  of	  Reelin	  and	  Aβ	  Levels	  of	  Reelin	  are	  altered	  in	  AD,	  with	  decreases	  reported	  in	  the	  frontal	  cortex	  of	  patients	  diagnosed	  with	  MCI	  (Herring	  et	  al.,	  2012)	  and	  increased	  Reelin	  expression	  in	  the	  cortex	  of	  
	   51	  
mild-­‐to-­‐moderate	   AD	   patients	   (Botella-­‐Lopez	   et	   al.,	   2006).	   Interestingly,	   increases	   in	   the	  CSF	  Reelin	   levels	   in	  Down’s	  syndrome,	  PD	  and	  FTD	  patients	  have	  been	  reported	  (Botella-­‐Lopez	  et	  al.,	  2006;	  Botella-­‐Lopez	  et	  al.,	  2010).	  This	  apparent	  difference	  may	  be	  explained	  by	  the	  sequence	  of	  AD	  progression,	  as	   the	  entorhinal	  cortex	   is	  among	  the	   first	  affected	  brain	  regions	   and	   the	   frontal	   cortex	   is	   affected	   later	   in	   the	   pathology.	   Reelin	   elevation	   is	  suggested	   to	   present	   a	   compensatory	   mechanism	   to	   increased	   Aβ	   load	   and	  neurodegeneration,	   as	   also	   Dab1	   is	   upregulated	   (Herring	   et	   al.,	   2012).	   Interestingly,	  intraneuronal	   injection	   of	   Aβ	   into	   rat	   hippocampal	   slices	   is	   shown	   to	   antagonize	   Reelin	  signaling	  at	  the	  synapse	  to	  inhibit	  LTP	  induction	  in	  the	  mouse	  brain	  (Nomura	  et	  al.,	  2012;	  Walsh	  et	  al.,	  2002).	  	  	  ApoE	  can	  compete	  with	  Reelin	  for	  VLDLR	  and	  ApoER2	  binding	  depending	  on	  its	  lipidation	  state	   (Zhao	   et	   al.,	   2014;	   Tokuda	   et	   al.,	   2000).	   Astrocytes	   load	   ApoE	  with	   cholesterol	   and	  amyloid,	   to	   be	   transported	   into	   neurons	   and	   out	   of	   the	   brain,	  mainly	   through	   LRP1	   and	  VLDLR	  (Verghese	  et	  al.,	  2013;	  Liu	  et	  al.,	  2007;	  Bu	  et	  al.,	  2006;	  Deane	  et	  al.,	  2008).	  ApoE4	  is	  often	   poorly	   lipidated,	   thus	   both	   clearing	   amyloid	   inefficiently	   and	   inhibiting	   Reelin	  signaling	   by	   sequestering	   ApoER2,	   NMDA	   and	   AMPA	   receptors	   into	   the	   recycling	  endosomes	   (Tokuda	   et	   al.,	   2000;	   Hoe	   and	   Rebeck,	   2005;	   Chen	   et	   al.,	   2010).	   This	   is	  suggested	  to	  lead	  to	  increased	  amyloid	  load	  and	  AD	  pathology,	  as	  well	  as	  decreased	  survival	  signaling	  and	  altered	  synaptic	  plasticity	  in	  neurons	  (Hayashi	  et	  al.,	  2009;	  Frey	  et	  al.,	  2006;	  Kim	  et	  al.,	  2009a;	  Tokuda	  et	  al.,	  2000;	  Chen	  et	  al.,	  2010).	  	  
2.4.3.5	  ApoE	  and	  Aβ	  clearance	  Aβ	  is	  cleared	  from	  the	  brain	  through	  both	  ApoE-­‐dependent	  and	  independent	  routes.	  Aβ	  is	  cleared	   from	  the	  brain	  by	  direct	  protealytic	  cleavage,	  microglial	  phagocytosis	   followed	  by	  lysosomal	  degradation	  and	  efflux	  across	  the	  BBB	  (Kanekiyo	  and	  Bu,	  2014;	  Mawuenyega	  et	  al.,	  2010).	  Lipoprotein	  receptors	  LRP1,	  VLDLR	  and	  LDLR	  play	  a	  pivotal	  role	  in	  Aβ	  clearance	  by	  binding	  and	  endocytosing	  Aβ	  and	  ApoE-­‐Aβ	  complexes.	  The	  different	  ApoE	  isoforms	  have	  different	  Aβ	  clearance	  capabilities,	  with	  ApoE2	  being	  the	  most	  efficient	  and	  ApoE4	  the	  least	  efficient.	   The	   clearance	   efficiency	   can	   also	   be	   affected	   by	  ApoE	   lipidation,	   the	   addition	   of	  cholesterol	  onto	   lipid-­‐poor	  ApoE	   in	  astrocytes	  by	  ABC-­‐family	   transporters	  such	  as	  ABCA1	  (Jiang	  et	  al.,	  2008).	  Lipidated	  ApoE	  clears	  Aβ	  more	  efficiently	  as	  evidenced	  by	  reduced	  Aβ	  levels	  in	  ABCA1	  overexpressing	  mouse	  models	  (Wahrle	  et	  al.,	  2008).	  Coincidentally,	  ApoE4	  isoform	  is	  less	  lipidated,	  possibly	  further	  reducing	  its	  clearance	  capabilities	  and	  causing	  its	  detrimental	   effect	   on	   AD	   risk.	   In	   addition,	   the	   ApoE4	   isoform	   has	   a	   lesser	   effect	   on	   cell-­‐
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mediated	  Aβ	  endocytosis	  and	  clearance	  (Li	  et	  al.,	  2012)	  as	  well	  as	  an	  inhibitory	  effect	  on	  the	  Aβ-­‐degrading	  enzyme	  insulin-­‐degrading	  enzyme	  (Qiu	  et	  al.,	  1998).	  	  Interestingly,	   ApoE2	   and	   ApoE3	   are	   shuttled	   across	   the	   BBB	   by	   both	   LRP1	   and	   VLDLR,	  whereas	  ApoE4	  primarily	  binds	  to	  VLDLR	  at	  the	  BBB,	  thus	  showing	  a	  reduced	  Aβ	  efflux	  rate	  across	   the	   BBB	   in	   the	   mouse	   brain	   (Deane	   et	   al.,	   2004;	   Deane	   et	   al.,	   2008).	   Although	  blocking	   LDLR	   did	   not	   affect	   ApoE-­‐dependent	   Aβ	   efflux	   (Deane	   et	   al.,	   2008),	   recent	  evidence	  shows	  that	  LDLR	  may	  play	  a	  central	  role	  in	  regulating	  Aβ	  efflux	  indirectly	  without	  significantly	   affecting	   Aβ	   production	   (Kim	   et	   al.,	   2009b).	   Castellano	   and	   colleagues	  speculate	  that	  increased	  LDLR	  expression	  in	  neurons	  and	  astrocytes	  would	  actually	  reduce	  ApoE	   levels	   in	   the	  brain	  altogether,	  allowing	   free	  Aβ	  to	  be	  more	  efficiently	  cleared	  across	  the	  BBB	  by	  LRP1	  and	  other	  transporters	  (Cal	  et	  al.,	  2012).	  Whether	  reducing	  or	  increasing	  ApoE	  would	  be	  beneficial	   to	   inhibit	  Aβ	  accumulation	   is	  under	  debate	  due	   to	   the	   complex	  factors	  of	   ligand	  binding,	  receptor	  abundance,	   isoforms	  and	  lipidation	  states.	  In	  a	  recently	  published	   study,	   researchers	   showed	   that	   retinoid	   X	   receptor	   antagonist	   bexarotene	  increased	  ApoE	  expression	  and	  enhanced	  the	  clearance	  of	  soluble	  Aβ	  from	  the	  brain	  of	  an	  AD	  model	  mouse	  (Cramer	  et	  al.,	  2012).	  However,	  follow-­‐up	  studies	  confirmed	  that	  whereas	  bexarotene	  increased	  Aβ	  efflux,	  amyloid	  plaque	  remained	  unaffected	  (Veeraraghavalu	  et	  al.,	  2013).	  
2.4.3.6	  Effects	  on	  neuronal	  viability	  Lipoprotein	   receptors	   are	   also	   implicated	   in	   the	   control	   of	   neuronal	   viability.	   Reelin	  signaling	  through	  ApoER2	  and	  VLDLR	  supports	  neuronal	  viability	  and	  synaptic	  function	  by	  activation	  of	  the	  PI3K/Akt	  pathway	  (Bock	  et	  al.,	  2003;	  Beffert	  et	  al.,	  2006a)	  and	  facilitating	  LTP	   formation	   by	  modulation	   of	   the	  NMDA	   receptors	   (Beffert	   et	   al.,	   2005;	  Weeber	   et	   al.,	  2002;	   Beffert	   et	   al.,	   2006a).	   Additionally,	   ApoER2	   and	   its	   exon	   19	   domain-­‐dependent	  interactions	   with	   JIP1/2	   can	   directly	   modulate	   the	   pro-­‐apoptotic	   JNK-­‐signaling	   pathway	  (Beffert	   et	   al.,	   2006b).	   Interestingly,	   clusterin/ApoJ	   can	   interact	  with	  ApoER2	  and	  VLDLR	  (Leeb	  et	  al.,	  2014)	  and	  has	  both	  anti-­‐apoptotic	  and	  pro-­‐apoptotic	  functions	  (Kim	  and	  Choi,	  2011).	  The	  secreted	  form	  is	  anti-­‐apoptotic	  (Boggs	  et	  al.,	  1996)	  whereas	  the	  nuclear	  form	  of	  clusterin	   has	   pro-­‐apoptotic	   effects	   in	   the	   rat	   brain,	   by	   interacting	   with	   the	   Bcl-­‐2	   family	  proteins	  (Kim	  and	  Choi,	  2011).	  	  In	  addition,	  ApoER2	  interacts	  with	  selenoprotein	  P	  (Sepp1)	  to	  retain	  high	  selenium	  levels	  in	  the	   brain.	   Selenium	   is	   needed	   for	   neuronal	   survival	   and	   in	   testes	   for	   sperm	  maturation	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(Steinbrenner	  and	  Sies,	  2013;	  Olson	  et	  al.,	  2007),	  the	  sites	  coinciding	  with	  high	  expression	  levels	  of	  ApoER2.	  Failure	  to	  reach	  sufficient	  selenium	  levels	  in	  CNS	  neurons	  leads	  to	  severe	  neurodegeneration,	   making	   the	   mechanism	   ensuring	   sufficient	   neuronal	   selenium	  extremely	  crucial	  (Byrns	  et	  al.,	  2014).	  In	  Sepp1	  and	  ApoER2	  knockout	  mice,	  mild	  selenium	  deficiency	   is	   enough	   to	   reduce	   brain	   selenium	   by	   over	   50%	   resulting	   in	   severe	  neurodegeneration.	  However,	   normal	   levels	   of	   Sepp1	   and	  ApoER2	   that	   enrich	   circulating	  selenium	   into	   neurons	   can	   overcome	   even	   an	   extreme	   selenium	  deficiency.	   This	   is	  made	  possible	  by	   the	   interaction	  of	   Sepp1	  and	  ApoER2	  at	  both	   the	  BBB	  as	  well	   as	   in	   the	  brain	  cells	  (Byrns	  et	  al.,	  2014;	  Burk	  et	  al.,	  2014;	  Burk	  et	  al.,	  2007).	  	  	  LRP4	  is	  also	  implicated	  in	  controlling	  neuronal	  viability	  in	  an	  ApoE-­‐dependent	  fashion	  (Lu	  et	   al.,	   2007).	   LRP4	   ligand-­‐binding	   region	  was	   shown	   to	  be	   crucial	   for	   the	  maintenance	  of	  neuronal	   viability	   (Lu	   et	   al.,	   2007).	   In	   the	   absence	   of	   brain-­‐specific	   LRP4,	   mice	   display	  cognitive	  deficits	  characterized	  by	  reduced	  spine	  density	  and	  spontaneous	  release	  events	  in	  the	  hippocampus	  (Gomez	  et	  al.,	  2014).	  	  To	   summarize,	   lipoprotein	   receptors	   hold	   a	   host	   of	   important	   physiological	   and	  pathophysiological	   functions	   systemically	   and	   in	   the	   CNS,	   warranting	   further	   studies	   on	  this	  multifunctional	  receptor	  class.	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2.5	  PCSK9	  as	  a	  regulator	  of	  lipoprotein	  receptors	  Proprotein	  convertase	  subtilisin	  kexin/type	  9	  (PCSK9)	  is	  a	  protein	  secreted	  by	  the	  liver	  into	  the	   bloodstream,	   which	   downregulates	   cell	   surface	   levels	   of	   LDLR	   and	   increases	   the	  circulating	  levels	  of	  LDL	  cholesterol	  (Qian	  et	  al.,	  2007).	  PCSK9	  was	  initially	  identified	  as	  an	  apoptosis-­‐upregulated	   protein,	   termed	   as	   neuronal	   apoptosis	   regulated	   convertase-­‐1	  (NARC-­‐1)	  (Chiang	  et	  al.,	  2001).	  However,	  the	  discovery	  of	  PCSK9	  as	  the	  third	  genetic	  locus	  implicated	   in	  autosomal	  dominant	  hypercholesterolemia	   focused	   future	  research	   towards	  its	  systemic	  role	  in	  cholesterol	  metabolism	  and	  the	  potential	  of	  PCSK9	  as	  a	  pharmacological	  target	  in	  the	  treatment	  of	  hypercholesterolemia	  (Abifadel	  et	  al.,	  2003).	  Intriguingly,	  loss-­‐of-­‐function	   and	   gain-­‐of-­‐function	   variants	   of	   PCSK9	   in	   humans	   cause	   hypo-­‐	   and	  hypercholesterolemia,	   respectively,	  without	   any	  other	  prevalent	   or	  malicious	  phenotypes	  (Abifadel	  et	  al.,	  2003).	  This	  notion	  has	  prompted	  the	  rapid	  development	  of	  PCSK9	  inhibitors	  as	   an	   anti-­‐hypercholesterolemic	   therapy,	   and	   especially	   PCSK9	   antibodies	   have	   shown	  great	  efficacy	  and	  good	  safety	  profiles	  in	  phase	  III	  clinical	  trials	  (Cui	  et	  al.,	  2015).	  	  
2.5.1	  PCSK9	  gene	  expression	  and	  mode	  of	  function	  PCSK9	  is	  primarily	  expressed	  in	  the	  liver,	  small	   intestine,	  kidneys	  and	  the	  cerebellum	  and	  telencephalon	   during	   brain	   development	   (Seidah	   et	   al.,	   2003).	   In	   adulthood,	   PCSK9	   is	  mainly	  expressed	  in	  the	  liver,	  kidney	  medulla,	  the	  external	  granule	  layer	  of	  the	  cerebellum	  and	   the	  olfactory	  peduncle	   in	   the	  brain	   (Seidah	  et	   al.,	   2003;	  Rousselet	   et	   al.,	   2011).	   Since	  PCSK9	   is	   secreted	   into	   the	  bloodstream,	   it	   has	   the	  potential	   to	   affect	   organs	   that	   express	  LDLR,	  VLDLR,	  ApoER2	  and	  LRP1	  (Schmidt	  et	  al.,	  2008).	  The	  circulating	  levels	  in	  the	  plasma	  follow	   a	   diurnal	   rhythm	   with	   concentrations	   between	   160-­‐780	   ng/ml,	   whereas	   the	   CSF	  levels	   remain	   remarkably	   constant	   at	   concentrations	   between	   2-­‐8	   ng/ml	   (Chen	   et	   al.,	  2014d).	   Interestingly,	   there	   is	   no	   significant	   correlation	   between	   plasma	   and	   CSF	  concentration	  levels,	  suggesting	  different	  control	  mechanisms	  and	  sources	  of	  systemic	  and	  CSF	  PCSK9	  (Chen	  et	  al.,	  2014d).	  	  	  The	   human	   PCSK9	   gene	   comprises	   of	   12	   exons	   encoding	   a	   692	   aa	   protein.	   Full-­‐length	  PCSK9	   consists	   of	   four	   domains:	   a	   signal	   peptide	   (aa	   1-­‐30),	   pro-­‐domain	   (aa	   31-­‐152),	   a	  subtilisin-­‐like	  catalytic	  domain	  (aa	  153-­‐451)	  and	  a	  C-­‐terminal	  cysteine-­‐rich	  region	  (aa	  452-­‐692)	  (Lambert	  et	  al.,	  2009).	  The	  signal	  peptide	  targets	  the	  protein	  to	  the	  ER	  where	  PCSK9	  is	  folded,	   followed	   by	   processing	   in	   the	   Golgi	   apparus	   and	   secretion	   through	   the	   secretory	  pathway.	   PCSK9	   is	   processed	   by	   autocleavage	   into	   a	   14	   kDa	   pro-­‐domain	   and	   a	   63	   kDa	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fragment	   in	  the	  ER	  (Lambert	  et	  al.,	  2009).	  The	  pro-­‐domain	  remains	  attached	  to	  the	  active	  site	  of	  PCSK9	  by	  non-­‐covalent	  binding.	  Autoprocessing	  is	  required	  by	  PCSK9	  to	  exit	  the	  ER	  (Peterson	  et	   al.,	   2008).	   PCSK9	  autoprocessing	  destines	   the	  protein	   for	   secretion.	   In	   some	  PCSK9	  polymorphisms,	  autocleavage	  is	  inhibited	  and	  PCSK9	  is	  retained	  in	  the	  ER.	  However,	  their	   ability	   to	   degrade	   LDL	   receptors	   may	   still	   remain	   intact	   (Poirier	   et	   al.,	   2009),	  suggesting	  an	  additional	  intracellular	  LDLR	  degrading	  pathway	  (Figure	  2.11).	  Recently,	  an	  intracellular	   interaction	  between	   cIAP-­‐1/TRAF2	  complex	  and	  PCSK9	  was	   reported	   (Xu	  et	  al.,	   2012).	   This	   complex	  was	   shown	   to	   affect	   PCSK9	   secretion,	   PCSK9	   ubiquitination	   and	  lysosomal	   determination,	   thus	   providing	   further	   evidence	   of	   an	   intracellular	   processing	  route	  (Xu	  et	  al.,	  2012).	  	  The	  presence	  of	  LDLR	  controls	  PCSK9	  trafficking.	  If	  LDLR	  is	  not	  expressed,	  PCSK9	  is	  mainly	  present	  in	  the	  ER,	  whereas	  association	  of	  PCSK9	  with	  LDLR	  primarily	  promotes	  its	  post-­‐ER	  Golgi	   plasma	   membrane	   localization,	   depending	   on	   cell	   type.	   In	   loss-­‐of-­‐function	   PCSK9	  mutants,	   this	   endosomal	   and	   lysosomal	   localization	   is	   lost	   (Nassoury	   et	   al.,	   2007).	   The	  catalytic	  domain	  has	  a	  typical	  active	  triad	  of	  aspartic	  acid,	  histidine	  and	  serine	  amino	  acid	  residues,	  and	  is	  required	  for	  the	  maturation	  of	  PCSK9.	  However,	  further	  protease	  function	  is	   blocked	   by	   the	   non-­‐covalently	   bound	   pro-­‐domain	   (Nassoury	   et	   al.,	   2007).	   Residues	  located	  at	   the	  apex	  of	   the	  catalytic	  domain	  are	  responsible	   for	  binding	  the	  EGF	  domain	  of	  LDL	  receptors	  (Zhang	  et	  al.,	  2007).	  The	  C-­‐terminal	  domain	  contains	  3	  sub-­‐domains	  and	  is	  associated	  with	   an	   increased	   affinity	   to	   LDL	   receptors	   following	   endosomal	   acidification	  and	  directing	   the	  complex	   for	   lysosomal	  degradation	  (Zhang	  et	  al.,	  2007;	  Benjannet	  et	  al.,	  2010),	  possibly	   involving	  an	  adaptor	  protein	  (Zhang	  et	  al.,	  2008).	   In	   fact,	  recently	  a	  novel	  pH-­‐dependent	   interaction	   between	   PCSK9	   and	  APP-­‐like	   protein	   2	  was	   discovered,	  which	  promotes	   lysosomal	   delivery	   of	   PCSK9	   into	   lysosomes	   (DeVay	   et	   al.,	   2013).	   Also,	   an	  autosomal	   recessive	  hypercholesterolemia	  gene	   is	  needed	   for	   the	   internalization	  of	  LDLR	  and	  PCSK9	  in	  hepatocytes	  (Qian	  et	  al.,	  2007).	  	  
2.5.2	  PCSK9	  function	  PCSK9	  plays	  a	  central	  role	  in	  organ	  development	  and	  controls	  the	  levels	  of	  circulating	  LDL	  cholesterol	  during	  adulthood	  (Seidah	  et	  al.,	  2003;	  Benjannet	  et	  al.,	  2004).	  Mechanistically,	  PCSK9	  binds	  to	  the	  EGF-­‐A	  domain	  of	  the	  LDL	  receptors	  LDLR,	  VLDLR,	  ApoER2	  and	  LRP1	  to	  target	   them	   for	   degradation	   in	   lysosomes	   (Poirier	   et	   al.,	   2008).	   The	   binding	   affinities	   for	  LDLR,	  VLDLR	  and	  ApoER2	  binding	  were	  calculated	  from	  Biacore	  experiments	  to	  be	  386	  nM,	  379	  nM	  and	  516	  nM,	  respectively	  (Liu	  et	  al.,	  2010).	  PCSK9	  was	  recently	  also	  shown	  to	  bind	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LRP1	  in	  murine	  B16F1	  melanoma	  cancer	  cells	  that	  have	  LDLR	  that	  are	  insensitive	  to	  PCSK9	  downregulation	  (Canuel	  et	  al.,	  2013).	  The	  mode	  of	  PCSK9	  function	  on	  LDLR	  is	  reviewed	  in	  Figure	  2.12.	  
	  
Figure	  2.12:	  The	  basic	  model	  of	  PCSK9	  function.	  PCSK9	  is	  produced	  in	  the	  ER,	  processed	  through	  
the	  Golgi	   and	   targeted	   for	   secretion.	   Secreted	   PCSK9	   binds	   lipoprotein	   receptors	   at	   the	   EGF-­‐
domain	  to	  facilitate	  endocytosis	  of	  the	  complex.	  PCSK9	  competes	  with	  LDL	  for	  LDLR	  binding	  and	  
destines	  LDLR-­‐PCSK9	  complex	  into	  the	  late	  endosomes	  and	  lysosomes	  for	  degradation.	  A	  direct	  
intracellular	  route	  has	  been	  suggested	  via	  cIAP-­‐1/TRAF2-­‐mediated	  PCSK9	  translocation	  into	  the	  
lysosomes	  (Xu	  et	  al.,	  2012).	  	  In	  addition	  to	  regulating	  systemic	  cholesterol	  homeostasis,	  PCSK9	  is	  also	  implicated	  in	  liver	  regeneration,	  and	  neuronal	  differentiation	  and	  development	  in	  the	  cerebral	  cortex	  between	  embryonic	   days	   12	   and	   15	   in	   mice	   (Seidah	   et	   al.,	   2003).	   Reelin	   signaling,	   mediated	   by	  VLDLR	   and	   ApoER2	   in	   the	   developing	   CNS,	  might	   explain	   the	   role	   of	   PCSK9	   in	   neuronal	  development	  (Perez-­‐Garcia	  et	  al.,	  2004).	  	  PCSK9-­‐/-­‐	  mice	  also	  display	  lower	  levels	  of	  ApoE	  in	  telencephalon	  at	  embryonic	  day	  12.5	  and	   in	  cerebellum	  at	  postnatal	  day	  7,	  but	  not	   in	   the	  adult	   brain	   (Rousselet	   et	   al.,	   2011).	   Circulating	   PCSK9	   originating	   from	   the	   liver	   was	  recently	  shown	  to	  also	  modulate	  VLDLR	  levels	  in	  adipose	  tissue	  in	  vivo,	  lowering	  the	  build	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up	  of	  adipose	  tissue	  (Roubtsova	  et	  al.,	  2011).	  They	  also	  reported	  increased	  visceral	  fat	  mass	  of	  PCSK9-­‐/-­‐	  mice	  (Roubtsova	  et	  al.,	  2011).	  Other	  proposed	  roles	  include	  a	  nephrogenic	  role	  observed	  between	  P6	  and	  P12	  in	  rat	  pups	  (Seidah	  et	  al.,	  2003).	  	  
2.5.2.1	  Transcriptional	  and	  post-­‐translational	  regulation	  of	  PCSK9	  PCSK9	   function	   can	   be	   modulated	   at	   various	   levels.	   Cleavage	   by	   proprotein	   convertase	  members	   furin	  and	  proprotein	  convertase	  5/6A	   inactivate	  PCSK9	  (Benjannet	  et	  al.,	  2006)	  and	   prevent	   LDL	   receptor	   degradation	   (Essalmani	   et	   al.,	   2011).	   Adaptor	   molecule	  lipoprotein	   receptor-­‐associated	   protein	  may	   also	   alter	   PCSK9	   binding	   to	   LDLR	   in	   the	   ER	  (Shan	  et	  al.,	  2008).	  On	  the	  cell	  surface,	  LDL	  competes	  with	  PCSK9	  for	  LDLR	  binding	  (Fisher	  et	   al.,	   2007).	   Dimerization	   of	   PCSK9	   enhances	   degradation-­‐promoting	   function,	   and	   this	  property	  is	  enhanced	  by	  VLDL	  and	  inhibited	  by	  HDL	  (Fan	  et	  al.,	  2008).	  Hence,	  lipoproteins	  also	  modulate	   PCSK9	   function.	   Mutations	   at	   the	   sites	   associated	   with	   PCSK9	   processing,	  LDLR	   binding	   and	   dimerization	   properties	   all	   have	   the	   capability	   to	   significantly	   alter	  PCSK9	   function	   and	   the	   existing	   naturally	   occurring	  mutants	   are	   a	   prime	   example	   of	   the	  versatility	  of	  PCSK9	  (Abifadel	  et	  al.,	  2009).	  	  Annexin	  2A	  functions	  as	  an	  endogenous	  inhibitor	  of	  PCSK9	  (Seidah	  et	  al.,	  2012;	  Mayer	  et	  al.,	  2008).	  Annexin	  2A	  inhibits	  PCSK9	  binding	  to	  LDLR	  and	  is	  expressed	  in	  the	  endothelial	  cells	  of	  lung,	  intestines	  and	  adrenal	  glands.	  This	  localization	  pattern	  is	  suggested	  to	  explain	  why	  PCSK9	   fails	   to	   control	   LDLR	   levels	   in	   some	   extrahepatic	   tissues	   including	   the	   adrenals	  (Mayer	  et	   al.,	   2008).	   Interestingly,	   annexin	  2A	   is	   also	   implicated	   in	  different	   cancers,	   and	  PCSK9	  is	  shown	  to	  promote	  cancer	  metastasis	  (Sun	  et	  al.,	  2012).	  	  In	   hepatocytes,	   expression	   of	   PCSK9	   is	   transcriptionally	   regulated	   by	   SREBP-­‐2	   and	  hepatocyte	   nuclear	   factor	   1	   alpha	   (HNF-­‐1α)	   through	   cooperative	   function,	   as	   HNF-­‐1α	  binding	   site	   mutation	   significantly	   reduces	   the	   ability	   of	   SREBP-­‐2	   to	   induce	   PCSK9	  expression	  (Dubuc	  et	  al.,	  2004;	  Li	  et	  al.,	  2009).	  Promoter	  sites	  SRE	  and	  Sp1	  are	  common	  to	  both	   LDLR	   and	   PCSK9.	   Statins	   upregulate	   the	   expression	   of	   LDLR	   and	   PCSK9	   through	  SREBP-­‐2	  by	  reducing	  cellular	  cholesterol	  levels	  (Dubuc	  et	  al.,	  2004).	  In	  contrast,	  berberine	  downregulates	  PCSK9	  expression	  through	  HNF1a	  and	  SREBP2	  in	  vitro	  and	  in	  vivo	  (Li	  et	  al.,	  2009).	  However,	  in	  humans	  the	  effects	  are	  debatable,	  as	  statins	  and	  berberine	  seem	  to	  have	  a	  similar	  effect	  on	  circulating	  PCSK9	  levels	  (Jia	  et	  al.,	  2014).	  PCSK9	  is	  also	  upregulated	  by	  liver	  X	  receptor	  (LXR)	  stimulation	  and	  ezetimibe	  (Hong	  et	  al.,	  2014;	  Scotti	  et	  al.,	  2011).	  Also	  PPARα	  and	  PPARγ	  differentially	  regulate	  PCSK9	  expression.	  Fibrates	  are	  shown	  to	  decrease	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PCSK9	   levels	   via	   the	   PPARa	   pathway	   (Wu	   et	   al.,	   2012c;	   Sanderson	   et	   al.,	   2010).	  Interestingly,	   caspase-­‐3	   has	   the	   ability	   to	   activate	   SREBPs	   in	   early	   apoptosis	   induction	  phase	  (Ola	  et	  al.,	  2011),	  suggesting	  a	  mechanism	  for	  PCSK9	  upregulation	  during	  apoptosis.	  
2.5.2.2	  PCSK9	  polymorphisms	  in	  hyper-­‐	  and	  hypocholesterolemia	  Naturally	   occurring	   PCSK9	   mutations	   and	   polymorphisms	   result	   in	   changes	   of	   PCSK9	  function.	  Gain-­‐of-­‐function	  PCSK9	  mutations	  cause	  hypercholesterolemia	  by	  enhancing	   the	  degradation	  of	  LDLR	  in	  hepatocytes	  and	  subsequently	  increase	  the	  levels	  of	  circulating	  LDL	  cholesterol	   (Benjannet	   et	   al.,	   2004).	   Loss-­‐of-­‐function	   PCSK9	   mutations	   prevent	   PCSK9	  autoprocessing	   or	   lower	   LDLR	   binding	   affinity	   resulting	   in	   hypocholesterolemia.	  Interestingly,	   PCSK9	   inactivation	   also	   modulates	   HDL	   levels	   (Choi	   et	   al.,	   2013).	   The	  localization	   of	   a	   number	   of	   polymorphisms,	   located	   mostly	   within	   the	   prodomain	   and	  carboxyterminal	  regions,	  is	  projected	  on	  the	  PCSK9	  gene	  structure	  in	  Figure	  2.13.	  	  
	  
Figure	   2.13:	   Polymorphisms	   of	   PCSK9	   associated	   with	   increased	   (red)	   and	   decreased	   (green)	  
systemic	   LDL-­‐C.	   A:	   Alanine,	   C:	   Cysteine,	   D:	   Aspartic	   acid,	   F:	   Phenylalanine,	   L:	   Leucine,	   N:	  
Asparagine,	  R:	  Arginine,	  S:	  Serine,	  Y:	  Tyrosine.	  	  Different	  strategies	  for	  PCSK9	  inhibition	  are	  in	  development	  to	  treat	  hypercholesterolemia	  (Norata	  et	  al.,	  2014).	  Approaches	  such	  as	  antisense	  oligonucleotides,	  small	  interfering	  RNA,	  inhibitory	   adnectins	   specific	   against	   PCSK9	   and	   small	   molecule	   inhibitors	   have	   been	  developed,	  but	  none	  hold	  as	  much	  promise	  as	  the	  PCSK9-­‐targeted	  antibodies	  (Figure	  2.14)	  (Wierzbicki	  et	  al.,	  2013).	  	  	  Three	  PCSK9	  antibodies	  are	  currently	   in	  clinical	  trials:	   fully	  human	  antibodies	  alirocumab	  by	   Sanofi/Regeneron,	   evolocumab	   by	   Amgen	   and	   humanized	   antibody	   bococizumab	   by	  
	   59	  
Pfizer	   (Gouni-­‐Berthold	   and	   Berthold,	   2014).	   As	   of	   beginning	   of	   2015,	   7	   phase	   III	   clinical	  trials	  on	  evolocumab	  (AMG	  145;	  6	   trials)	  and	  alirocumab	  (REGN727/SAR236553;	  1	   trial)	  have	   been	   concluded	   (Gouni-­‐Berthold	   and	   Berthold,	   2014).	   These	   antibodies	   reduced	  plasma	   levels	   of	   LDL-­‐C	   by	   30-­‐70%	   in	   combination	   with	   or	   without	   statins	   or	   ezetimibe	  (Mendel-­‐2;	  (Koren	  et	  al.,	  2014)).	  Additionally,	  PCSK9	  antibodies	  significantly	  lowered	  total	  cholesterol,	   non-­‐HDL-­‐cholesterol,	   lipoprotein	  A,	   triglycerides	   in	   some	   trials	   and	  modestly	  increased	   HDL-­‐cholesterol	   (Mendel-­‐2;	   (Koren	   et	   al.,	   2014)).	   Administered	   once	   or	   twice	  monthly,	  evolocumab	  proved	  more	  effective	   than	  statins	  or	  ezetimibe,	  with	  no	  detectable	  neutralizing	  antibody	  formation	  or	  serious	  adverse	  effects	  (Mendel-­‐2;	  (Koren	  et	  al.,	  2014)).	  In	   addition,	   PCSK9	   antibodies	   were	   successful	   in	   reducing	   LDL-­‐cholesterol	   in	   patients	  suffering	   from	   familial	   hypercholesterolemia	   (Rutherford-­‐2,	   Tesla	   Part	   B;	   (Raal	   et	   al.,	  2014))	   or	   statin	   intolerance	   (GAUSS-­‐2;	   (Stroes	   et	   al.,	   2014)).	   Since	   most	   of	   the	  aforementioned	   trials	   have	   only	   been	   conducted	   for	   12	   weeks,	   with	   the	   Descartes	   trial	  being	   the	   only	   exception	   (52	   weeks)	   (Blom	   et	   al.,	   2014),	   trials	   with	   cardiovascular	  endpoints	   and	   longer	   trial	   times	   are	   still	   needed	   to	   fully	   assess	   the	   long-­‐term	   safety	   and	  efficacy	  of	  the	  PCSK9	  antibody	  therapy.	  	  
	  
Figure	  2.14:	  Rationale	  behind	  PCSK9	  inhibitor	  treatment	  to	  treat	  hypercholesterolemia	  with	  or	  
without	  statin	   treatment.	  Blunt-­‐headed	   lines	   indicate	   inhibition,	  whereas	  arrowheads	   indicate	  
activation.	  
2.5.2.3	  Atherosclerosis	  and	  inflammation	  Two	  independent	  population-­‐based	  studies	  link	  PCSK9	  gain-­‐of-­‐function	  mutations	  to	  large	  vessel	   and	   intracranial	   atherosclerosis-­‐induced	   stroke	   (Han	   et	   al.,	   2014;	   Abboud	   et	   al.,	  2007).	   Smooth	  muscle	   cells	   cultured	   from	   human	   atherosclerotic	   plaques	   secrete	   PCSK9	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that	  downregulates	  LDLR	  levels,	  and	  lowers	  LDL	  and	  VLDL	  uptake	  in	  macrophages	  (Ferri	  et	  al.,	  2012).	  These	  findings	  raise	  the	  possibility	  that	  PCSK9	  might	  inhibit	  foam	  cell	  formation	  (Ferri	   et	   al.,	   2012).	   However,	   PCSK9	   is	   positively	   correlated	   to	   atherosclerotic	   plaque	  formation	  and	  PCSK9	   inactivation	   reduces	   atherosclerotic	   lesion	   size	   (Denis	   et	   al.,	   2012).	  The	  proposed	  mechanism	  suggests	  that	  as	  PCSK9	  downregulates	  macrophage	  LDLR	  levels,	  cholesterol	   efflux	   is	   impaired.	   This	   in	   turn	   would	   result	   in	   lipid	   retention	   within	  macrophages,	   facilitating	   foam	   cell	   formation	   and	   increasing	   the	   risk	   of	   atherosclerosis	  (Shen	  et	  al.,	  2013).	  Whether	  PCSK9	  can	  also	  affect	  the	  protein	  levels	  of	  ApoER2	  or	  VLDLR	  in	  macrophages,	  has	  not	  been	  addressed.	  	  PCSK9	  inhibition	  is	  also	  associated	  with	  increased	  pathogenic	  lipid	  clearance	  via	  the	  LDLR,	  decreased	  inflammatory	  response	  and	  improved	  septic	  shock	  outcome	  (Walley	  et	  al.,	  2014).	  PCSK9	  is	  upregulated	   in	  response	  to	   lipopolysaccharide,	  zymosan	  and	  turpentine-­‐induced	  inflammation	  in	  mice	  (Feingold	  et	  al.,	  2008).	  The	  HNF-­‐1	  promoter	  element	  is	  shown	  to	  be	  responsible	  for	  the	  insulin	  and	  inflammation	  sensitivity	  of	  PCSK9	  (Lagace,	  2014).	  	  
2.5.2.4	  Role	  of	  PCSK9	  in	  cell	  death	  and	  AD	  pathogenesis	  LDLR,	   ApoER2	   and	   VLDLR	   bind	   numerous	   ligands	   to	   control	   cell	   signaling,	   cholesterol	  metabolism	  and	  cell	  survival	  through	  various	  pathways	  (Beffert	  et	  al.,	  2006b).	  However,	  in	  
vivo	   studies	   by	   researchers	   from	   Merck	   laboratory	   have	   reported	   that	   PCSK9	   does	   not	  significantly	  alter	  BACE1	  or	  Aβ	  levels	  in	  the	  adult	  mouse	  brain	  (Liu	  et	  al.,	  2010).	  In	  addition,	  the	  steady-­‐state	  levels	  of	  LDLR,	  VLDLR	  and	  ApoER2	  in	  the	  brain	  were	  not	  affected	  in	  PCSK9	  knockout	  or	  PCSK9-­‐overexpressing	  animals	  (Liu	  et	  al.,	  2010).	  In	  contrast	  to	  these	  findings,	  the	  lab	  of	  Nabil	  Seidah	  has	  shown	  that	  PCSK9-­‐/-­‐	  mice	  exhibit	  increased	  LDLR	  levels	  during	  development	  and	  stroke	  (Rousselet	  et	  al.,	  2011).	  PCSK9	  was	  upregulated	  in	  the	  ipsilateral	  dentate	  gyrus,	  a	  site	  of	  neurogenesis,	  after	  24	  hours	  post-­‐ischemia	  but	  not	  in	  the	  infarcted	  areas	  of	  the	  rat	  brain	  (Rousselet	  et	  al.,	  2011).	  ApoE	  levels	  were	  also	  lower	  in	  PCSK9-­‐/-­‐	  mice	  during	  development,	  but	  not	  in	  adulthood	  or	  after	  stroke	  (Rousselet	  et	  al.,	  2011).	  However,	  neuronal	  cell	  death	  around	  the	  lesion	  was	  not	  affected	  and	  also	  ApoER2	  and	  VLDLR	  levels	  were	  not	  assessed	  in	  this	  study.	  	  PCSK9	   was	   initially	   discovered	   in	   association	   with	   neuronal	   apoptosis.	   PCSK9	   has	   pro-­‐apoptotic	   functions	   in	   cerebellar	  granule	  neurons	   (CGN)	   (Bingham	  et	   al.,	   2006).	  PCSK9	   is	  expressed	  during	  potassium	  and	  serum	  deprivation-­‐induced	  apoptosis	   in	  CGN	  along	  with	  known	  apoptosis	  mediators	  such	  as	  caspase	  3	  and	  death	  receptor	  6	   (Chiang	  et	  al.,	  2001).	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Transfection	  of	  CGN	  with	  variants	  of	  PCSK9	  fused	  with	  GFP	  induced	  apoptosis	  in	  ∼40%	  of	  transfected	   cells	   (Bingham	   et	   al.,	   2006).	   The	   effect	   was	   milder	   than	   with	   caspase-­‐9	  transfection	   (∼60%	   cell	   death),	   but	   interestingly	   it	   was	   not	   completely	   reversible	   with	  caspase	   inhibitors,	   in	   contrast	   to	   the	   caspase-­‐9	   transfected	   cells.	   PCSK9	   variants	  with	   C-­‐terminal	  deletion	  mutants	  fail	  to	  respond	  to	  caspase	  inhibition	  (Bingham	  et	  al.,	  2006),	  but	  the	   exact	   mechanism	   of	   its	   function	   remains	   unclear.	   Recently,	   PCSK9	   RNAi	   mediated	  knockdown	   was	   shown	   to	   inhibit	   apoptosis	   in	   human	   umbilical	   vein	   endothelial	   cells	  (HUVEC)	  (Wu	  et	  al.,	  2012a),	  supporting	  its	  role	  as	  an	  apoptotic	  modulator.	  	  	  The	  hypothesis	  of	  a	  dual	  regulatory	  role	  of	  PCSK9	  in	  AD	  was	  recently	  reviewed	  (Wu	  et	  al.,	  2014).	   The	   pro-­‐apoptotic	   role	   of	   PCSK9	   is	   thought	   to	   involve	   the	   NF-­‐κB/Bax/caspase-­‐3	  pathway,	  whereas	  the	  proposed	  anti-­‐apoptotic	  role	  would	  be	  mediated	  by	  the	  regulation	  of	  BACE1	   levels	   and	   activity	   (Ko	   and	   Puglielli,	   2009;	   Jonas	   et	   al.,	   2008).	   However,	   genetic	  studies	   do	   not	   associate	   PCSK9	   or	   any	   of	   its	   variants	   with	   AD	   (Reynolds	   et	   al.,	   2010).	  However,	  there	  is	  conflicting	  evidence	  for	  whether	  PCSK9	  affects	  APP	  metabolism	  through	  BACE1	  modulation.	   In	   CHO	   and	   H4	   cell	   cultures,	   overexpressed	   human	  wild-­‐type	   PCSK9	  reciprocally	  regulated	  BACE1	  by	  acting	  on	  the	  early	  secretory	  pathway;	  hence	  an	  increase	  of	   PCSK9	   decreased	   BACE1	   levels	   (Jonas	   et	   al.,	   2008).	   This	   effect	   was	   dependent	   on	   the	  protease	  domain	  of	  PCSK9,	  necessary	   for	  PCSK9	  autoprocessing	  and	  maturation,	  and	  was	  specific	   to	   the	   non-­‐acetylated	   forms	   of	   BACE1	   (Jonas	   et	   al.,	   2008).	   In	   addition,	   similar	   to	  PCSK9	   levels	   in	   the	   CSF,	   BACE1	   does	   not	   exhibit	   diurnal	   variation	   and	   there	   was	   no	  significant	  correlation	  between	  PCSK9	  and	  BACE1	  in	  the	  CSF	  (Chen	  et	  al.,	  2014d).	  	  	  However,	  the	  potential	  effects	  of	  PCSK9	  on	  lipoprotein	  receptors	  may	  be	  more	  relevant	  to	  the	  AD-­‐related	  metabolic	  risk	  factors,	  such	  as	  hypercholesterolemia,	  than	  direct	  CNS	  effects.	  It	   could	   also	   be	   that	   steady-­‐state	   PCSK9	   CSF	   levels	   in	   healthy	   human	   subjects	   are	   not	  sufficient	   to	   affect	   BACE1	   or	   lipoprotein	   receptor	   levels,	   as	   highlighted	   by	   the	   60-­‐fold	  plasma:	  CSF	  PCSK9	  gradient	  (Chen	  et	  al.,	  2014d).	  It	  is	  feasible,	  however,	  that	  disease,	  injury	  or	   inflammation	  could	  elevate	   local	  or	  circulating	  CSF	  PCSK9	   levels	  and	  significantly	  alter	  BACE1	   and	   lipoprotein	   receptor	   function.	   Also	   the	   increased	   permeability	   of	   the	   BBB	  associated	  with	  brain	  injuries	  could	  increase	  CSF	  PCSK9	  levels.	  With	  an	  increasing	  focus	  on	  the	   development	   of	   PCSK9	   inhibitors,	   the	   full	   characterization	   of	   endogenous	   PCSK9	  functions	  in	  the	  brain	  and	  other	  extra-­‐hepatic	  tissues	  is	  warranted.	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2.6	  Berberine	  
2.6.1	  History	  and	  the	  traditional	  use	  of	  berberine	  Berberine	  is	  the	  main	  bioactive	  ingredient	  of	  Rhizoma	  coptidis	  root	  extract	  (also	  known	  as	  “Huanglian”	  in	  Chinese),	  which	  is	  also	  present	  in	  the	  roots,	  bark	  and	  flowers	  of	  many	  plants,	  including	  goldenseal,	  Hydrastis	  canadensis,	  and	  plants	  of	  the	  Berberis	  and	  Coptidis	   families	  (Figure	  2.15)(Jung	  et	  al.,	  2009;	  Ma	  et	  al.,	  2010).	  Modern	  scientific	  studies	  on	  berberine	  date	  back	  to	  the	  beginning	  of	   the	  20th	  century	  (Cromwell,	  1933).	  However,	   the	  earliest	  written	  descriptions	  of	  berberine	  containing	  extracts	  date	  back	  to	  the	  Han	  Dynasty	  200	  BC	  to	  200	  AD	   in	   China	   (Arayne	   et	   al.,	   2007).	   Berberine	   has	   been	   traditionally	   used	   as	   an	   antibiotic,	  anti-­‐diarrheal	  and	  detoxifying	  medicine	  (Yi	  et	  al.,	  2013).	  The	  recent	  decade	  has	  seen	  a	  surge	  of	   berberine-­‐related	   research,	   suggesting	   a	   plethora	   of	   medicinal	   applications	   for	  berberine,	   including	   antioxidant	   (Chen	   et	   al.,	   2012;	   Hsu	   et	   al.,	   2012),	   anti-­‐inflammatory	  (Choi	   et	   al.,	   2006),	   hypoglycemic	   (Tang	   et	   al.,	   2006;	   Chang	   et	   al.,	   2014b),	  hypocholesterolemic	   (Gu	   et	   al.,	   2014),	   anti-­‐diabetic	   (Chang	   et	   al.,	   2014b),	   anti-­‐AD	  (Durairajan	  et	  al.,	  2014;	  Durairajan	  et	  al.,	  2012;	  Xian	  et	  al.,	  2013),	  neuroprotective	  (Zhang	  et	  al.,	  2012b;	  Bae	  et	  al.,	  2013;	  Cui	  et	  al.,	  2009;	  Hsu	  et	  al.,	  2013),	  and	  anti-­‐cancer	  (Wang	  et	  al.,	  2010;	   Wu	   et	   al.,	   2012b;	   Yang	   and	   Huang,	   2013)	   properties.	   Although	   majority	   of	   these	  findings	  come	  from	  in	  vitro	  studies,	  studies	  on	  animal	  models	  and	  human	  cohorts	  support	  weight	   reducing,	   hypocholesterolemic	   and	   hypoglycemic	   properties	   of	   berberine	   by	  lowering	  total	  cholesterol,	  LDL	  cholesterol	  and	  triacylglycerides	  (Hu	  et	  al.,	  2012b;	  Kong	  et	  al.,	  2004;	  Yin	  et	  al.,	  2008).	  
	  
Figure	   2.15:	   The	   chemical	   structure	   of	   berberine	   present	   in	   the	   extracts	   of	  Coptidis	   and	  Berberis-­‐	   plant	  
species.	  Berberine	  belongs	  to	  the	  protoberberine	  family	  derived	  from	  tyrosine.	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2.6.2	  Berberine	  dosing	  and	  toxicity	  Berberine	  is	  generally	  accepted	  as	  safe	  for	  human	  use,	  although	  several	  reports	  have	  voiced	  concerns	  over	  the	  unregulated	  sale	  of	  berberine	  as	  a	  nutraceutical	  and	  the	  need	  for	  more	  extensive	   clinical	   safety	   studies	   (Yi	   et	   al.,	   2013;	   Cannillo	   et	   al.,	   2013).	   Recommended	  dosages	   for	   clinical	   use	  of	   berberine	   vary	  between	  0.5-­‐1.5	   g	  daily,	   taken	   in	   several	   doses	  during	   the	   day,	   which	   is	   generally	   well	   tolerated	   (Hu	   et	   al.,	   2012b;	   Derosa	   et	   al.,	   2012).	  These	   dosage	   levels	   translate	   into	   roughly	   5-­‐15	   mg/kg/day	   in	   humans,	   which	   would	  correspond	  to	  roughly	  30-­‐100	  mg/kg/day	  in	  rats	  and	  mice	  that	  have	  roughly	  6-­‐7	  fold	  faster	  metabolic	   rates.	   The	  most	   common	   side	   effect	   of	   berberine	   is	   gastrointestinal	   discomfort	  (Cannillo	   et	   al.,	   2013).	   Berberine	   has	   poor	   bioavailability	   through	   the	   gut,	   and	   berberine	  administration	  in	  human	  studies	  indicates	  that	  berberine	  reaches	  2-­‐10	  nM	  concentrations	  in	  the	  plasma	  (Spinozzi	  et	  al.,	  2014),	  although	  concentrations	  as	  high	  as	  560	  nM	  have	  been	  reported	  (Zeng	  and	  Zeng,	  1999).	  As	  berberine	   is	  shown	  to	  be	  rapidly	  eliminated	  from	  the	  plasma	   and	   accumulate	   in	   organs	   such	   as	   the	   liver,	   kidneys,	   lungs,	   heart	   and	   brain,	   the	  actual	  effective	   tissue-­‐specific	  berberine	  concentrations	   in	  humans	  are	  yet	   to	  be	  resolved.	  In	  rats,	  however,	  berberine	  was	  shown	  to	  have	  different	  kinetics	   in	   the	  plasma	  and	  brain	  (Wang	  et	  al.,	  2005a),	  with	  a	  concentration	  of	  1.67	  µM	  reached	  in	  the	  brain	  tissue	  with	  a	  100	  mg/kg	  dose	  3	  hours	  after	  administration	  (Durairajan	  et	  al.,	  2012).	  	  	  In	   animal	   studies,	   berberine	   toxicity	   depends	   largely	   on	   the	   route	   of	   administration.	   In	  mice,	   the	   median	   lethal	   dose	   (LD50)	   doses	   for	   intravenous	   (injected	   into	   the	   vein)	   and	  intraperitoneal	  (injected	  into	  the	  stomach	  cavity)	  injections	  were	  9.04	  g/kg	  and	  57.61	  g/kg,	  respectively	  (Kheir	  et	  al.,	  2010).	  LD50	  for	  intragastric	  or	  oral	  administration	  of	  berberine	  in	  mice	  could	  not	  be	  determined	  due	  to	  a	  limit	  in	  gastric	  berberine	  absorption	  even	  at	  doses	  up	   to	   83.2	   g/kg.	   Interestingly,	   the	   blood	   concentrations	   of	   berberine	   did	   not	   exceed	   0.5	  μg/ml	   or	   1.49	   μM	   (Kheir	   et	   al.,	   2010)	   by	   any	   type	   of	   administration	   even	   at	   the	   highest	  doses.	  This	  could	  be	  due	   in	  part	   to	  high	  binding	   to	  albumin,	   low	  bioavailability	  as	  well	  as	  plasma	   clearance	   due	   to	   excretion	   and	   organ	   accumulation,	   especially	   into	   the	   liver,	  kidneys,	  lungs,	  heart	  and	  brain	  (Ma	  et	  al.,	  2010;	  Wang	  et	  al.,	  2005b;	  Wang	  et	  al.,	  2005a;	  Tan	  et	  al.,	  2013).	  	  In	   acute	   toxicity	   studies	   of	   rat,	   LD50	   for	   oral	   berberine	   administration	   was	   shown	   to	   be	  713.57	   mg/kg,	   only	   roughly	   7-­‐20	   fold	   higher	   than	   what	   commonly	   used	   in	   animal	  experiments	  (Yi	  et	  al.,	  2013).	  Subchronic	  dosing	  of	  rats	  with	  berberine	  and	  other	  Rhizoma	  
coptidis	   alkaloids	   for	   90	   days	   revealed	   gender-­‐specific	   changes	   in	   body	   weight,	   relative	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organ	  weights	  and	  hematological	  parameters	  but	  no	  gross	  organ	  pathology.	  In	  female	  rats,	  berberine	   reduced	   body	  weight	  while	   increasing	   liver,	   kidney	   and	   brain	  weight.	   In	  male	  rats,	  liver,	  kidney	  and	  brain	  weights	  increased	  without	  an	  increase	  in	  body	  weight.	  In	  both	  sexes,	  stomach	  size	  was	  reduced	  together	  with	  blood	  levels	  of	  aspartate	  aminotransferase	  and	   γ-­‐glutamyltransferase.	   As	   markers	   of	   liver	   dysfunction,	   aminotransferase	   and	   γ-­‐glutamyltransferase	   reduction	  may	   indicate	   an	   improved	   liver	   function	   in	   the	   berberine-­‐treated	  rats	  (Yi	  et	  al.,	  2013).	  	  Typical	   oral	   berberine	   dosages	   in	   mouse	   and	   rat	   studies	   vary	   between	   10	   and	   100	  mg/kg/day,	  which	  are	  mostly	  well	  tolerated	  and	  in	  concert	  with	  the	  levels	  of	  human	  dosing	  (Kulkarni	  and	  Dhir,	  2008;	  Durairajan	  et	  al.,	  2012).	  Also,	  intraperitoneally	  and	  intravenously	  administered	  doses	  used	  in	  the	  studies	  are	  well	  below	  the	  LD50	  doses	  reported	  by	  Yi	  et	  al	  (Yi	  et	  al.,	  2013).	  However,	  several	  reports	  indicate	  that	  berberine	  might	  exacerbate	  toxicity	  of	  known	  neurotoxins	  such	  as	  1-­‐methyl-­‐4-­‐phenyl-­‐1,2,3,6-­‐tetrahydropyridine,	  which	  is	  used	  to	  generate	  PD	  animal	  models	  (Shin	  et	  al.,	  2013).	  In	  a	  PC-­‐12	  cell	  model,	  similar	  toxicity	  was	  observed	   with	   simultaneous	   berberine	   and	   cobalt	   chloride	   (CoCl2)	   application,	   but	   in	  contrast,	  preconditioning	  with	  berberine	  proved	  protective	  (Zhang	  et	  al.,	  2012a).	  	  	  Toxicity	   studies	   in	   cell	   lines	   indicate	   temporal-­‐,	   dose-­‐	   and	   cell	   type-­‐dependent	   toxic	  properties	  of	  berberine.	  In	  extracts	  such	  as	  Rhizoma	  coptidis,	  berberine	  is	  accompanied	  by	  other	   isoquinoline	   alkaloids	   such	   as	   coptidisine,	   palmatine	   and	   epiberberine	   (Yi	   et	   al.,	  2013).	   In	  comparison	  to	   the	  other	  alkaloids,	  berberine	  possesses	   the	  most	  robust	   toxicity	  (Ma	  et	  al.,	  2010;	  Imanshahidi	  and	  Hosseinzadeh,	  2008).	  Cell	  toxicity	  assays	  on	  the	  hepatic	  cell	   line	   HepG2	   and	   apidocyte	   cell	   line	   3T3-­‐L1	   indicate	   that	   the	   berberine	   concentration	  inducing	  a	  50%	  reduction	   in	  cell	  viability	  (IC50)	  after	  24-­‐hour	  treatment	  was	  48.17	  μg/ml	  and	  41.76	  μg/ml,	  respectively	  (Yi	  et	  al.,	  2013).	  With	  a	  molecular	  weight	  of	  336.3612	  g/mol,	  1	   μg/ml	   of	   berberine	   translates	   into	   a	   concentration	   of	   2.97	   μM.	   In	   another	   study,	   IC50	  values	   for	  six	  different	  cell	   lines	  (H9c2,	  RAW	  26.47,	  HepG2,	  PC-­‐12,	  Caco-­‐2	  and	  BALB/3T3	  cells)	  were	  42.6,	  21.2,	  35.2,	  41.7,	  >140,	  >140	  μg/ml	  after	  24-­‐hour	  incubation	  and	  27.6,	  8.1,	  12.4,	  20.1,	  111.8	  and	  102.3	  μg/ml	  after	  72-­‐hour	  incubation,	  respectively	  (Ma	  et	  al.,	  2010).	  In	  an	  immortalized	  murine	  hippocampal	  cell	  line	  HT-­‐22,	  berberine	  itself	  caused	  a	  reduction	  in	   cell	   viability	   at	   concentrations	   above	  3	  µM	  as	  measured	  by	  metabolic	   reduction	   assay,	  but	  did	  not	   induce	   lactate	  dehydrogenase	   (LDH)	  release	   indicating	  membrane	  disruption.	  However,	   30	   minute	   pretreatment	   with	   3-­‐30	   µM	   berberine	   showed	   a	   protective	   effect	  against	  homocysteic	  acid-­‐induced	  toxicity	  (Chen	  et	  al.,	  2014b;	  Chen	  et	  al.,	  2012).	  Similarly	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in	   NGF-­‐differentiated	   PC12	   cells	   and	   primary	   neurons,	   concentrations	   above	   1.5	   µM	  reduced	   cell	   viability	   (Hu	   et	   al.,	   2012a).	   These	   data	   indicate	   that	   berberine	   toxicity	   is	  dependent	  on	  the	  cell	  type	  and	  treatment	  time.	  	  
2.6.3	  Therapeutic	  potential	  of	  berberine	  Berberine	   is	   a	   multifunctional	   alkaloid,	   which	   has	   shown	   hypoglycemic	   and	  hypocholesterolemic	   potential	   in	   human	   studies	   (Chang	   et	   al.,	   2014b).	   Additionally,	   in	   a	  number	  of	  animal	  and	  cell-­‐based	  studies	  berberine	  has	  shown	  potential	  against	  a	  number	  of	   indications	   including	   dyslipidemias	   (Xiao	   et	   al.,	   2012),	   diabetes	   (Zhu	   and	  Qian,	   2006),	  hypercholesterolemia	   (Pisciotta	  et	  al.,	  2012),	   ischemia	   (Zhou	  et	  al.,	  2008;	  Cui	  et	  al.,	  2009;	  Benaissa	   et	   al.,	   2009)	   and	   AD	   (Durairajan	   et	   al.,	   2012).	   These	   proposed	   activities	   are	  attributed	   to	   multiple	   targets	   and	   effects,	   including	   AMPK	   activation,	   insulin	   receptor	  regulation,	  mitochondrial	  complex	  I	   inhibition,	  LDLR	  upregulation,	  PCSK9	  downregulation	  and	  BACE1,	  cholinesterase	  and	  monoamine	  oxidase	  inhibition	  (Yao	  et	  al.,	  2013;	  Jung	  et	  al.,	  2009).	  
2.6.3.1	  Diabetes	  and	  associated	  diseases	  Animal	  studies	  have	  elucidated	   that	  berberine	   improves	  glycemic	  control	   through	  several	  pathways	   including	  AMPK	  activation	   (Chang	  et	  al.,	  2014b).	  AMPK	  acts	  as	  a	  major	  cellular	  metabolic	  sensor.	  Partial	  mitochondrial	  complex	  I	  inhibition	  decreases	  cellular	  respiration	  and	   activates	   AMPK	   through	   increased	   AMP:	   ATP	   ratio.	   As	   a	   result,	   AMPK	   activation	  promotes	  mitochondrial	  biogenesis	  and	  antioxidant	  defenses,	  and	  increases	  the	  expression	  of	  glucose	  transporters	  and	  glycolytic	  enzymes	  (Canto	  et	  al.,	  2009).	  Hence,	  AMPK	  activation	  boosts	  the	  ATP	  generating	  capability	  of	  the	  cell	  while	  suppressing	  pathways	  utilizing	  ATP.	  AMPK	  is	  activated	  by	  berberine	  and	  common	  diabetes	  drugs	  metformin	  and	  rosiglitazone,	  but	   fasting	   and	   caloric	   restriction	   can	   also	   activate	  AMPK	   (McCarty,	   2014).	  Hence,	  AMPK	  activation	   is	   a	   key	   hypoglycemic	   function	   of	   berberine	   to	   promote	   glucose	   uptake	   and	  glycolysis	  (Turner	  et	  al.,	  2008).	  	  	  Berberine	   has	   shown	   efficacy	   against	   diabetes	   in	   several	   human	   clinical	   studies.	  Administering	   berberine	   1	   g	   daily	   for	   2	   months	   improved	   the	   markers	   of	   diabetes	   and	  dyslipidemia	  in	  patients	  with	  T2DM:	  lower	  levels	  of	  fasting	  blood	  glucose,	  hemoglobin	  A1c,	  triglycerides	  and	  insulin	  (Zhang	  et	  al.,	  2010).	  Effect	  sizes	  on	  fasting	  blood	  glucose,	  20-­‐35%	  reduction,	   and	   hemoglobin	   A1c	   were	   comparable	   to	   standard	   diabetes	   drugs	  metformin	  (1.5g	   daily)	   and	   rosiglitazone	   (4	   g	   daily).	   Interestingly,	   fasting	   blood	   glucose	   and	   liver	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enzyme	  profiles	  were	  both	  improved	  in	  patients	  suffering	  from	  the	  hepatitis	  B	  and	  C	  liver	  infections,	   indicating	  an	  additional	  benefit	  for	  patients	  suffering	  from	  liver	  disease	  (Zhang	  et	  al.,	  2010).	  In	  the	  associated	  human	  cell	  line	  studies,	  berberine	  increases	  insulin	  receptor	  mRNA	  and	  protein	  expression	  in	  an	  Akt-­‐dependent	  manner	  (Zhang	  et	  al.,	  2010).	  Similarly,	  in	   T2DM	   patients	   with	   dyslipidemias,	   3-­‐month	   administration	   of	   berberine	   1	   g	   daily	  significantly	  reduced	  fasting	  glucose	   levels,	  hemoglobin	  A1c,	   triglycerides,	   total	  cholesterol	  and	  LDL-­‐C	  (Zhang	  et	  al.,	  2008).	  In	  another	  study,	  berberine	  was	  administered	  in	  an	  extract	  form	   of	   Berberis	   aristata	   and	   coupled	   with	   polyphenol-­‐containing	   extract	   to	   increase	  berberine	   absorption	   through	   the	   gut.	   In	   patients	   receiving	   varying	   cocktail	   of	   diabetes,	  antihypertensive	   and	   cholesterol-­‐lowering	   drugs,	   berberine	   add-­‐on	   treatment	   reduced	  hemoglobin	   A1c,	   total	   cholesterol,	   LDL-­‐C,	   triglycerides,	   basal	   insulin	   levels	   and	   insulin	  sensitivity	  and	  improved	  liver	  enzyme	  profiles	  (Di	  Pierro	  et	  al.,	  2012).	  	  	  Diabetes	   is	   often	   associated	   with	   conditions	   such	   as	   neuropathy	   and	   increased	  susceptibility	  to	  ischemic	  stress	  (Carlsson,	  2010).	  In	  a	  rat	  model	  of	  diabetes,	  high-­‐fat	  diet-­‐fed	  rats	  treated	  with	  streptozotosin	  exhibit	  diabetic	  symptoms	  including	  reduced	  ability	  to	  cope	  with	  myocardial	  damage	  (Chen	  et	  al.,	  2014).	  Berberine	  administration	  for	  3	  weeks	  at	  the	  end	  of	  a	  12-­‐week	  diabetes	   induction	  period	  protected	  myocardiocytes	   from	  apoptosis	  induced	   by	  myocardial	   ischemia.	   This	   effect	  was	  mediated	   by	   increased	   AMPK	   and	   PI3K	  signaling	  and	  decreased	  caspase-­‐3	  activation	  (Chen	  et	  al.,	  2014a).	  
2.6.3.2	  Dyslipidemias	  and	  atherosclerosis	  In	   addition	   to	   improving	   glycemic	   control,	   berberine	   has	   also	   shown	   efficacy	   against	  dyslipidemias	  in	  human	  and	  animal	  studies	  (Zhang	  et	  al.,	  2008;	  Gu	  et	  al.,	  2010;	  Marazzi	  et	  al.,	   2011;	   Wei	   et	   al.,	   2012).	   Berberine	   reduced	   triglyceride	   and	   cholesterol	   levels	   in	  dyslipidemic	  patients	   (Zhang	  et	  al.,	  2008).	   Interestingly,	  berberine	  decreases	  plasma	   lipid	  concentrations	   differently	   from	   statins.	   In	   vivo,	   four-­‐week	   berberine	   (30	   mg/kg)	  pretreatment	   in	   mice	   was	   shown	   to	   prevent	   dyslipidemia	   and	   lower	   increased	  inflammatory	  markers	  after	  high	  cholesterol	  diet	  and	  lipopolysaccharide	  injection	  (Xiao	  et	  al.,	  2012).	  In	  support	  of	  these	  findings,	  berberine	  administration	  (400	  mg/kg/d)	  of	  high-­‐fat	  diet-­‐fed	  rats	  increased	  the	  hepatic	  mRNA	  levels	  of	  SREBP-­‐2	  and	  LDLR,	  and	  lowered	  HNF1	  levels.	  	  	  These	  differences	  have	  been	  shown	  to	  arise	   from	  the	   transactivation	  differences	  between	  the	   SRE	   and	   HNF1	   promoter	   elements	   in	   HepG2	   and	   primary	   hepatocytes.	   Whether	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berberine	  affects	  circulating	  PCSK9	   levels	   in	  humans	  remains	  unknown.	   Interestingly,	   the	  development	   of	   berberine	   analogues	   has	   also	   revealed	   berberine	   derivatives	   with	   an	  increased	   efficacy	   towards	   AMPK	   activation	   and	   LDLR	   upregulation	   (Wang	   et	   al.,	   2012).	  Berberine	  has	  been	  shown	  to	  modulate	  LDLR	  and	  PCSK9	  levels	  in	  HepG2	  cells	  by	  affecting	  their	   proximal	   promoter	   sites	   for	   SREBP	   and	   HNF1	   (Dong	   et	   al.,	   2014;	   Li	   et	   al.,	   2009;	  Cameron	   et	   al.,	   2008).	   Additionally,	   10	   to	   30	   μM	   berberine	   could	   inhibit	   the	   increase	   in	  PCSK9	  mRNA	  and	  protein	   levels	   induced	  by	  statins	  by	  blocking	   the	   transactivation	  of	   the	  HNF1	  promoter	  site	  required	  for	  PCSK9	  transcription	  (Cameron	  et	  al.,	  2008).	  Interestingly,	  however,	  berberine	  treatment	   in	  vivo	   increased	  circulating	  plasma	  PCSK9	  levels	  similar	  to	  simvastatin	  (Jia	  et	  al.,	  2014).	  	  	  Berberine	   is	   also	   suggested	   to	   exert	   anti-­‐atherogenic	   function	   by	   inhibiting	   foam	   cell	  formation	  by	   reducing	   lipid	   accumulation	   in	  macrophages.	   These	   effects	  were	  dependent	  on	   the	  activation	  of	   SIRT1	  and	  AMPK,	   and	  downregulation	  of	  PPARγ	   (Chi	   et	   al.,	   2014).	   In	  mice	   deficient	   in	   ApoE,	   berberine	   reduced	   atherogenesis	   via	   an	   AMPK-­‐dependent	  mechanism	  (Wang	  et	  al.,	  2011).	  
2.6.3.3	  Arrhythmia	  Berberine	   inhibits	   potassium	   (K+)-­‐outward	   currents.	   Berberine	   acutely	   inhibits	   hERG	  currents	   and	   prolongs	   action	   potential	   duration	   in	   cardiomyocytes	   (Li	   et	   al.,	   2001a).	  Berberine	  disrupts	  hERG	  channel	  trafficking	  by	  activating	  the	  UPR	  through	  ATF-­‐6	  cleavage	  (Zhang	  et	  al.,	  2014).	  This	  resulted	  in	  ubiquinated	  hERG,	  which	  was	  restricted	  to	  the	  ER	  and	  degraded	  in	  lysosomes	  and	  proteosomes	  (Zhang	  et	  al.,	  2014).	  These	  effects	  were	  prominent	  already	  with	  1	  µM	  concentration	  of	  berberine	  (Zhang	  et	  al.,	  2014).	  	  	  Berberine	   is	   shown	   to	   have	   arrhythmic	   effects	   by	   prolonging	   the	  QT	   phase	   due	   to	   hERG	  channel	   inhibition	   (Orvos	   et	   al.,	   2015;	   Li	   et	   al.,	   2001a;	   Rodriguez-­‐Menchaca	   et	   al.,	   2006).	  Surprisingly,	   patients	   suffering	   from	   congestive	   heart	   failure	   are	   shown	   to	   benefit	   from	  berberine	   treatment.	   In	   addition	   to	   conventional	   therapy,	   berberine	   improved	   left-­‐ventricular-­‐ejection-­‐fraction	   and	   exercise	   capacity	   and	   decreased	   mortality	   in	   several	  studies	  (Chen	  et	  al.,	  2014a;	  Zeng	  and	  Zeng,	  1999).	  In	  contrast,	  berberine	  administration	  was	  shown	  to	  cause	  bradycardia	  in	  an	  otherwise	  healthy	  adult	  (Cannillo	  et	  al.,	  2013).	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2.6.4	  Evidence	  for	  anti-­‐AD	  effects	  of	  berberine	  
2.6.4.1	  Evidence	  from	  animal	  AD	  models	  Berberine	  treatment	  also	  reduces	  some	  aspects	  of	  amyloid	  pathology	   in	  animal	  models	  of	  AD.	  In	  an	  Aβ40-­‐induced	  rat	  model	  of	  AD,	  50	  mg/kg	  intragastric	  administration	  of	  berberine	  for	   14	   days	   after	   the	   Aβ40-­‐injection	   improved	   spatial	   memory	   and	   reduced	   the	  inflammation	  markers	  IL-­‐1β	  and	  inducible	  nitrogen	  oxygen	  synthase	  (Zhu	  and	  Qian,	  2006).	  In	  the	  TgCRND8	  mouse	  AD	  model	  expressing	  Swedish	  and	  Indiana	  APP	  mutations,	  daily	  25	  mg/kg	   intragastric	   berberine	   administration	   for	   6	   months	   reduced	   learning	   deficits,	  improved	   long-­‐term	   memory	   retention	   and	   reduced	   plaque	   burden	   (Durairajan	   et	   al.,	  2012).	  Higher	  dose	  (100	  mg/kg)	  had	  a	  lesser	  effect	  on	  both	  the	  cognitive	  and	  pathological	  outcomes,	   indicating	   a	   bell-­‐shaped	   dose-­‐response	   curve	   and	   dose-­‐dependent	   effects	   of	  berberine	  (Durairajan	  et	  al.,	  2012).	  	  
2.6.4.2	  In	  vitro	  effects	  of	  berberine	  and	  related	  concoctions	  on	  APP	  and	  Tau	  metabolism	  Berberine	  and	  related	  concoction	  formulations	  are	  known	  to	  affect	  APP	  and	  Aβ	  metabolism	  (Durairajan	   et	   al.,	   2014;	  Durairajan	   et	   al.,	   2012).	  Rhizoma	   coptidis	   is	   the	  main	  berberine-­‐containing	  root	  extract,	  which	  also	  contains	  significant	  quantities	  of	  the	  alkaloids	  coptisine,	  palmatine	   and	   epiberberine	   (Yi	   et	   al.,	   2013).	   Huanglian-­Jie-­Du-­Tang	   is	   a	   medicinal	  concoction	   that	   has	   been	   used	   to	   treat	   cerebral	   ischemia	   in	   traditional	   Chinese	  medicine	  (Durairajan	  et	  al.,	  2014).	  The	  four	  components	  of	  the	  concoction	  include	  Rhizoma	  coptidis,	  
Radix	   scutellariae,	  Cortex	  phellodendri	   and	  Fructus	  gardenia.	  The	  concoction	   lacking	  Radix	  
scutellairiae	  proved	  more	  effective	  in	  reducing	  APP	  and	  Aβ	  than	  berberine	  or	  the	  individual	  components	  of	  the	  concoction.	  Radix	  scutellairiae	  itself	  significantly	  increases	  levels	  of	  full-­‐length	  APP,	  APP	  phosphorylation	  and	  sAPPα	  and	  sAPPβ	  secretion	  in	  N2a-­‐SwedAPP	  cells	  at	  doses	   as	   low	   as	   375	   ng/ml,	   whereas	   the	   APP	   lowering	   effects	   of	   the	   other	   components	  needed	   concentrations	   above	   12.5	   µg/ml	   to	   be	   effective	   (Durairajan	   et	   al.,	   2014).	   At	  concentrations	   exceeding	   3.125	  µM,	   berberine	   alone	   significantly	   decreased	  APP	   and	   but	  had	  only	  a	  marginal	  effect	  on	  intracellular	  Aβ42	  levels	  (Durairajan	  et	  al.,	  2014).	  In	  PC12	  cells,	  
Cortex	  phellodendri	  extracts	  protected	  against	  Aβ	  toxicity	  (Xian	  et	  al.,	  2013).	  	  Another	   Rhizoma	   coptidis-­‐extracted	   isoquinoline	   alkaloid	   jatrorrhizine	   protected	   rat	  cortical	  neurons	  against	  Aβ25-­‐35	  toxicity	  by	  suppressing	  caspase-­‐3	  activity	  and	  cyt-­‐c	  release	  (Luo	   et	   al.,	   2012).	   In	   human	   glioma	   H4	   cells,	   berberine	   reduced	   Aβ	   levels	   at	   an	   IC50	   of	  around	  5	  µM	  without	  affecting	  the	  Aβ40/Aβ42	  ratio	  and	  shifted	  APP	  processing	  towards	  the	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α-­‐secretase	  pathway	  (Asai	  et	  al.,	  2007).	  Similarly,	  berberine	   (1-­‐20	  µM)	  decreased	  Aβ	   and	  BACE1	   levels	   in	  HEK293-­‐APPSwe	  cells	   (Zhu	  et	  al.,	  2011).	  These	  effects	  were	  dependent	  on	  the	   activation	   of	   the	   ERK1/2	   pathway	   (Zhu	   et	   al.,	   2011).	   In	   N2a-­‐APPSwe	   cells,	   20	   µM	  berberine	   also	   significantly	   reduced	  APP	  phosphorylation	   and	  C-­‐terminal	   fragment	   levels	  (Durairajan	  et	  al.,	  2012).	  In	  primary	  mouse	  microglia	  and	  BV2	  microglial	  cell	  line,	  berberine	  inhibited	  the	  production	  of	  inflammatory	  cytokines	  IL-­‐6	  and	  MCP-­‐1	  induced	  by	  Aβ25-­‐35	  (Jia	  et	   al.,	   2012).	   Additionally,	   Aβ25-­‐35	   induced	   the	   activation	   of	   NF-­‐κB,	   Akt,	   p38	   and	   ERK1/2	  pathways,	  which	  were	   inhibited	  by	  5	  µM	  berberine.	   Interestingly,	  berberine	  activated	   the	  p38	  pathway	  independent	  of	  the	  Aβ25-­‐35	  treatment	  (Jia	  et	  al.,	  2012).	  	  	  Berberine	   also	   affects	   Tau	   phosphorylation.	   In	   Tau-­‐expressing	   HEK293	   cells,	   20	   µg/ml	  berberine	  significantly	  reduced	  Tau	  phosphorylation	  induced	  by	  calyculin	  A,	  a	  phosphatase	  2A	   inhibitor	  and	  a	  cellular	   toxin	  (Yu	  et	  al.,	  2011).	  Berberine	  restored	   the	  phosphatase	  2A	  activity,	   inhibited	  GSK3β	  activation	  and	  partially	  prevented	  calyculin	  A	   induced	  cell	  death	  (Yu	  et	   al.,	   2011).	   In	  N2a-­‐APPSwe	   cells,	   berberine	   concentrations	  above	  5	  µM	  activated	  Akt	  and	  inhibited	  GSK3β	  (Durairajan	  et	  al.,	  2012).	  
2.6.4.3	  Esterase	  inhibitor	  activity	  of	  berberine	  Berberine	  also	  possesses	  weak	  acetylcholine	  esterase	  inhibitor	  activity	  (Jung	  et	  al.,	  2009).	  Structural	   studies	   indicate	   that	   the	   hydrophobic	   surface	   of	   berberine	   interacts	   with	   the	  hydrophobic	   residues	   of	   AChE,	   BChE	   and	  monoamine	   oxidases	   (Kong	   et	   al.,	   2001;	   Ji	   and	  Shen,	  2012).	  Berberine	  and	  its	  related	  compounds	  exhibit	  AChE	  inhibitory	  activity	  with	  IC50	  values	  ranging	  between	  9	  and	  30	  µM	   in	  vitro	  (Ingkaninan	  et	  al.,	  2006).	  In	  cell	   free	   in	  vitro	  assays,	  berberine	  and	  its	  five	  related	  protoberberine	  alkaloids	  present	  in	  Rhizoma	  Coptidis	  exhibited	   AChE	   inhibitory	   activities	   ranging	   0.44-­‐1.07	   µM	   and	   butyrylcholinesterase	  inhibitory	   (BChE)	   activities	   ranging	  3.32	   –	  6.84	  µM	  (Jung	   et	   al.,	   2009).	  Berberine	  did	  not	  exhibit	  significant	  ONOO-­‐	  scavenging	  or	  BACE1	  inhibitory	  activity	  in	  cell	  free	  assays,	  or	  ROS	  inhibitory	  activity	  in	  isolated	  rat	  kidney	  mitochondria	  (Jung	  et	  al.,	  2009).	  A	  combination	  of	  berberine	  and	  protoberberine	  alkaloid	  palmatine	  was	  shown	  to	  have	  synergistic	  effect	  on	  AChE	   (Mak	  et	   al.,	   2014).	  Additionally,	   a	   series	  of	  berberine	  derivatives	   showed	   improved	  AChE	  and	  BChE	  inhibitory	  activities	  and	  reduced	  Aβ42	  aggregation	  in	  cell-­‐free	  assays	  (Shan	  et	  al.,	  2011).	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2.6.4.4	  Development	  of	  berberine	  derivatives	  and	  prodrugs	  Researchers	   at	   the	   lab	   of	   Xing-­‐Shu	   Li	   have	   generated	   numerous	   berberine	   derivatives	   to	  improve	   antioxidant	   properties,	   cholinesterase	   inhibitor	   activity	   and	   Aβ	   aggregation	  inhibitory	   activity	   of	   berberine.	   In	   one	   study,	   berberine	   was	   reacted	   with	   benzediol,	  melatonin	  and	  ferulic	  acid	  (Jiang	  et	  al.,	  2011).	  Two	  hybrids	  showed	  improved	  potential	  as	  novel	   anti-­‐AD	   drugs.	   Berberine-­‐pyrocatechol	   hybrid	   displayed	   increased	   AchE	   inhibitory	  activity	  and	  berberine-­‐hydroquinone	  showed	  increased	  antioxidant	  capabilities,	   increased	  AChE	  inhibitory	  activity	  and	  improved	  Aβ	   inhibition	  at	  20	  µM	  (Jiang	  et	  al.,	  2011).	  Another	  series	  of	  berberine	  derivatives	  revealed	  a	  9-­‐N-­‐substituted	  berberine	  derivative	  was	  found	  to	   be	   a	   good	   antioxidant,	   and	   potent	   AChE	   (IC50	   =	   0.027	  µM	  vs.	   0.374	  µM	  of	   berberine),	  BChE	   (18.2	  µM	  vs	   0.713	  µM)	   and	  Aβ	   aggregation	   inhibitor	   (IC50	   =	   2.73	  µM)	   (Shan	   et	   al.,	  2011;	  Huang	  et	  al.,	  2010).	  	  Taken	   together,	   berberine,	   berberine	   derivatives	   and	   their	   related	   alkaloids	   have	  multifunctional	   properties	   that	   are	   shown	   to	   affect	   central	   processes	   related	   AD	  pathogenesis	  (Figure	  2.16).	  However,	  the	  lack	  of	  human	  data	  and	  the	  numerous	  side	  effects	  of	  berberine,	  warrant	  comprehensive	  studies	  in	  humans	  to	  assess	  the	  safety	  and	  efficacy	  of	  berberine	  in	  the	  treatment	  of	  NDDs.	  
	  
Figure	   2.16:	   Summary	   of	   suggested	   anti-­‐AD	   properties	   of	   berberine.	   Green	   and	   red	   lines	  
indicate	   neuroprotective	   and	   neurotoxic	   effects,	   respectively.	   Blunt-­‐headed	   lines	   indicate	  
inhibition,	  whereas	  arrowheads	  indicate	  activation.	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3	  Aims	  	  The	   major	   aim	   of	   this	   Thesis	   was	   to	   investigate	   the	   effect	   of	   PCSK9	   and	   berberine	   on	  lipoprotein	  receptors	  and	  neuronal	  cell	  death.	  	  The	  specific	  aims	  of	  this	  Thesis	  were	  to:	  	  
1.	   Investigate	   the	   role	   and	   mechanism	   of	   PCSK9	   in	   the	   regulation	   of	   neuronal	  
apoptosis	  (I).	  
	  
2.	  Investigate	  the	  effects	  and	  mechanisms	  of	  berberine	  on	  neuronal	  viability	  (II).	  
	  
3.	   Study	   the	   regulation	   of	   lipoprotein	   receptor	   expression	   in	   neurons	   under	   stress	  
(III).	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4	  Materials	  and	  Methods	  Detailed	   practical	   descriptions	   of	   the	   methodology	   are	   available	   in	   the	   materials	   and	  methods	   sections	  of	   the	  adjoining	  publications	   (I-­‐III).	  The	   following	   sections	  describe	   the	  relevance	   and	   general	   design	   of	   the	   methods	   utilized	   in	   the	   present	   studies.	   All	   animal	  tissues	   were	   extracted	   in	   accordance	   with	   the	   local	   University	   of	   Helsinki	   animal	   care	  committee	  guidelines	  (animal	  license	  KEK14-­‐030).	  
4.1	  Reagents	  Below	  are	   listed	  the	  relevant	  reagents,	  kits	  and	  assays	  used	  to	  conduct	   the	  studies	  (Table	  4.1).	  
Reagent	  /	  Kit	  /	  Assay	   Producer	   Application	  /	  Function	  
Maxima	  SYBR	  Green	   Thermo	  Scientific	   qPCR	  fluorescent	  detection	  
RNeasy	  extraction	  kit	   Qiagen	   RNA	  extraction	  
Dynazyme	  cDNA	  synthesis	  kit	   Thermo	  Scientific	   cDNA	  synthesis	  
Staurosporine	   Sigma	   Broad	  range	  kinase	  inhibitor,	  cytotoxin	  
Wortmannin	   Sigma	   PI3K	  inhibitor	  
U0126	   Sigma	   ERK1/2	  inhibitor	  
SP600125	   Sigma	   JNK	  inhibitor	  
Sulfasalazine	   Sigma	   NF-­‐kB	  inhibitor	  
PP2	   Sigma	   Src	  kinase	  inhibitor	  
AP5	   Sigma	   NMDA	  receptor	  competitive	  antagonist	  
MK-­‐801	   Sigma	   NMDA	  receptor	  noncompetitive	  antagonist	  
Memantine	   Sigma	   NMDA	  receptor	  noncompetitive	  antagonist	  
Cyclosporin	  A	   Sigma	   MOMP	  inhibitor,	  calcineurin	  inhibitor	  
Cobalt	  chloride	  (CoCl2)	   Sigma	   Chemical	  hypoxia	  inducer	  
Hydrogen	  peroxide	  (H2O2)	   Sigma	   Oxidative	  stress	  inducer	  
Thapsigargin	   Sigma	   ER	  Ca2+-­‐ATPase	  inhibitor	  
Rotenone	   Sigma	   Mitochondrial	  complex	  I	  inhibitor	  
FK506	   Ascent	  Technologies	   Calcineurin	  inhibitor	  
Hoechst	   Invitrogen	   Nuclear	  stain	  
Berberine	  chloride	   Sigma	   Multifunctional	  root	  extract	  
Z-­‐VAD-­‐FMK	   Santa	  Cruz	   Pan-­‐caspase	  inhibitor	  
Resazurin	  sodium	  salt	   Life	  Technologies	   Metabolic	  activity	  assay	  
CellTiter-­‐Glo®	   Promega	   ATP-­‐based	  cell	  viability	  assay	  
CytoTox-­‐96®	   Promega	   LDH-­‐release	  based	  cell	  toxicity	  assay	  
JC-­‐10	   Abcam	   Mitochondrial	  membrane	  potential	  assay	  
CM-­‐H2DCFDA	   Life	  Technologies	   Oxidative	  stress	  assay	  	  
Table	  4.1:	  List	  of	  reagents	  used	  in	  studies	  I-­‐III.	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4.2	  Primary	  neuron	  cultures	  Cerebellar	  granule	  neurons	  (CGN)	  were	  dissected	  from	  the	  brains	  of	  mouse	  pups	  (postnatal	  days	  6-­‐8).	  CGN	  are	   the	  most	  numerous	  and	  homogenous	  neuronal	  population	  of	   the	  CNS.	  Cerebellar	  expression	  peak	  of	  PCSK9	  takes	  place	  around	  postnatal	  day	  7,	  hence	  CGN	  were	  chosen	  as	  the	  preferred	  cell	  death	  model	  to	  study	  the	  function	  of	  endogenous	  PCSK9	  (Miller	  and	  Johnson,	  1996).	  In	  contrast	  to	  other	  primary	  neurons,	  CGN	  require	  high	  potassium	  (25	  mM)	   growth	   medium	   concentration	   to	   support	   the	   survival	   of	   glutamatergic	   neurons	   in	  
vitro	  (Yan	  et	  al.,	  1994).	  	  	  Hippocampal	  neurons	  (HCN)	  were	   isolated	   from	  Wistar-­‐rat	  embryos	  (embryonic	  day	  18).	  Dissociated	  primary	  neuron	  cultures	  and	  hippocampal	  slice	  preparations	  are	  preferred	   in	  
vitro	   models	   for	   studies	   of	   neurite	   and	   spine	   morphology,	   LTP	   and	   electrophysiological	  experiments	  (Collin	  et	  al.,	  1997;	  Emptage	  et	  al.,	  1999).	  HCN	  are	  larger	  in	  size	  but	  fewer	  in	  number	  in	  comparison	  to	  CGN	  and	  develop	  an	  arborized	  and	  elaborate	  dendritic	  tree	  and	  mature	   spines	   within	   14-­‐21	   days	   in	   dissociated	   cultures	   in	   vitro	   (Emptage	   et	   al.,	   1999).	  Dorsal	  root	  ganglion	  neurons	  (DRGN)	  were	   isolated	   from	  Wistar-­‐rat	  embryos	  (embryonic	  day	  15).	  Cultured	  DRGN	  sprout	  long	  axons	  dependent	  on	  NGF	  and	  are	  utilized	  in	  studies	  of	  axonal	  degeneration	  (Melli	  and	  Hoke,	  2009).	  	  
4.3	  Neuronal	  treatments	  Neuronal	  stress	  and	  cell	  death	  were	  induced	  by	  a	  number	  of	  compounds	  mimicking	  specific	  types	  of	  cell	  injury	  and	  stress	  (Table	  4.1).	  Serum	  and	  potassium	  deprivation	  of	  CGN	  (I)	  was	  used	   as	   a	   model	   of	   developmental	   apoptosis	   (Coffey	   et	   al.,	   2000).	   Staurosporine	   (I)	   is	   a	  potent	  multi-­‐kinase	  inhibitor,	  which	  is	  also	  used	  as	  an	  apoptosis-­‐inducer	  (Caballero-­‐Benitez	  and	  Moran,	  2003).	  Berberine	  (II-­‐III)	  was	  used	  at	  varying	  concentrations	  to	  cause	  acute	  and	  mild	  neuronal	  stress.	  Rotenone	  (II-­‐III)	   is	  a	  potent	  complex	  I	   inhibitor,	  which	   is	  commonly	  used	   for	   mimicking	   mitochondrial	   neuronal	   stress	   related	   to	   PD	   and	   in	   studies	   of	  mitochondrial	  function	  (Betarbet	  et	  al.,	  2000).	  Glutamate	  (II-­‐III)	   is	  required	  by	  neurons	  in	  small	   concentrations,	   however,	   higher	   concentrations	   of	   glutamate	   are	   used	   to	   induce	  excitotoxicity,	   a	   hallmark	   of	   many	   NDDs	   (Schulz	   et	   al.,	   1996;	   Papadia	   and	   Hardingham,	  2007).	  Hydrogen	  peroxide	  (H2O2)	  (II-­‐III)	  induces	  oxidative	  stress	  in	  cells	  (Zhu	  et	  al.,	  2013).	  Cobalt	   chloride	   (CoCl2)	   activates	   hypoxia-­‐induced	   factor	   1	   alpha	   (HIF-­‐1α)	   and	   is	   used	   to	  mimic	   hypoxic	   conditions	   (II-­‐III)	   (Jones	   and	   Bergeron,	   2001;	   Ambrosini	   et	   al.,	   2015).	  Thapsigargin	   is	   an	   inhibitor	   of	   the	   ER	   Ca2+-­‐ATPase,	   which	   increases	   cytosolic	   Ca2+	   levels	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through	   release	   from	   intracellular	   stores,	   resulting	   in	   concomitant	   induction	  of	  ER	   stress	  (Irving	  et	  al.,	  1992).	  	  Inhibitors	  and	  lentiviral	  transductions	  were	  used	  to	  control	  specific	  pathway	  activation	  and	  gene	  expression,	  respectively.	  Pan-­‐caspase	   inhibitor	  z-­‐VAD-­‐FMK	  efficiently	  blocks	  caspase	  activation	   and	   caspase-­‐dependent	   apoptosis	   (I-­‐II).	   SP600125,	   U0126,	   Wortmannin	   and	  sulfosalazine	  were	  used	  as	  specific	  inhibitors	  of	  JNK,	  ERK,	  PI3K	  and	  NF-­‐κB	  kinase	  pathways,	  respectively	   (I).	   NMDA	   receptor	   inhibitors	   MK-­‐801	   and	   memantine	   are	   non-­‐competitive	  channel	   blockers	   that	   inhibit	   NMDA	   receptor-­‐mediated	   Ca2+	   influx	   and	   prevent	  excitotoxicity	   (II).	   Cyclosporine	   A	   is	   used	   as	   an	   immunosuppressant	   and	   inhibits	   both	  calcineurin	  and	  mitochondrial	  outer	  membrane	  permeabilization	  (MOMP)	  (II).	  FK-­‐506	  was	  used	  as	  a	  specific	  calcineurin	  inhibitor	  (II).	  
4.4	  Immunofluorescence	  imaging	  Immunofluorescence	   microscopy	   (I-­‐III)	   was	   used	   for	   high	   resolution	   imaging	   of	  intracellular	   targets	   and	   the	   assessment	   of	   their	   relative	   levels	   and	   morphology.	  Intracellular	  proteins	  and	  DNA	  were	  labelled	  with	  specific	  primary	  antibodies	  or	  stains,	  and	  coupled	   with	   fluorescent	   secondary	   antibodies	   to	   allow	  microscopic	   visualization	   (Table	  4.2).	   Both	   confocal	   (Carl	   Zeiss	   LM5)	   and	   epifluorescence	  microscopes	   (Carl	   Zeiss	   Imager	  M1)	  were	  used	  to	  take	  the	  images	  for	  microscopic	  analysis	  and	  publication	  figures.	  
4.5	  Protein	  analysis	  Western	  blotting	  (I-­‐III)	  is	  the	  standard	  method	  for	  analyzing	  the	  protein	  content	  of	  cell	  and	  tissue	  samples.	  Briefly,	  homogenized,	  heated	  and	  reduced	  cell	  culture	  protein	  samples	  were	  resolved	   in	  BisTris	   gels	   for	  one	  hour	  at	  160	  volts.	  The	   size-­‐separated	  proteins	  were	   then	  transferred	   onto	   a	   PVDF	   membrane	   and	   probed	   with	   protein-­‐	   or	   post-­‐translational	  modification-­‐	  specific	  antibodies	  (Table	  4.2).	  This	  analysis	  method	  is	  crucial	  for	  dissecting	  signaling	  pathways	  and	  determining	  the	  expression	  levels	  and	  activation	  states	  of	  specific	  proteins	  at	  predetermined	  timepoints.	  	  Below	  is	  the	  list	  of	  antibodies	  used	  for	  both	  immunofluorescence	  microscopy	  and	  Western	  blotting	  (Table	  4.2).	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Antibody	   Producer	   Catalog	  number	   Application	   Concentration	  
Primary	  antibodies	   	  	   	  	   	  	   	  	  
NGF	   Chemicon	   MAB52602	   Functional	  block	   0.5	  ug/ml	  
ApoE	   Santa	  Cruz	   sc-­‐6384	   WB	   1:500	  
cleaved	  caspase-­‐3	   Cell	  signaling	   9661	   WB	   1:1000	  
phospho-­‐c-­‐Jun	   Cell	  signaling	   2361	   WB,	  IF	   1:1000,	  1:250	  
VLDLR	   Santa	  Cruz	   sc-­‐20745	   WB	   1:500	  
VLDLR	   R&D	  systems	   MAB2258	   WB	   1:1000	  
GAPDH	   Millipore	   MAB374	   WB	   1:1000	  
ApoER2	   Sigma	   A3481	   WB	   1:1000	  
beta-­‐tubulin	  III	  (TUJ1)	   Covance	   MMS-­‐435P	   IF	   1:1000	  
beta-­‐tubulin	  III	  (TUJ1)	   Covance	   MRB-­‐435P	   IF	   1:1000	  
AIF	   Cell	  signaling	   5318	   IF	   1:500	  
MAP2	   Sigma	   M4403	   IF	   1:500	  
beta-­‐tubulin	  I+II	   Sigma	   T8535	   WB	   1:1000	  
TOM-­‐20	   Santa	  Cruz	   sc-­‐11415	   IF	   1:500	  
AIF	   Cell	  signaling	   5318	   IF	   1:500	  
HIF-­‐1alpha	   Abcam	   ab1	   IF	   1:500	  
beta-­‐catenin	   Biorbyt	   orb89771	   IF	   1:500	  
PARP	   Cell	  signaling	   9532	   WB	   1:500	  
	  IF-­‐2°	  antibodies	   	  	   	  	   	  	   	  	  
AF-­‐488	  Goat-­‐anti-­‐Mouse	   Invitrogen	   A11001	   IF	   1:2000	  
AF-­‐568	  Goat-­‐anti-­‐Mouse	   Invitrogen	   A11004	   IF	   1:2000	  
AF-­‐488	  Donkey-­‐anti-­‐Rabbit	   Invitrogen	   A21206	   IF	   1:2000	  
AF-­‐568	  Donkey-­‐anti-­‐Rabbit	   Invitrogen	   A10042	   IF	   1:2000	  
	  WB-­‐2°	  antibodies	   	  	   	  	   	  	   	  	  
HRP-­‐anti-­‐mouse	   GE-­‐Healthcare	   NA931V	   WB	   1:6000	  
HRP-­‐anti-­‐rabbit	   GE-­‐Healthcare	   NA934V	   WB	   1:6000	  
HRP-­‐anti-­‐goat	   Sigma	   A5420	   WB	   1:6000	  
	  
Table	   4.2:	   List	   of	   antibodies	   used	   for	   Western	   blotting	   (WB)	   and	   immunofluorescence	   (IF)	  
analysis.	  AF:	  AlexaFluor,	  HRP:	  Horseradish	  peroxidase-­‐conjugated.	  
4.6	  Cell	  viability	  assays	  Cell	   viability	   and	   cell	   death	   can	  be	  measured	   in	   a	  number	  of	  ways.	  As	  discussed	   in	  2.3.1,	  molecular	  pathways,	  progression	  and	  morphological	  hallmarks	  of	  cell	  death	  differ	  between	  cell	   death	   types.	   Neurites	   stained	   with	   neuronal	   specific	   β-­‐tubulin	   III	   marker	   TUJ1	   and	  nuclei	  stained	  with	  Hoechst	  were	  used	  for	  morphological	  assessment	  of	  neuronal	  viability	  (I-­‐III).	   Damaged	   or	   dying	   neurons	   displayed	   degeneration	   of	   neuronal	   processes,	   and	  fragmentation	   and	   condensation	   of	   the	   cell	   nuclei.	   Additionally,	   neuronal	   specific	   TUJ1	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staining	  allowed	  simultaneous	  confirmation	  of	  cell	   identity	  from	  the	  minority	  of	  glial	  cells	  present	  in	  the	  culture.	  	  Cell	  viability	  was	  additionally	  assessed	  by	  a	  number	  of	  molecular	  assays,	  which	  all	  measure	  slightly	   different	   aspects	   of	   cell	   function	   or	   integrity	   (Rampersad,	   2012).	   Increased	  membrane	   permeability	   and	   cell	   rupture	   results	   in	   the	   release	   of	   intracellular	  molecules	  into	   the	   surrounding	  media,	   including	   lactate	   dehydrogenase	   (LDH).	   LDH	   concentrations	  were	  measured	  from	  the	  culture	  medium	  to	  assess	  the	  loss	  of	  cell	   integrity	  and	  cell	  death	  (II).	  Decline	  in	  the	  ATP	  content	  within	  a	  culture	  well	  correlates	  with	  decreased	  cell	  viability	  and	  metabolic	  homeostasis,	  indicating	  changes	  in	  the	  balance	  between	  ATP	  production	  and	  ATP	   expenditure.	   The	   CellTiter-­‐Glo®	   ATP	   assay	   was	   used	   to	   elucidate	   the	   effects	   of	  different	  berberine	  concentrations	  on	  neuronal	  viability	  (II).	  Additionally,	  resazurin	  sodium	  salt	   (Alamar	   blue	   assay)	  was	   used	   to	   assess	   the	   reductive	   potential	   of	   the	   neuronal	   cells	  over	  time	  in	  culture,	  with	  the	  reduction	  of	  resazurin	  into	  fluorescent	  resorufin	  correlating	  with	   general	   metabolic	   activity	   and	   cell	   viability.	   All	   of	   the	   aforementioned	   assays	   were	  analyzed	  with	  a	  spectrometer	  (Victor3	  1420,	  PerkinElmer)	  with	  the	  specific	  wavelengths	  of	  absorption	  or	  fluorescence	  corresponding	  to	  the	  underlying	  chemical	  reactions	  in	  the	  assay.	  	  Mitochondria	   are	   a	   central	   organelle	   for	   cellular	   respiration	   and	  metabolism,	   but	   also	   in	  mediating	  cell	  death	  (Nicholls	  and	  Budd,	  2000).	  The	  role	  of	  mitochondria	   in	  neuronal	  cell	  death	  was	  assessed	  by	  changes	   in	  mitochondrial	  morphology	  and	   function.	  Mitochondrial	  morphology	  was	  assessed	  by	   lentiviral	  overexpression	  of	  GFP-­‐tagged	  mitochondrial	  outer	  membrane	   protein	   25	   and	   immunofluorescence	   staining	   of	   the	   endogenous	   outer	  mitochondrial	   membrane	   protein	   TOM-­‐20.	   High	   magnification	   immunofluorescence	  microscopy	   revealed	   a	   change	   in	   mitochondrial	   morphology	   from	   normal	   elongated	   to	  swollen	   and	   rounded,	  which	   is	   characteristic	   of	  mitochondrial	   dysfunction	   and	   cell	   death	  (II)	   (Nicholls,	   2008).	   Additionally,	   measures	   of	   mitochondrial	   membrane	   potential	   and	  oxidative	   stress	   with	   JC-­‐10	   and	   CM-­‐H2DCFDA	   assays,	   respectively,	   were	   used	   to	   assess	  mitochondrial	   function.	  The	   loss	   of	  mitochondrial	  membrane	  potential	   (II)	   and	   increased	  oxidative	  stress	  (II-­‐III)	  indicate	  mitochondrial	  dysfunction.	  
4.7	  DNA	  and	  RNA	  The	  efficiency	  of	   transfecting	  primary	  cultured	  neurons	  with	   foreign	  DNA	  or	  RNA	   is	  poor	  with	  the	  traditional	  transfection	  methods	  suitable	  for	  most	  cell	  lines.	  However,	  viral	  vectors	  can	   be	   produced	   and	   loaded	   with	   DNA	   or	   RNA	   to	   overexpress	   or	   suppress	   proteins	   of	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interest	  with	  high	  efficacy	  and	   low	  toxicity	   (Salozhin	  and	  Bol'shakov,	  2010;	  Anliker	  et	  al.,	  2010).	   Lentiviral	   particles	  were	   produced	   in	  HEK-­‐293T	   cells	  with	   different	   short	   hairpin	  RNA	   sequences	   and	   the	   plasmids	   encoding	   viral	   structural	   elements,	   pPAX.2	   and	   pMD.G	  (Table	  4.3).	  	  	  
Gene	   Source	   shRNA	  clone	  
Ctrl	  shRNA	   OpenBiosystems	  /	  GE	  Healthcare	   RHS6848	  
PCSK9	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000032784-­‐G1	  
PCSK9	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000032785-­‐G2	  
PCSK9	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000032786-­‐G3	  
PCSK9	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000032787-­‐F11	  
PCSK9	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000032788-­‐F12	  
ApoER2	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000176508	  
ApoER2	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000177833	  
ApoER2	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000178706	  
ApoER2	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000176636	  
ApoER2	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000177656	  
VLDLR	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000127069	  
VLDLR	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000127070	  
VLDLR	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000127071	  
VLDLR	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000127072	  
VLDLR	   OpenBiosystems	  /	  GE	  Healthcare	   TRCN0000127073	  
	  
Table	  4.3:	  List	  of	  lentiviral	  shRNA	  constructs	  purchased	  from	  OpenBiosystems	  /	  GE	  Healthcare.	  	  Relative	  levels	  of	  mRNA	  were	  assessed	  by	  real-­‐time	  quantitative	  polyribose	  chain	  reaction	  (qPCR)	  (II-­‐III)	  and	  semi-­‐quantitative	  methods	  (I).	  Briefly,	  RNA	  was	  isolated	  from	  neuronal	  cell	   cultures	  with	  RNeasy	   kit	   and	   reverse-­‐transcribed	   into	   complementary	  DNA.	   Samples	  were	  then	  multiplied	  with	  appropriate	  gene-­‐specific	  primers	  to	  assess	  the	  relative	  levels	  of	  gene	  expression	  (Table	  4.4).	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Gene	   Forw/Rev	   Species	   Sequence	  5’	  -­‐>	  3’	  
	  	   	  	   	  	   	  	  
GAPDH	   Forw	   human,	  mouse	   ACCCCTTCATTGACCTCAACTACATGG	  
	  	   Rev	   human,	  mouse	   ATCCACAGTCTTCTGGGTGGCA	  
PCSK9	   Forw	   mouse	   CTGCTCCAGAGGTCATCACAGTC	  
	  	   Rev	   mouse	   CAGGGAACCAGGCCATGTTGATG	  
ApoER2	   Forw	   human,	  mouse	   GACGAGGACGACTGCCCCAA	  
	  	   Rev	   human,	  mouse	   GTCCCATCCCCACACTGGAACTC	  
VLDLR	   Forw	   human,	  mouse	   GTGCAGCTGGGTTTGAACTGATAGATAGG	  
	  	   Rev	   human,	  mouse	   GTCTTAGAAGCCGCATCAGTCCAGTAG	  
LDLR	   Forw	   human,	  mouse	   GACACCTGCAGCCAGCTCTG	  
	  	   Rev	   human,	  mouse	   CCCCTTTCTTGATCTTGGCGGG	  
LRP1	   Forw	   human,	  mouse	   ATTGTGGCTGCTGACAGCAAACGA	  
	  	   Rev	   human,	  mouse	   GTGCATTTGGGGCCCGTGAAG	  
LRP4	   Forw	   mouse,	  rat	   ATCTCACTGGACACCGATGA	  
	  	   Rev	   mouse,	  rat	   TCTGCTCGCCTGATAACATC	  
LRP5	   Forw	   mouse	   GAGCTGCTGCACAGAACATT	  
	  	   Rev	   mouse	   TCCTGCCAGAAGAGAACCTT	  
LRP6	   Forw	   mouse	   AGTGATCTCTCAGGTGCCAA	  
	  	   Rev	   mouse	   TGGACCTTGGTTCTTCCTTC	  	  
Table	  4.4:	  Primers	  used	  for	  qPCR.	  
4.8	  Statistical	  analysis	  All	   experimental	   data	   (I-­‐III)	   presented	  was	   gathered	   from	  minimum	   of	   three	   repetitions	  from	  at	   least	   two	  different	  batches	  of	  cells.	  Microsoft	  Excel	  and	  GraphPad	  Prism	  software	  were	   used	   for	   statistical	   analyses	   and	   the	   generation	   graphs	   presented	   in	   the	   adjoining	  publications.	   All	   figures	  were	   compiled	   using	   Photoshop	   CS4.	   Statistical	   significance	  was	  evaluated	   with	   Student’s	   t-­‐test	   or	   ANOVA,	   where	   appropriate,	   with	   the	   significance	  threshold	  set	  at	  p	  <	  0.05	  (*),	  with	  p	  <	  0.005	  (**)	  and	  p	  <	  0.001	  (***).	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5	  Results	  
5.1	  Anti-­‐apoptotic	  effects	  of	  endogenous	  PCSK9	  reduction	  in	  neurons	  (I)	  
5.1.1	  Inhibition	  of	  the	  c-­‐Jun/caspase-­‐3	  apoptotic	  pathway	  	  PCSK9	   is	   associated	  with	  modulation	   of	   apoptosis	   in	   neurons	   and	   human	   umbilical	   vein	  endothelial	  cells	  (HUVEC).	  Overexpression	  of	  PCSK9	  in	  CGN	  induces	  apoptosis	  (Bingham	  et	  al.,	  2006)	  and	  the	  reduction	  of	  endogenous	  PCSK9	  is	  associated	  with	  lower	  activation	  of	  the	  caspase-­‐3-­‐apoptotic	   pathway	   induced	   by	   oxidized-­‐LDL	   in	   HUVECs	   (Wu	   et	   al.,	   2012a).	   In	  postnatal	  mice	   cerebellum,	   the	   endogenous	   expression	   peak	   of	   PCSK9	   coincides	   with	   an	  active	  developmental	  elimination	  phase	  of	  cerebellar	  granule	  neurons	  (CGN)	  characterized	  by	   increased	   activation	   of	   apoptotic	   pathways	   (Coffey	   et	   al.,	   2000;	   Monti	   et	   al.,	   2002).	  However,	  the	  role	  of	  PCSK9	  in	  the	  apoptotic	  cascade	  has	  remained	  poorly	  understood.	  	  	  Potassium/serum	   (K5)	  deprivation	   triggers	   robust	   JNK-­‐	   and	   caspase-­‐dependent	  neuronal	  apoptosis	  in	  CGN	  in	  vitro,	  mimicking	  the	  developmental	  elimination	  phase	  in	  vivo	  (Coffey	  et	  al.,	  2002).	  We	  produced	  short	  hairpin	  RNA	  (shRNA)-­‐containing	  lentiviral	  particles	  targeting	  PCSK9,	  ApoER2	  and	  VLDLR	  mRNA	   to	   elucidate	   their	   role	   in	  K5	  deprivation	   (K5)-­‐induced	  CGN	  apoptosis.	  CGN	  were	  transduced	  with	  lentiviral	  vectors	  3-­‐4	  days	  prior	  to	  starting	  other	  treatments	  to	  downregulate	   the	  endogenous	  expression	  of	  PCSK9,	  ApoER2	  and	  VLDLR	  by	  RNA	   interference	   (RNAi).	   The	   silencing	   efficacies	   of	   the	   different	   gene-­‐specific	   shRNA	  constructs	   were	   tested	   by	   RT-­‐PCR	   and	  Western	   blotting;	   with	   downregulation	   efficacies	  ranging	  between	  30-­‐50%	  (I	  /	  Figure	  1C	  &	  Suppl.	  Figure	  1).	  For	  PCSK9,	  a	  maximum	  of	  90%	  protein	  downregulation	  was	  achieved	  as	  determined	  by	  Western	  blotting	  (I	  /	  Figure	  1B).	  	  	  Interestingly,	  PCSK9	  lentiviral	  downregulation	  reduced	  the	  basal	   levels	  of	  phosphorylated	  nuclear	   c-­‐Jun,	   an	   early	   mediator	   of	   apoptosis	   (I	   /	   Figure	   1E).	   Combined	   with	   K5	  deprivation,	   levels	   of	   phosphorylated	   c-­‐Jun	   remained	   40-­‐50%	   lower	   in	   PCSK9	  RNAi	   CGN	  between	  2	  and	  9	  hours	  post-­‐apoptosis	  induction	  (I	  /	  Figure	  2A,C,E,G).	  Similarly,	  caspase-­‐3	  cleavage	   was	   reduced	   by	   over	   50%	   between	   4	   and	   24	   hours	   post-­‐treatment	   (I	   /	   Figure	  2B,D).	   The	   percentage	   of	   neurons	   displaying	   condensed	   or	   fragmented	   nuclei	   began	  increasing	  after	  4	  hours	  in	  both	  control	  and	  PCSK9	  RNAi	  CGN	  (I	  /	  Figure	  2H),	  although	  cell	  viability	   remained	   higher	   in	   PCSK9	  RNAi	   CGN	   at	   all	   timepoints	   between	  4	   and	   24	   hours,	  which	   coincided	  with	   the	   temporal	  pattern	  of	   caspase-­‐3	   inhibition	   (I	   /	   Figure	  2D).	  These	  data	  indicate	  that	  PCSK9	  downregulation	  modulates	  the	  activation	  of	  c-­‐Jun	  and	  caspase-­‐3.	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5.1.2	  Differential	  modulation	  of	  ApoER2,	  VLDLR	  and	  ApoE	  protein	  expression	  PCSK9	  is	  an	  endogenous	  downregulator	  of	  LDLR,	  but	  is	  also	  known	  to	  bind	  and	  degrade	  the	  lipoprotein	  receptors	  ApoER2,	  VLDLR	  and	  LRP1,	  depending	  on	  the	  conditions	  and	  cell	  type	  (Poirier	  et	  al.,	  2008;	  Roubtsova	  et	  al.,	  2011;	  Canuel	  et	  al.,	  2013).	   	  CGN	  and	  HUVEC	  express	  various	   lipoprotein	  receptors,	   including	  ApoER2,	  VLDLR	  and	  LDLR	  (Stannard	  et	  al.,	  2001;	  Pacheco	   et	   al.,	   2001;	  Wu	   et	   al.,	   2012a;	   Perez-­‐Garcia	   et	   al.,	   2004;	   Sinagra	   et	   al.,	   2008).	   To	  elucidate	   the	   possible	   effects	   of	   PCSK9	   downregulation	   on	   lipoprotein	   receptors,	   the	  relative	  protein	  levels	  of	  ApoER2	  and	  VLDLR	  in	  CGN	  were	  determined	  by	  Western	  blotting	  (I	   /	   Figure	   3A-­‐D).	   PCSK9	   RNAi	   cells	   displayed	   1.5-­‐fold	   higher	   ApoER2	   protein	   levels	   at	  baseline	  and	  they	  remained	  elevated	  throughout	  K5	  deprivation	  when	  compared	  to	  control	  cells	   (I	   /	   Figure	   3B,D).	   Interestingly,	   PCSK9	   RNAi	   did	   not	   alter	   VLDLR	   levels	   (I	   /	   Figure	  3B,C).	  We	  further	  assessed	  the	  role	  of	  ApoER2	  and	  VLDLR	  on	  caspase-­‐3	  cleavage	  following	  K5	  deprivation	  and	  PCSK9	  RNAi	  by	  ApoER2	  and	  VLDLR	  RNAi.	  ApoER2	  RNAi	  reversed	  the	  protective	  effect	  of	  PCSK9	  RNAi	  on	  cell	  death	  as	  measured	  by	  caspase-­‐3	  cleavage	  (I	  /	  Figure	  3E,F).	  In	  contrast,	  downregulation	  of	  VLDLR	  in	  addition	  to	  PCSK9	  RNAi	  did	  not	  affect	  c-­‐Jun	  or	   caspase-­‐3	   activation,	   suggesting	   that	   ApoER2	   and	   VLDLR	   have	   differential	   roles	   in	  modulating	  caspase-­‐3-­‐dependent	  apoptotic	  cascade	  in	  CGN	  (I	  /	  Figure	  3E,F).	  	  	  ApoER2	   and	   VLDLR	   can	   bind	   multiple	   ligands,	   including	   Reelin	   and	   ApoE,	   and	   are	  implicated	  in	  the	  regulation	  of	  several	  kinase	  pathways	  including	  PI3K	  (Bock	  et	  al.,	  2003),	  JNK	  (Stockinger	  et	  al.,	  2000;	  Helbecque	  et	  al.,	  2003),	  ERK1/2	  (Lee	  et	  al.,	  2014a)	  and	  NF-­‐κB	  (Li	  et	  al.,	  2007).	  ApoE4	  is	  major	  risk	  factor	  for	  AD,	  and	  is	  shown	  to	  participate	  in	  neuronal	  signaling	  pathways	  (Holtzman	  et	  al.,	  2012).	  In	  mice,	  only	  one	  ApoE	  variant	  exists	  which	  is	  comparable	   to	   the	   common	  human	  ApoE3	  variant	   in	   function	   (Yamahara,	   1976).	  ApoE	   is	  primarily	   produced	   and	   secreted	   by	   glial	   cells,	   but	   also	   neurons	   are	   known	   to	   produce	  ApoE	   under	   certain	   circumstances	   (Rolyan	   et	   al.,	   2011).	   Increased	   ApoE	   production	   is	  associated	  with	  brain	  injury	  in	  animal	  models,	  presumably	  to	  support	  lipid	  and	  cholesterol	  debris	  clearance	  and	  neuronal	  regeneration	  (Cartagena	  et	  al.,	  2008;	  White	  et	  al.,	  2001).	  	  We	   assessed	   the	   levels	   of	   cell-­‐bound	   ApoE	   in	   CGN	   under	   K5	   deprivation	   (Figure	   5.1).	  Interestingly,	   the	   levels	   of	   cell-­‐bound	   ApoE	   were	   differentially	   regulated	   in	   PCSK9	   RNAi	  CGN	   and	   control	   cells.	   Six-­‐hour	   K5	   deprivation	   increased	   ApoE	   protein	   levels	   in	   control	  cells	  and	  decreased	  them	  in	  PCSK9	  RNAi	  cells	  (Figure	  5.1).	  As	  shown	  in	  the	  Western	  blot,	  culture	  medium	  sample	  taken	  before	  K5	  induction	  shows	  an	  accumulation	  of	  ApoE	  during	  a	  week	  of	  culture,	  whereas	  the	  fresh	  K5	  medium	  shows	  no	  sign	  of	  ApoE	  accumulation	  within	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the	   6-­‐hour	   treatment.	   Taken	   together,	   these	   data	   show	   that	   PCSK9	   RNAi	   affects	   the	  lipoprotein	  receptor	  protein	  expression	  of	  ApoER2	   in	  CGN,	   reduces	  caspase-­‐3	  cleavage	   in	  an	   ApoER2-­‐dependent	   manner	   and	   alters	   the	   levels	   of	   cell-­‐bound	   ApoE	   following	   K5	  apoptotic	  stimulus.	  
	  
Figure	  5.1:	  ApoE	  levels	   in	  CGN	  cultures.	  Representative	  Western	  blot	  of	  cell	   lysates	  and	  media	  
detected	  with	  mouse	  specific	  ApoE	  antibody	  and	  GAPDH	  for	  sample	  control.	  Intracellular	  ApoE	  
levels	   were	   reduced	   in	   PCSK9	   RNAi	   cells	   following	   K5	   deprivation,	   in	   contrast	   to	   an	   increase	  
seen	  in	  control	  cells	  (unpublished	  data).	  	  
5.1.3	  JNK-­‐dependent	  and	  independent	  roles	  of	  PCSK9	  RNAi	  protection	  Since	   ApoER2	   and	   VLDLR	   participate	   in	   numerous	   downstream	   signaling	   pathways,	   we	  reasoned	   that	   the	  anti-­‐apoptotic	  effect	  of	  PCSK9	  suppression	  may	  be	   linked	   to	   the	  kinase	  pathways	  upstream	  of	  caspase-­‐3	  activation.	  The	  major	  PI3K,	  JNK,	  ERK1/2	  and	  NF-­‐κB	  kinase	  signaling	  pathways	  were	   inhibited	  with	  wortmannin,	  SP600125,	  U0126	  and	  sulfasalazine,	  respectively	  (I	  /	  Figure	  5).	  JNK	  and	  ERK1/2	  inhibition	  had	  a	  synergistic	  effect	  with	  PCSK9	  RNAi	  on	  caspase-­‐3	  inhibition	  (I	  /	  Figure	  5A,B),	  whereas	  PI3K	  and	  NF-­‐κB	  inhibition	  partially	  reversed	   the	   effect	   of	   PCSK9	   RNAi	   on	   caspase-­‐3	   cleavage	   (I	   /	   Figure	   5C,D).	   This	   is	   in	  accordance	   with	   the	   known	   pro-­‐	   and	   anti-­‐apoptotic	   roles	   of	   the	   kinase	   pathways	   in	   the	  regulation	  of	  neuronal	   cell	   death	   (reviewed	   in	  Chapter	  2.3.2).	   For	   example,	   JNK	   signaling	  participates	   in	   pro-­‐apoptotic	   signaling	   through	   c-­‐Jun	   phosphorylation.	   Interestingly,	   the	  effects	   of	   PCSK9	  RNAi	  were	   not	   completely	   reversed	   by	   either	   PI3K	   or	  NF-­‐κB	   inhibition,	  possibly	  indicating	  the	  involvement	  of	  multiple	  or	  synergistic	  neuroprotective	  pathways.	  	  	  Lastly,	   we	   explored	   the	   extent	   of	   PCSK9	   RNAi	   neuroprotection	   in	   other	   paradigms	   of	  neuronal	   apoptosis	   and	   axonal	   degeneration:	   staurosporine-­‐induced	   apoptosis	   in	   CGN	  (Ramiro-­‐Cortes	   and	   Moran,	   2009)	   and	   NGF-­‐deprivation	   induced	   axonal	   degeneration	   in	  dorsal	   root	   ganglion	   neurons	   (DRGN).	   PCSK9	   RNAi	   reduced	   caspase-­‐3	   cleavage	   and	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increased	  cell	  viability	  of	  CGN	  treated	  with	  staurosporine	  (I	  /	  Figure	  6A-­‐C),	  an	  effect	   that	  was	   not	   potentiated	   by	   JNK	   inhibition	   with	   SP600125	   (I	   /	   Figure	   6C).	   In	   the	   NGF-­‐deprivation	   deprivation	   model	   of	   DRGN,	   PCSK9	   RNAi	   reduced	   axonal	   degeneration	   as	  assessed	  by	  an	   increased	  proportion	  of	   intact	  axons	   (I	  /	  Figure	  6D,E).	  DRGN	  also	  express	  the	  lipoprotein	  receptors	  LDLR	  and	  ApoER2	  (Kosacka	  et	  al.,	  2011)	  and	  axonal	  degeneration	  in	   DRGN	   caused	   by	   NGF-­‐withdrawal	   is	   partially	   JNK-­‐dependent	   (Gold	   et	   al.,	   1993;	  Middleton	   and	  Davies,	   2001).	   Taken	   together,	   these	   data	   suggest	   that	   downregulation	   of	  endogenous	   PCSK9	   in	   primary	   neurons	   is	   neuroprotective	   through	   both	   JNK-­‐dependent	  and	  independent	  pathways.	  	  
	   83	  
5.2	  Mechanisms	  of	  berberine-­‐mediated	  neurotoxicity	  (II)	  
5.2.1	  Micromolar	  berberine	  concentrations	  cause	  neuronal	  cell	  death	  in	  vitro	  Berberine	   is	   the	   primary	   bioactive	   alkaloid	   of	   root	   extracts	   used	   in	   traditional	   Chinese	  medicine	  and	  has	  shown	  efficacy	  in	  human	  studies	  against	  dyslipidemias	  (Xiao	  et	  al.,	  2012),	  diabetes	   (Zhu	   and	   Qian,	   2006)	   and	   hypercholesterolemia	   (Pisciotta	   et	   al.,	   2012).	  Additionally,	   in	   studies	   utilizing	   animal	   and	   cell	   models,	   berberine	   has	   shown	   efficacy	  against	   ischemia	   (Zhou	   et	   al.,	   2008;	   Cui	   et	   al.,	   2009;	   Benaissa	   et	   al.,	   2009)	   and	   AD	  (Durairajan	   et	   al.,	   2012).	   However,	   the	   neuron-­‐specific	   effects	   of	   berberine	   are	   poorly	  understood	  as	  both	  neuroprotective	  (Yoo	  et	  al.,	  2006b;	  Cui	  et	  al.,	  2009;	  Bae	  et	  al.,	  2013;	  Hsu	  et	   al.,	   2013)	   and	   neurotoxic	   properties	   (Kwon	   et	   al.,	   2010;	   Shin	   et	   al.,	   2013)	   have	   been	  described.	  	  	  Using	   murine	   CGN	   and	   rat	   hippocampal	   (HCN)	   primary	   neuron	   cultures,	   we	   tested	  berberine	   concentrations	   between	   10	   nM	   to	   10	   µM	   to	   establish	   a	   safe	   berberine	  concentration	  window	  (II	  /	  Figure	  1).	  Surprisingly,	  six-­‐hour	  treatment	  with	  1	  µM	  berberine	  was	   sufficient	   to	   decrease	   cellular	   ATP	   content,	   indicating	   an	   effect	   on	   cell	   viability	   (II	   /	  Figure	  1D).	  Berberine	   concentrations	  3	  and	  10	  µM	  caused	  a	   robust	   effect	  on	  nuclear	  and	  neuritic	   morphology,	   as	   assessed	   by	   nuclear	   and	   tubulin	   staining	   (Figure	   1A,B).	  Additionally,	  3	  and	  10	  µM	  berberine	  decreased	  ATP	  content	   to	  a	   similar	  extent	  at	  both	  6	  and	   24	   hours,	   indicating	   a	   dose-­‐	   rather	   than	   time-­‐dependent	   effect	   of	   berberine	  administration	  on	  neuronal	  viability	  (II	  /	  Figure	  1D,E).	  Our	  data	  indicate	  that	  neurons	  are	  sensitive	   to	   even	   low	   micromolar	   concentrations	   of	   berberine	   in	   vitro,	   although	   a	   wide	  range	  of	   in	  vitro	  concentrations	  of	  berberine,	  between	  0.1	  nM	  and	  300	  µM,	  are	  frequently	  reported	  in	  the	  literature.	  	  To	   assess	   whether	   varying	   concentrations	   of	   berberine	   have	   an	   additive	   or	   protective	  functions	  in	  CGN	  undergoing	  apoptosis,	  as	  described	  in	  some	  cell	  lines	  (Cui	  et	  al.,	  2009;	  Bae	  et	   al.,	   2013;	   Hsu	   et	   al.,	   2013).	   We	   induced	   apoptosis	   with	   serum/potassium	   (K5)	  deprivation	   and	   0.1	  µM	   staurosporine	   (STS)	   in	   combination	  with	   berberine	   (10	   nM	   to	   3	  
µM).	   Interestingly,	   whereas	   K5	   deprivation	   modestly	   reduced	   cell	   viability	   at	   6	   hours	  compared	  to	  control	  (K25),	  CGN	  did	  not	  display	  a	  sharp	  decrease	   in	  viability	  after	  0.3	  µM	  berberine	  seen	  with	  K25.	  Instead,	  combining	  K5	  deprivation	  with	  3	  µM	  berberine	  improved	  the	  resistance	  of	  CGN	  against	  berberine	  toxicity	  in	  the	  ATP	  assay	  (Figure	  5.2).	  In	  contrast,	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staurosporine	  significantly	  reduced	  cell	  viability	  and	  cotreatment	  with	  berberine	  resulted	  in	  exacerbated	  cell	  toxicity	  dose-­‐dependently.	  	  
	  
Figure	   5.2:	   Fluorescent	   measurement	   of	   cellular	   ATP	   levels.	   CGN	   treated	   for	   6	   hours	   with	  
berberine	   (0.01	   –	   3	  µM)	   in	   K25	  media	   (circle,	   intact	   line),	   K5	  media	   (square,	   dotted	   line)	   or	  
staurosporine	  (STS)	  0.1	  µM	  (triangle,	  dashed	  line)	  show	  variable	  effects	  on	  cellular	  ATP	  levels.	  n	  
=	  3,	  p	  <	  0.001	  (***)	  between	  K25	  and	  STS-­‐groups,	  and	  p	  <	  0.005	  (**)	  between	  K25	  and	  K5	  at	  3	  
µM	  berberine	  (unpublished	  data).	  	  
5.2.2	  Effects	  of	  micromolar	  berberine	  on	  mitochondrial	  function	  and	  integrity	  Berberine	   is	   known	   to	   selectively	   localize	   to	   the	   mitochondria,	   disrupt	   mitochondrial	  function	  and	  induce	  apoptosis	  in	  cancer	  lines	  when	  applied	  at	  higher	  doses	  (Pereira	  et	  al.,	  2007;	  Wang	  et	  al.,	  2012;	  Pereira	  et	  al.,	  2008).	  We	  hypothesized	  that	  berberine	  might	  cause	  neurotoxicity	   through	   mitochondrial	   effects,	   as	   neurons	   are	   particularly	   sensitive	   to	  mitochondrial	   disruptions	   and	   dysfunction	   (Nicholls,	   2008).	   We	   utilized	   mitochondrial	  assays	   and	   immunofluorescence	   imaging	   to	   determine	   the	   effects	   of	   berberine	   on	  mitochondrial	  function	  and	  integrity.	  The	  loss	  of	  mitochondrial	  membrane	  potential	  and	  a	  decrease	   in	  mitochondrial	  metabolic	   activity	  were	   early	   events	   in	   berberine-­‐induced	   cell	  death	  apparent	  after	  one	  hour	  post-­‐treatment	  (II	  /	  Figure	  2F,H).	  Increased	  oxidative	  stress	  correlated	  with	   the	   loss	   of	   neuronal	   cell	   viability	   seen	   after	   2	   hours	   of	   10	  µM	  berberine	  treatment	   (II	   /	   Figure	   2G).	   Mitochondrial	   morphology	   was	   also	   affected,	   as	   neuronal	  mitochondria	   became	   swollen	   and	   rounded	   after	   one	   hour	   (II	   /	   Figure	   2E).	   Further	  supporting	   the	   importance	   of	   mitochondria	   in	   berberine-­‐mediated	   neuronal	   cell	   death,	  cyclosporine	   A,	   a	   calcineurin	   and	   MOMP	   inhibitor,	   partially	   reversed	   berberine	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neurotoxicity	  independent	  of	  its	  calcineurin	  inhibitory	  activity	  (II	  /	  Figure	  3).	  Interestingly,	  mitochondria	   in	   adjacent	   glial	   cells	   did	   not	   display	   similar	   mitochondrial	   swelling,	  suggesting	  a	  cell	  type-­‐specific	  mitochondrial	  effect	  at	  10	  µM	  berberine	  (II	  /	  Figure	  2E).	  	  	  In	   addition	   to	   its	   mitochondrial	   effects,	   berberine	   is	   known	   to	   modulate	   both	   caspase-­‐dependent	  and	  independent	  apoptotic	  pathways	  in	  cancer	  cells	  (Hwang	  et	  al.,	  2006;	  Wang	  et	   al.,	   2012).	  We	   assessed	   the	   possible	   involvement	   of	   caspase-­‐3	   cleavage,	   a	   hallmark	   of	  caspase-­‐dependent	   apoptosis,	   on	   berberine-­‐induced	   neuronal	   cell	   death.	   Caspase-­‐3	  cleavage	  was	   not	   affected	   by	   berberine	   treatment	   and	   pan-­‐caspase	   inhibitor	   z-­‐VAD-­‐FMK	  did	   not	   affect	   berberine-­‐induced	   cell	   death	   (II	   /	   Figure	   2A-­‐D;	   Figure	   5.3).	   To	   support	  caspase-­‐3	  independent	  role	  in	  berberine-­‐mediated	  cell	  death,	  we	  also	  assessed	  the	  level	  of	  c-­‐Jun	  phosphorylation	  and	  the	  levels	  of	  PARP,	  a	  target	  of	  caspase	  cleavage	  (Chaitanya	  et	  al.,	  2010).	   There	   was	   a	   sustained	   dose-­‐dependent	   decrease	   in	   full	   length	   PARP,	   with	   an	  increased	  level	  of	  a	  roughly	  60	  kDa	  fragment	  (PARP	  F2;	  Figure	  5.3)	  and	  no	  visible	  89	  kDa	  caspase-­‐cleaved	   fragment	   (PARP	   F1;	   Figure	   5.3)	   as	   seen	   in	   the	   serum/potassium	   (K5)	  condition	  (last	  lane;	  PARP-­‐F1)	  (Figure	  5.3).	  	  	  
	  
Figure	   5.3:	   Representative	  Western	   blot	   (A)	   and	   quantitation	   of	   full	   length	   (FL)	   and	   F2-­‐PARP	  
fragments	   (B,C).	   PARP	   staining	  did	  not	  display	   the	   caspase-­‐cleaved	  89	   kDa	   cleavage	   fragment	  
seen	   in	   K5	   deprivation	   induced	   apoptotic	   cells	   (last	   lane,	   K5;	   A).	   Instead,	   roughly	   a	   60	   kDa	  
fragment	   (PARP-­‐F2)	   was	   present	   in	   berberine-­‐treated	   cells,	   possibly	   indicating	   an	   alternative	  
executioner	   protease.	  GAPDH	   levels	  were	   decreased	   in	   3	   and	   10	  µM	  berberine	   treated	   cells,	  
likely	  due	  to	  extensive	  cell	  damage	  (unpublished	  data).	  n	  =	  3,	  p	  <	  0.05	  (*),	  p	  <	  0.001	  (***).	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5.2.3	  NMDA	  receptor	  antagonists	  prevent	  berberine	  neurotoxicity	  Increased	   MOMP,	   mitochondrial	   swelling	   and	   the	   activation	   of	   caspase-­‐independent	   cell	  death	  pathways	  are	  characteristic	  of	  excitotoxic	  cell	  death	  in	  neurons	  (Yu	  et	  al.,	  2003).	  As	  berberine-­‐mediated	   cell	   death	  was	   shown	   to	   be	   caspase-­‐independent	   and	  progress	  more	  rapidly	   than	   apoptotic	   cell	   death	   observed	   in	   the	   first	   study	   (I),	   we	   hypothesized	   that	  excitotoxic	  mechanisms	  may	  be	  involved.	  NMDA	  receptor	  antagonists	  attenuate	  excitotoxic	  cell	  death	  of	  neurons	  in	  vivo	  and	  in	  vitro	  (Volbracht	  et	  al.,	  2006).	  We	  therefore	  tested	  the	  possible	   involvement	   of	   NMDA	   receptors	   in	   berberine-­‐mediated	   neurotoxicity	   by	  cotreating	   CGN	   and	   HCN	   with	   non-­‐competitive	   inhibitors	   MK-­‐801	   and	   memantine	  (Volbracht	   et	   al.,	   2006).	  MK-­‐801	   and	  memantine	   completely	   inhibited	   berberine-­‐induced	  neurotoxicity	  in	  both	  CGN	  and	  HCN	  cultures	  as	  seen	  by	  the	  preserved	  nuclear	  and	  neuritic	  morphology	   (II	   /	   Figure	   4).	   Interestingly,	   memantine	   is	   approved	   for	   the	   symptomatic	  treatment	  of	  moderate-­‐to-­‐severe	  AD.	  These	  data	   indicate	   that	  NMDA	   receptor	   function	   is	  central	  to	  berberine	  neurotoxicity.	  
5.2.4	  Berberine	  pretreatment	  potentiates	  glutamate	  and	  rotenone	  toxicity	  Both	   neuroprotective	   and	   neurotoxic	   properties	   of	   berberine	   have	   been	   suggested	   in	  previous	  literature	  (Zhang	  et	  al.,	  2012b;	  Shin	  et	  al.,	  2013).	  To	  elucidate	  whether	  lower	  (30-­‐300	  nM)	   subtoxic	   concentrations	   of	   berberine	   as	   a	   pre-­‐treatment	   affect	   the	   sensitivity	   of	  neurons	   to	   additional	   excitotoxic	   and	   metabolic	   stress	   by	   glutamate	   and	   rotenone,	  respectively,	   we	   pretreated	   CGN	   for	   16	   hours	   with	   berberine	   and	   then	   added	   subtoxic	  doses	   of	   glutamate	   or	   rotenone	   for	   6	   hours.	   Berberine	   pretreatment	   of	   300	   nM	   together	  with	  glutamate	  and	  of	  30	  nM	  with	  rotenone,	  reduced	  cell	  viability	  as	  assessed	  by	  LDH	  assay	  and	  morphological	  assessment	  (II	  /	  Figure	  5	  and	  6)	  (5.2.1).	  	  	  	  Taken	   together,	   these	   data	   suggest	   that	   micromolar	   concentrations	   of	   berberine	   have	  neurotoxic	  properties	  in	  primary	  neuron	  cultures.	  Also,	  nanomolar	  concentrations	  relevant	  to	  concentrations	  reached	  by	  oral	  dosing	   in	  animals	  and	  humans	  can	  make	  neurons	  more	  susceptible	   to	   secondary	   insults,	   such	   as	   glutamate	   or	  mitochondrial	   toxins.	   Importantly,	  berberine	  neurotoxicity	  can	  be	  prevented	  or	  partially	  inhibited	  by	  NMDAR	  antagonists	  and	  MOMP	  inhibition,	  respectively.	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5.3	  VLDLR	  is	  upregulated	  in	  response	  to	  neuronal	  stress	  (III)	  
5.3.1	  Regulation	  of	  neuronal	  lipoprotein	  receptors	  and	  PCSK9	  by	  berberine	  Lipoprotein	  receptors	  hold	  important	  systemic	  and	  CNS	  roles,	  whereas	  PCSK9	  can	  regulate	  neuronal	   lipoprotein	   receptor	   expression	   and	   apoptosis	   (I).	   As	   shown	   in	   Study	   I,	   PCSK9	  downregulation	   is	   neuroprotective	   in	   an	   ApoER2-­‐dependent	   fashion	   (I).	   Interestingly,	  berberine	   is	   shown	   to	   downregulate	   PCSK9	   expression	   in	   hepatocytes	   in	   vitro	   through	  SREBP	   and	   HNF	   transcription	   factors	   (Dong	   et	   al.,	   2014;	   Li	   et	   al.,	   2009;	   Cameron	   et	   al.,	  2008),	   although	   recent	   in	   vivo	   studies	   indicate	   that,	   similar	   to	   statins,	   plasma	   PCSK9	  concentrations	  can	  be	  increased	  with	  berberine	  administration	  in	  high-­‐fat	  diet	  red	  rats	  (Jia	  et	  al.,	  2014).	  Berberine	  is	  shown	  to	  have	  neuroprotective	  properties	  (Yoo	  et	  al.,	  2006b;	  Cui	  et	  al.,	  2009;	  Bae	  et	  al.,	  2013;	  Hsu	  et	  al.,	  2013),	  but	  the	  potential	  role	  of	  berberine-­‐induced	  PCSK9	  and	  lipoprotein	  receptor	  modulation	  in	  neurons	  remains	  unexplored.	  	  	  We	   previously	   showed	   that	   in	   vitro,	   berberine	   by	   itself	   has	   neurotoxic	   properties	   at	  concentrations	  exceeding	  1	  µM	  (II).	  In	  this	  study,	  we	  used	  qPCR	  to	  assess	  the	  mRNA	  levels	  of	  PCSK9	  and	  lipoprotein	  receptors	  LDLR,	  VLDLR,	  ApoER2,	  LRP1,	  LRP4,	  LRP5	  and	  LRP6	  in	  CGN.	   When	   added	   at	   a	   concentration	   of	   1	   µM,	   berberine	   differentially	   regulated	   the	  expression	  of	  PCSK9	  and	  lipoprotein	  receptors	  at	  the	  transcriptional	   level	  (III	  /	  Figure	  1).	  After	  24	  hours	  of	  1	  µM	  berberine	  treatment,	  the	  expression	  of	  PCSK9	  (0.60-­‐fold)	  and	  LDLR	  (0.42-­‐fold)	  were	   reduced,	   ApoER2	   and	   LRP4	   remained	   unaffected,	   and	   the	   expression	   of	  VLDLR	   (2.64-­‐fold),	   LRP1	   (1.94-­‐fold),	   LRP5	   (2.26-­‐fold)	   and	   LRP6	   (1.99-­‐fold)	   were	  upregulated.	  At	  a	  lower	  concentration	  of	  0.1	  µM,	  which	  did	  not	  affect	  cellular	  ATP	  levels	  or	  affect	   neuronal	   viability	   (II),	   berberine	   did	   not	   affect	   the	   transcriptional	   expression	   of	  PCSK9	  or	  any	  of	  the	  lipoprotein	  receptors	  (III	  /	  data	  not	  shown).	  LRP1	  showed	  a	  trend	  of	  increase	  by	  1.57-­‐fold	  after	  6-­‐hour	  treatment	  (III	  /	  Figure	  1A),	  but	  interestingly,	  VLDLR	  was	  the	   only	   gene	   significantly	   upregulated	   after	   6	   hours	   of	   1	  µM	  berberine	   treatment	   (2.16-­‐fold),	  suggesting	  an	  acute	  response	  and	  potentially	  different	  mechanism	  compared	  to	  other	  lipoprotein	  receptors.	  
5.3.2	  Increased	  HIF-­‐1α 	  levels	  correlate	  with	  VLDLR	  upregulation	  VLDLR	  expression	  is	  known	  to	  be	  upregulated	  by	  several	  transcription	  factors	  including	  the	  hypoxia	  and	  stress-­‐responsive	  HIF-­‐1α	  (Sundelin	  et	  al.,	  2013;	  Wang	  et	  al.,	  2014;	  Sanderson	  et	   al.,	   2010)	   in	   contrast	   to	   the	   other	   lipoprotein	   receptors.	   Coincidentally,	   berberine	   is	  shown	   to	  modulate	   several	   transcription	   factors,	   including	   HIF-­‐1α	   (Zhang	   et	   al.,	   2012a),	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Nrf2	   (Chen	  et	   al.,	   2012;	  Hsu	   et	   al.,	   2012;	  Hsu	   et	   al.,	   2013),	   PPAR	   (Zhou	  and	  Zhou,	   2010),	  SREBP1/2	   (Jia	   et	   al.,	   2014)	   and	  HNF1	   (Dong	   et	   al.,	   2014).	   Based	   on	   this	   information,	  we	  hypothesized	   that	   berberine	   upregulates	   VLDLR	   by	   stabilizing	   HIF-­‐1α	   levels.	  Immunofluorescence	  staining	  of	  HIF-­‐1α	  revealed	  a	  significant	   increase	  in	  the	  intracellular	  accumulation	  of	  HIF-­‐1α	   after	  6	  hours,	   at	   levels	   comparable	  with	  CoCl2,	   a	  positive	   control	  that	  mimics	  hypoxia	  and	  induces	  the	  stabilization	  of	  HIF-­‐1α	  (III	  /	  Figure	  2).	  However,	  this	  effect	  was	  not	  evident	  after	  24	  hour	  berberine	  administration,	  indicating	  a	  transient	  effect	  of	  berberine	  on	  HIF-­‐1α	  stabilization.	  	  
5.3.3	  Cellular	  stressors	  increase	  VLDLR	  expression	  Based	   on	   our	   previous	   study,	   berberine	   causes	   neuronal	   stress,	   including	   oxidative	   and	  mitochondrial	  stress,	  and	   increases	  the	  sensitivity	  of	  neurons	  to	  additional	  stressors	  such	  as	   glutamate	   and	   rotenone	   at	   subtoxic	   concentrations	   of	   1	   µM	   and	   below	   (II).	   We	  postulated	   that	   since	  1	  µM	  berberine	  decreased	   cellular	  ATP	   levels	   (II)	   in	   contrast	   to	  0.1	  
µM,	   transcriptional	   changes	   in	   VLDLR,	   VLDLR	   expression	   was	   upregulated	   by	   neuronal	  stress.	   VLDLR	   is	   known	   to	   be	   upregulated	   due	   to	   hypoxic	   injury	   (Yang	   et	   al.,	   2014)	   and	  inflammation	  (Nguyen	  et	  al.,	  2013)	  depending	  on	  the	  cell	  and	  tissue	  type.	  We	  used	  hypoxia-­‐mimic	  CoCl2,	  mitochondrial	  complex	  I	  inhibitor	  rotenone	  and	  the	  ER	  Ca2+-­‐	  ATPase	  inhibitor	  thapsigargin	   to	   induce	   various	   types	   of	   neuronal	   stress	   and	   assess	   whether	   berberine-­‐induced	  VLDLR	  upregulation	  is	  specific	  to	  a	  certain	  type	  of	  neuronal	  stress.	  	  	  The	  concentrations	  used	  for	  rotenone,	  thapsigargin	  and	  CoCl2	  were	  20	  nM,	  200	  nM	  and	  200	  
µM,	  respectively.	  These	  concentrations	  are	  below	  their	  relative	  acutely	  toxic	  in	  vitro	  doses	  reported	   in	   the	   literature	   (Yang	  et	   al.,	   2004;	  Yadava	  and	  Nicholls,	   2007;	  Yao	  et	   al.,	   1999)	  and	   they	  did	  not	  decrease	  cell	  viability	  of	   the	  CGN	  cultures	  within	   the	  24-­‐hour	   treatment	  period,	  as	  assessed	  by	  morphological	  assessment	  of	  neurites	  and	  nuclei	  (III	  /	  Figure	  3A,B).	  Interestingly,	  all	  of	  these	  stressors	   increased	  VLDLR	  mRNA	  levels	  between	  2.5	  to	  9.5-­‐fold,	  with	  thapsigargin	  inducing	  the	  largest	  increase,	  an	  affect	  also	  reflected	  on	  the	  protein	  levels	  (III	  /	  Figure	  4A-­‐C).	  The	  levels	  of	  oxidative	  stress	  in	  the	  treated	  CGN	  measured	  with	  the	  CM-­‐H2DCFDA	  assay	  revealed	  that	  only	  CoCl2	   increased	  oxidative	  stress,	   indicating	  that	  VLDLR	  was	  upregulated	  independently	  of	  oxidative	  stress	  (III	  /	  Figure	  3C).	  	  	  
5.3.4	  Berberine	  affects	  GSK3β 	  phosphorylation	  and	  β -­‐catenin	  levels	  VLDLR	  is	  known	  to	  inhibit	  Wnt	  signaling	  by	  heterodimerizing	  with	  LRP6	  on	  the	  cell	  surface	  via	  ectodomain	  interaction,	  facilitating	  endocytosis	  and	  directing	  the	  receptor	  complex	  for	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degradation	  (Lee	  et	  al.,	  2014b).	  Berberine	  also	  inhibits	  the	  Wnt	  signaling	  pathway,	  partially	  explaining	   its	   anti-­‐tumor	   activity	   (Albring	   et	   al.,	   2013;	   Wu	   et	   al.,	   2012b).	   The	  multifunctional	   kinase	   GSK3β	   regulates	   the	   stabilization	   of	   β-­‐catenin,	   the	   transcriptional	  effector	  of	  canonical	  Wnt	  signaling.	  We	  assessed	   the	  possible	  effects	  of	  BBR	  treatment	  on	  Wnt	   signaling	   in	   CGN	   by	   determining	   the	   levels	   of	   GSK3β	   serine-­‐9	   phosphorylation,	  indicative	  of	  GSK3β	  activity	  level	  (Pospisil	  et	  al.,	  2006)	  and	  the	  intracellular	  β-­‐catenin	  levels	  by	  immunofluorescence	  staining.	  	  Treatment	  with	  1	  µM	  BBR	  for	  24	  hours	  increased	  the	  phosphorylation	  of	  GSK3β	  by	  1.3-­‐fold	  (p	  =	  0.0412),	  with	  a	  trend	  of	  increase	  observed	  with	  0.1	  µM	  BBR	  (p	  =	  0.0537)	  (Figure	  5A,B).	  Interestingly,	  cellular	  β-­‐levels	  showed	  a	  biphasic	  pattern	  with	  1	  µM	  BBR	  treatment,	  with	  a	  decrease	  at	  6	  hours	  and	  an	   increase	  at	  24	  hours	  post-­‐treatment	   (Figure	  5C).	  Considering	  that	  the	  transcriptional	  expression	  of	  Wnt	  signaling	  co-­‐receptors	  LRP5	  and	  LRP6	  were	  also	  increased	   after	   24-­‐hour	   treatment,	   this	   could	   indicate	   a	   compensatory	   response	   to	  decreased	   Wnt	   signaling	   at	   6	   hours	   potentially	   involving	   the	   acute	   increase	   in	   VLDLR	  protein	   expression.	   Taken	   together,	   these	   results	   show	   that	   VLDLR	   expression	   is	  upregulated	  by	  neuronal	  stress	  and	  is	  linked	  to	  modulation	  of	  neuronal	  Wnt	  signaling.	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6	  Discussion	  
6.1	  Study	  I	  –	  PCSK9	  modulation	  in	  neurons	  The	  postnatal	  expression	  peak	  of	  PCSK9	  in	  the	  brain	  takes	  place	  in	  the	  cerebellum	  at	  a	  time	  of	  developmental	  neuronal	  pruning.	  Earliest	  studies	  of	  PCSK9	  implicate	  its	  role	  in	  neuronal	  apoptosis,	   but	   the	   interaction	   of	   PCSK9	   with	   the	   neuronal	   cell	   death	   machinery	   has	  remained	   elusive.	   The	   results	   of	   our	   study	   indicate	   that	   decreasing	   endogenous	   PCSK9	  expression	   in	  neurons	  has	  neuroprotective	   effects	  by	   reducing	   caspase-­‐3	   activation	   in	   an	  ApoER2-­‐dependent	   manner	   in	   the	   K5	   deprivation	   model	   mimicking	   developmental	  neuronal	   apoptosis.	   PCSK9	   RNAi	   increased	   the	   protein	   levels	   of	   ApoER2	   in	   CGN	   and	  reduced	   the	   phosphorylation	   of	   c-­‐Jun	   and	   the	   cleavage	   of	   caspase-­‐3.	   PCSK9	   RNAi	   also	  inhibited	   caspase-­‐3	   cleavage	   in	   staurosporine-­‐induced	   apoptosis,	   independent	   of	   JNK	  kinase	   function.	   Also	   PCSK9	   RNAi	   reduced	   axonal	   degeneration	   in	   NGF-­‐deprived	   DRGN.	  ApoER2	  is	  known	  to	  regulate	  neuronal	  survival	  in	  vivo	  (Beffert	  et	  al.,	  2006)	  and	  our	  findings	  support	   the	   anti-­‐apoptotic	   role	   of	   ApoER2.	   Interestingly,	   VLDLR	   protein	   levels	   remained	  unaffected	   by	   PCSK9	   RNAi,	   and	   unlike	   ApoER2,	   VLDLR	   RNAi	   did	   not	   reverse	   the	   anti-­‐apoptotic	   effects	   of	   PCSK9	   RNAi.	   These	   results	   highlight	   the	   functional	   separation	   of	   the	  closely	   associated	   ApoER2	   and	   VLDLR	   receptors	   in	   controlling	   neuronal	   viability	   and	  apoptotic	  pathways.	  	  PCSK9	   RNAi	   affected	   the	   levels	   of	   ApoE	   in	   CGN,	   especially	   during	   K5	   deprivation,	   when	  CGN-­‐associated	   ApoE	   was	   decreased	   compared	   to	   control.	   Whether	   this	   effect	   is	   due	   to	  reduced	   production,	   increased	   clearance	   or	   changes	   in	   ApoE	   receptor	   expression	   or	  localization	  goes	  beyond	  the	  scope	  of	  this	  study.	  However,	  it	  is	  feasible	  that	  ApoE	  and	  other	  ligands	  such	  as	  Reelin	  contribute	  to	  the	  effects	  of	  PCSK9	  RNAi	  through	  ApoER2	  and	  other	  lipoprotein	   receptors.	   As	   a	   limitation	   of	   our	   study,	   the	   role	   of	   Reelin,	   ApoE	   and	   other	  lipoprotein	  receptors	  were	  not	  thoroughly	  assessed.	  Ideally,	  the	  results	  of	  this	  study	  should	  be	   replicated	   in	   transgenic	   animal	   models,	   preferably	   in	   mice	   or	   rats,	   since	   PCSK9	  knockdown	   in	   zebrafish	   results	   in	   the	   disorganization	   of	   the	   CNS	   and	   prenatal	   death	  (Poirier	  et	  al.,	  2006).	  	  	  This	   study	   also	   provides	   an	   interesting	   insight	   into	   the	   interactions	   between	   PCSK9	   and	  ApoER2,	  and	  suggests	  that	  modulation	  of	  ApoER2	  is	  the	  key	  event	  in	  rapid	  PCSK9-­‐mediated	  induction	  of	  developmental	  neuronal	  apoptosis	   in	  the	  developing	  cerebellum	  (Figure	  6.1).	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ApoER2	  is	  prominently	  expressed	  in	  neurons	  where	  it	  is	  associated	  with	  the	  JNK	  signaling	  pathway	   and	   functions	   as	   a	   selenoprotein	   receptor	   to	   ensure	   sufficient	   selenium	   intake	  essential	   for	   neuronal	   survival	   (Burk	   et	   al.,	   2007;	   Burk	   et	   al.,	   2014;	   Byrns	   et	   al.,	   2014;	  Kurokawa	   et	   al.,	   2014).	   Reelin	   signaling	   through	   ApoER2	   also	   promotes	   synaptic	  strengthening	   via	   LTP	   through	  Dab1-­‐dependent	  NMDA	   receptor	   upregulation	   (Hoe	   et	   al.,	  2006a;	  Sinagra	  et	  al.,	  2005).	  	  
	  
Figure	   6.1:	   Summarizing	   figure	   of	   the	   proposed	   effects	   of	   PCSK9	  RNAi	   on	   neuronal	   apoptosis	  
pathways	  in	  K5	  deprivation	  model	  of	  CGN.	  ApoER2	  has	  a	  dual	  role	  in	  inhibiting	  the	  JNK	  signaling	  
pathway	   and	   promoting	   the	   PI3K	   signaling	   pathway	   (Beffert	   et	   al.,	   2006b;	   Leeb	   et	   al.,	   2014).	  
Green	   and	   red	   lines	   indicate	   anti-­‐apoptotic	   and	   pro-­‐apoptotic	   functions,	   respectively.	   Blunt-­‐
headed	  lines	  indicate	  inhibition,	  whereas	  arrowheads	  indicate	  activation.	  	  
	  A	  recent	  study	  suggests	  an	  additional	  mechanism	  for	  PCSK9-­‐mediated	  apoptosis:	  Xu	  et	  al.	  reported	  a	  direct	  interaction	  between	  the	  cIAP1/TRAF2	  complex	  and	  PCSK9	  protein	  (Xu	  et	  al.,	   2012).	   Our	   own	   unpublished	   preliminary	   data	   also	   suggests	   that	   PCSK9	   can	   bind	  cIAP1/2	   in	   CGN.	   The	   cIAP1/TRAF2	   complex	   inhibits	   the	   TNFα-­‐signaling	   pathway	   and	  prevents	   apoptosis	   (Wang	   et	   al.,	   1998;	   Rothe	   et	   al.,	   1995).	   The	   IAP	   family	   proteins	   also	  directly	   inhibit	   caspase	   activation	   (Trapp	   et	   al.,	   2003;	   Deveraux	   and	   Reed,	   1999).	   These	  observations	  suggest	  that	  PCSK9	  may	  also	  promote	  apoptosis	  by	  sequestering	  intracellular	  cIAP1,	  directly	  affecting	  the	  available	  pool	  of	  cIAPs.	  However,	  it	  remains	  unknown	  how	  the	  mostly	   intravesicular	   and	   extracellular	   PCSK9	   would	   get	   access	   to	   the	   cytosolic	  TRAF2/cIAP	  complex.	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  The	   extent	   of	   PCSK9-­‐mediated	   regulation	   of	   lipoprotein	   receptors	   in	   the	   brain	   in	   vivo	  remains	   under	   debate	   (Trapp	   et	   al.,	   2003;	   Deveraux	   and	   Reed,	   1999).	   PCSK9	  polymorphisms	  in	  humans	  or	  animal	  models	  show	  no	  alterations	  in	  cognitive	  functions	  or	  brain	  development	  apart	   from	   the	   systemic	   cholesterol-­‐dependent	  effects	   (Chernogubova	  et	  al.,	  2012;	  Mbikay	  et	  al.,	  2013;	  Tran-­‐Dinh	  et	  al.,	  2014).	  The	  lack	  of	  detectable	  CNS	  effects	  of	  PCSK9	  may	  be	  due	  to	  the	  60-­‐fold	  lower	  (4-­‐8	  ng/ml)	  circulating	  levels	  of	  PCSK9	  in	  the	  CSF	  when	  compared	  to	  the	  plasma	  (Chen	  et	  al.,	  2014d).	  However,	  the	  deletion	  of	  a	  DNA	  region	  including	   a	   cluster	   of	   genes	   including	   ApoER2,	   PCSK9	   and	   Dab1,	   was	   shown	   to	   cause	  developmental	   CNS	   defects	   and	  mental	   retardation	   in	   a	   patient	   (Mulatinho	   et	   al.,	   2008).	  Whether	   these	   effects	   were	   purely	   dependent	   on	   the	   loss	   of	   Dab1	   and	   defective	   Reelin	  signaling,	   or	   if	   PCSK9	   contributed	   to	   the	   phenotype	   remains	   unknown	   (Mulatinho	   et	   al.,	  2008).	  	  	  Interestingly,	  the	  evidence	  from	  animal	  studies	  indicates	  that	  PCSK9	  can	  be	  upregulated	  in	  response	   to	   transient	   middle	   cerebral	   artery	   occlusion	   ischemia	   in	   the	   ipsilateral	   rat	  dentate	   gyrus	   after	   24	   hours,	   but	   not	   acutely	   after	   6	   hours	   or	   in	   the	   infarct	   core	   or	  penumbra	   (Rousselet	   et	   al.,	   2011).	  This	   could	   indicate	  a	  physiological	   role	  on	   lipoprotein	  receptor	   function,	   migration,	   and	   neurogenesis	   or	   as	   a	   stress	   response	   rather	   than	   as	   a	  mediator	  of	   apoptosis	   (Lan	  et	   al.,	   2010).	  Additionally,	  PCSK9	  knockdown	   increased	  LDLR	  levels	   in	   the	   brain.	   However,	   the	   effects	   on	   VLDLR	   and	   ApoER2	   were	   not	   reported	  (Rousselet	   et	   al.,	   2011).	   Potential	   effects	   of	   PCSK9	  modulation	   on	   ApoER2	   protein	   levels	  and	   selenoprotein	   homeostasis	   may	   have	   direct	   consequences	   on	   neuronal	   viability	   and	  fertility	  (Steinbrenner	  and	  Sies,	  2013;	  Krol	  et	  al.,	  2012).	  	  	  Phase	   III	  clinical	  studies	  on	  a	  number	  of	  PCSK9	  antibodies	  have	  recently	  been	  completed.	  The	  efficacy	  of	  PCSK9	  antibodies	   in	   reducing	  circulating	  LDL-­‐C	   levels	  has	  been	  promising	  and	   the	   reported	   side	   effects	  minimal	   (Norata	   et	   al.,	   2014;	   McKenney	   et	   al.,	   2012).	   This	  novel	   class	   of	   drugs	   has	   shown	   superior	   effects	   on	   cholesterol	   levels	   in	   comparison	   to	  statins	  in	  hypercholesterolemic	  patients.	  Existing	  preclinical	  evidence	  suggests	  that	  PCSK9	  modulation	   on	   indications	   such	   as	   atherosclerosis,	   cancer,	   ischemia	   and	   AD	   should	   be	  carefully	  explored.	  These	  unresolved	  questions	  are	  crucial	  for	   future	  research	  and	  clinical	  work,	   as	   PCSK9	   modulation	   will	   become	   a	   more	   common	   therapeutic	   option	   in	   the	  treatment	  of	  hypercholesterolemia.	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6.2	  Study	  II	  –	  Neurotoxic	  properties	  of	  berberine	  Berberine	  is	  suggested	  to	  have	  both	  neuroprotective	  and	  neurotoxic	  properties	  (Zhou	  et	  al.,	  2008;	   Shin	   et	   al.,	   2013).	   Our	   study	   describes	   in	   detail	   how	   micromolar	   berberine	  concentrations,	   used	   in	   many	   in	   vitro	   studies,	   cause	   acute	   NMDA	   receptor	   and	  mitochondria-­‐dependent	   toxicity	   in	   primary	   neuron	   cultures.	   Even	   nanomolar	   berberine	  concentrations	  in	  the	  physiological	  range	  attained	  in	  the	  plasma	  by	  oral	  dosing	  in	  animals	  and	   humans,	   exacerbated	   staurosporine-­‐,	   glutamate-­‐	   and	   rotenone-­‐induced	   cell	   death	   in	  CGN.	   The	   lack	   of	   berberine-­‐mediated	   effects	   on	   caspase-­‐3	   activity	   and	   caspase	   inhibitor	  insensitivity	   suggest	   that	   berberine	   does	   not	   modulate	   the	   caspase	   pathway	   in	   our	  neuronal	  model	  at	  the	  reported	  concentrations.	  Instead,	  an	  excitotoxic	  type	  of	  neuronal	  cell	  death	   is	   more	   likely	   due	   to	   the	   crucial	   involvement	   of	   NMDA	   receptors	   and	   acute	  mitochondrial	  dysfunction.	  The	  progression	  of	  mitochondrial	  damage	  suggests	  that	  NMDA	  receptor-­‐mediated	  excitotoxicity	  and	  Ca2+	  -­‐influx	  are	  the	  most	  probable	  of	  cause	  berberine-­‐mediated	  neuron-­‐specific	  cell	  death.	  	  	  Pharmacological	  studies	  on	  berberine	  suggest	  that	  it	  is	  efficiently	  cleared	  from	  the	  plasma	  in	  both	  animals	  and	  humans,	  but	  that	  berberine	  can	  also	  accumulate	  in	  organs	  such	  as	  the	  liver,	  lungs	  and	  the	  brain,	  shown	  to	  reach	  up	  to	  1.5	  µM	  concentration	  in	  the	  rat	  brain	  (Zeng	  and	  Zeng,	  1999;	  Liu	  et	  al.,	  2014b;	  Spinozzi	  et	  al.,	  2014;	  Wang	  et	  al.,	  2005a).	  The	  presence	  of	  the	   increase	   in	   a	   cleavage	   fragment	   of	   PARP1	   (PARP-­‐F2)	   suggests	   the	   involvement	   of	   an	  alternative	   protease,	   such	   as	   calpain,	   in	   berberine-­‐induced	   cell	   death	   (Figure	   5.3)	  (Chaitanya	  et	  al.,	  2010).	  	  	  This	   study	   suggests	   that	   both	   NMDA	   receptor	   and	  mitochondrial	   function	   are	   central	   to	  berberine-­‐induced	  neurotoxicity.	  In	  other	  studies,	  berberine	  efficacy	  is	  mainly	  attributed	  to	  its	   actions	  on	   the	  mitochondria	  and	   ion	  currents,	   especially	  potassium	  currents	   (Wang	  et	  al.,	  2004a).	  Interestingly,	  substituting	  the	  25	  mM	  potassium	  chloride	  (KCl)	  culture	  medium	  into	   5	   mM	   KCl	   culture	   medium	   increased	   the	   tolerance	   of	   CGN	   to	   3	   µM	   berberine.	   This	  could	  suggest	   that	   the	  25	  mM	  KCl	  depolarizing	  medium	  exacerbated	  berberine	   toxicity	   in	  this	  particular	  primary	  neuron	  model.	  Alternatively,	  berberine	  may	  exert	  a	  direct	  agonistic	  activity	   on	   NMDA	   receptors.	   This	   view,	   however,	   is	   not	   supported	   by	   the	   literature,	   as	  berberine	   has	   NMDA	   current	   inhibitory	   activity	   at	   a	   relatively	   high	   IC50	   of	   55.3	   µM	   in	  
Xenopus	  leavis	  oocytes	  (Yoo	  et	  al.,	  2006a).	  In	  the	  same	  study,	  berberine	  pretreatment	  also	  reduced	  the	  binding	  of	  radioactively	  labelled	  MK-­‐801,	  suggesting	  that	  berberine	  may	  affect	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MK-­‐801	   binding	   affinity.	   These	   data	   suggest	   that	   neurons	   are	   sensitive	   to	   berberine	  depending	  on	  the	  potassium	  content	  of	  the	  medium	  and	  additional	  cellular	  stressors,	  such	  as	   staurosporine.	   Berberine	   accumulates	   in	   energized	   mitochondria,	   likely	   due	   to	   the	  attraction	   of	   negatively	   charged	   mitochondrial	   lumen	   and	   positively	   charged	   berberine	  (Pereira	   et	   al.,	   2008).	  Within	   the	  mitochondria,	   berberine	   is	   known	   to	   specifically	   inhibit	  mitochondrial	  complex	  I	  at	  a	  target	  site	  downstream	  of	  rotenone	  (Pereira	  et	  al.,	  2008).	  Also,	  berberine	   interacts	   with	   the	   adenine	   nucleotide	   transporter,	   a	   component	   of	   the	  mitochondrial	  membrane	   transition	  pore,	   at	   a	   similar	   binding	   site	   as	   bongkrekic	   acid,	   an	  inhibitor	  of	  ANT,	  which	  potently	  protects	  from	  NMDA	  receptor-­‐induced	  neuronal	  apoptosis	  (Pereira	  et	  al.,	  2007).	  Although	  the	  current	  study	  did	  not	  assess	   the	  exact	  binding	  sites	  of	  berberine,	   it	   is	   feasible	   that	   both	   mitochondrial	   permeabilization	   and	   oxidative	  phosphorylation	  were	  affected	  as	  evidenced	  by	  mitochondrial	  swelling	  and	  the	  reduction	  in	  cellular	  ATP	  content	  (Johnson-­‐Cadwell	  et	  al.,	  2007;	  Nicholls	  et	  al.,	  2007).	  	  	  Evidence	   is	   growing	   in	   support	   for	   berberine	   as	   a	   multitarget	   drug	   candidate	   against	  metabolic	  disorders	  and	  NDDs,	  such	  as	  AD	  (Chang	  et	  al.,	  2014b;	  Durairajan	  et	  al.,	  2012).	  In	  AD	  animal	  models,	  the	  effects	  berberine	  on	  pathological	  hallmarks,	  such	  as	  amyloid	  plaques	  and	   NFTs,	   are	   encouraging	   (Durairajan	   et	   al.,	   2014;	   Ji	   and	   Shen,	   2011;	   Durairajan	   et	   al.,	  2012;	   Zhu	   and	   Qian,	   2006).	   However,	   the	   lack	   of	   proper	   cellular	   models	   and	   lack	   of	  consensus	  on	   relevant	  berberine	  concentrations	  hinder	   the	  understanding	  of	   the	  neuron-­‐specific	   properties	   of	   berberine.	   Some	   reports	   show	   that	   berberine	   pretreatment	   could	  precondition	   neurons	   against	   injury.	   However,	   application	   simultaneously	   with	   or	   after	  stressful	   stimuli	   can	   exacerbate	   the	   injury	   (Zhang	   et	   al.,	   2012a;	   Shin	   et	   al.,	   2013).	   This	  brings	   into	  question	  whether	  chronic	  berberine	   treatment	  of	  metabolic	  disorders	   such	  as	  dyslipidemia	  or	  T2DM	  can	  also	  provide	  a	  preventive	  or	  protective	  effect	  against	  ischemia	  or	  the	  development	  of	  AD	  pathogenesis;	  or	  whether	  berberine	  administration	  after	  the	  onset	  of	   AD	   or	   ischemic	   event	   will	   exacerbate	   or	   protect	   neurons	   from	   further	   injury.	  Additionally,	   the	   development	   of	   berberine-­‐related	   alkaloid	   pro-­‐drugs	   targeted	   at	  increasing	  bioavailability,	  reduce	  toxicity	  and	  provide	  an	  improved	  “magic	  bullet”,	  such	  as	  berberine	  prodrugs,	  to	  target	  these	  severe	  metabolic	  and	  CNS	  diseases.	  However,	  increased	  bioavailability	  may	   also	   results	   in	   accumulation	   in	   CNS,	  which	   raises	   further	   concerns	   of	  safety	  in	  chronic	  administration.	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6.3	  Study	  III	  –	  Differential	  regulation	  of	  neuronal	  lipoprotein	  receptors	  	  Environmental	   and	   metabolic	   factors,	   toxins	   and	   disease	   can	   induce	   neuronal	   stress	  through	   multiple	   pathways.	   Multifunctional	   lipoprotein	   receptors	   are	   associated	   with	  cellular	  metabolism	  and	  cell	  viability	  pathways.	  Our	  previous	  study	  showed	  that	  PCSK9	  is	  implicated	   in	   controlling	   neuronal	   viability	   (I)	   and	   that	   berberine,	   a	   potential	   PCSK9	  downregulator,	   induces	  neuronal	   stress	  and	  cell	  death	   (II).	   In	   this	   study,	  we	  showed	   that	  lipoprotein	  receptors	  LDLR,	  VLDLR,	  ApoER2,	  LRP1,	  LRP4,	  LRP5	  and	  LRP6	  and	  PCSK9	  are	  differentially	   regulated	   by	   subtoxic	   levels	   of	   berberine	   in	   CGN.	   After	   24	   hour	   berberine	  treatment,	   LDLR	   and	   PCSK9	   levels	   were	   decreased,	   ApoER2	   and	   LRP4	   levels	   remained	  unchanged	   and	   VLDLR,	   LRP1,	   LRP5	   and	   LRP6	   levels	   were	   increased.	   Most	   strikingly,	  berberine	   increased	   VLDLR	   expression	   after	   both	   6-­‐hour	   and	   24-­‐hour	   treatments,	  differently	  from	  the	  other	  observed	  genes.	  	  Interestingly,	  the	  specific	  upregulation	  of	  VLDLR	  mRNA	  and	  protein	  levels	  was	  prominent	  with	   various	   subtoxic	   stressors	   including	   berberine,	   CoCl2,	   rotenone	   and	   thapsigargin.	  VLDLR	  mRNA	   upregulation	   was	   not	   dependent	   on	   the	   level	   of	   oxidative	   stress,	   but	   was	  potentiated	   by	   cytosolic	   Ca2+	   increase	   induced	   by	   thapsigargin.	   Although	   ApoER2	   and	  VLDLR	  serve	  partly	  compensatory	  roles	  as	  components	  of	  the	  Reelin	  pathway,	  results	  from	  our	   previous	   study	   (I)	   suggest	   differential	   roles	   for	   ApoER2	   and	   VLDLR	   as	   regulators	   of	  neuronal	   apoptosis	   in	   CGN.	   Recently	   it	   was	   shown	   that	   BDNF	   also	   upregulates	   VLDLR	  expression	   in	   primary	   neurons,	   whereas	   Reelin	   post-­‐translationally	   functions	   as	   a	  downregulator	   of	   VLDLR	   protein	   levels	   (Do	   et	   al.,	   2013).	   Interestingly,	   VLDLR	   knockout	  causes	  AMD-­‐type	  retinal	  degeneration	  due	  to	  neoangiogenesis	   in	  animal	  models	  and	  AMD	  itself	   involves	   HIF-­‐1α	   activation	   that	   would	   predict	   VLDLR	   upregulation	   (Haines	   et	   al.,	  2006).	  Further	  studies	  on	  VLDLR	  upregulation	  in	  neurons	  in	  vivo	  are	  warranted.	  	  In	   our	   neuronal	   model,	   LDLR	   expression	   was	   downregulated	   by	   berberine	   treatment,	  whereas	  PCSK9	  levels	  showed	  a	  trend	  of	  decreased	  mRNA	  expression,	  in	  line	  with	  previous	  
in	   vitro	   findings	   (Cameron	   et	   al.,	   2008).	   Previous	   literature	   suggests	   that	   berberine	   can	  downregulate	  PCSK9	  levels	  and	  upregulate	  LDLR	  levels	  in	  HepG2	  cells,	  and	  potentially	  act	  synergistically	   with	   statins	   to	   prevent	   statin-­‐induced	   PCSK9	   upregulation	   (Dong	   et	   al.,	  2014;	  Pisciotta	  et	  al.,	  2012;	  Xiao	  et	  al.,	  2012).	  Berberine	  has	  been	  shown	  to	  downregulate	  SREBP-­‐1,	  β-­‐catenin	  and	  PPARγ,	  but	  upregulate	  SREBP-­‐2	  transcriptional	  pathways	  (Hu	  et	  al.,	  2010;	   Jia	  et	  al.,	  2014;	  Choi	  et	  al.,	  2006;	  Albring	  et	  al.,	  2013).	  As	  both	  PCSK9	  and	  LDLR	  are	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sterol-­‐sensitive	  and	  are	  transcriptionally	  controlled	  by	  SREBP,	  it	  is	  plausible	  that	  berberine	  downregulated	  LDLR	  and	  PCSK9	  expression	  in	  an	  SREBP-­‐dependent	  fashion	  in	  our	  model,	  potentially	  through	  increased	  lipid	  uptake	  via	  increased	  VLDLR	  and	  LRP1	  levels.	  However,	  whether	  similar	  effects	  would	  be	  seen	  in	  neurons	  in	  vivo	  remains	  to	  be	  seen.	  	  Berberine	  treatment	  also	  increased	  the	  protein	  levels	  of	  HIF-­‐1α	  and	  decreased	  the	  levels	  of	  
β-­‐catenin	   in	   CGN	   at	   the	   6	   hour	   treatments	   timepoint,	   an	   effect	   that	   was	   reversed	   at	   24	  hours	  (Yeh	  et	  al.,	  2011).	  This	  type	  of	  biphasic	  HIF-­‐1α	  -­‐mediated	  transcriptional	  regulation	  has	   been	   previously	   described	   in	   several	   cell	   types:	   hypoxic	   mesenchymal	   stem	   cells	  (Deutsch	  et	  al.,	  2011),	  nitric	  oxide-­‐exposed	  U2OS	  cells	  (Berchner-­‐Pfannschmidt	  et	  al.,	  2007)	  and	   in	  neurons	  under	   ischemic	   conditions	   (Yeh	  et	   al.,	   2011).	   Increased	   stabilization	  of	  β-­‐catenin	   at	   24	  hours	  was	   accompanied	  with	   increased	  GSK3β	   phosphorylation,	   suggesting	  that	  canonical	  Wnt	  signaling	  activity	  has	  been	  altered.	   Interestingly,	   the	  hypoxia	  pathway	  and	  HIF-­‐1α	   can	  be	  both	  up	  and	  downregulated	  by	  berberine,	  depending	  on	   cell	   type	  and	  treatment	  conditions	  (Lin	  et	  al.,	  2004;	  Zhang	  et	  al.,	  2012a).	  	  	  The	   dysregulation	   of	   HIF-­‐1α	   and	   Wnt	   signaling	   pathways	   is	   implicated	   in	   metabolic	  disorders	   and	   NDDs,	   such	   as	   diabetes	   and	   AD,	   respectively	   (Purro	   et	   al.,	   2014).	   In	   AD,	  decreased	  Wnt	  signaling	  in	  neurons	  is	  implicated	  in	  the	  upregulation	  of	  GSK3β	  activity	  and	  increased	   Tau	   phosphorylation	   and	  Aβ	   generation	   (Caricasole	   et	   al.,	   2004).	   Interestingly,	  chronic	  stress	  is	  also	  implicated	  in	  the	  development	  of	  dyslipidemias	  suggesting	  that	  stress-­‐induced	   VLDLR	   dysregulation	   may	   be	   associated	   with	   metabolic,	   neurological	   and	  psychiatric	   conditions	   (Devaki	   et	   al.,	   2013).	   VLDLR	   binds	   to	   LRP5/6	   and	   negatively	  regulates	  Wnt	  signaling	  (Chen	  et	  al.,	  2007).	  LRP5/6	  are	  paralogs	  acting	  as	  Wnt	  coreceptors	  with	  the	  Frizzled	  receptor	  in	  the	  canonical	  Wnt	  pathway.	  Our	  in	  vitro	  results	  suggest	  that	  an	  early	   (6	   h)	   and	   specific	   VLDL	   upregulation	   coincides	  with	   a	   transient	   downregulation	   of	  Wnt/β-­‐catenin	   signaling,	   which	   is	   later	   (24	   h)	   compensated	   by	   upregulation	   of	   LRP5/6.	  Whether	  this	  finding	  is	  recapitulated	  in	  vivo	  remains	  to	  be	  seen.	  	  Taken	  together,	  the	  results	  of	  our	  study	  indicate	  that	  lipoprotein	  receptors	  and	  PCSK9	  are	  differentially	   regulated	   by	   neuronal	   stress	   in	   neurons.	   Interestingly,	   berberine	   had	   a	  reciprocal	   and	   biphasic	   effects	   on	   neuronal	   HIF-­‐1α	   and	   β-­‐catenin	   levels,	   potentially	  modulating	  a	  number	  of	  physiological	  and	  pathophysiological	  functions	  in	  neurons.	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7	  Conclusions	  and	  Future	  Prospects	  The	   studies	   presented	   in	   this	   Thesis	   provide	   important	   novel	   insight	   into	   the	   role	   and	  function	   of	   PCSK9	   and	   berberine	   as	   modulators	   of	   lipoprotein	   receptor	   function	   and	  neuronal	  cell	  viability.	  PCSK9,	  lipoprotein	  receptors	  and	  neuronal	  cell	  death	  play	  a	  central	  role	   in	   metabolic	   disorders	   as	   well	   as	   neurodegenerative	   diseases,	   such	   as	   Alzheimer’s	  disease.	   Currently,	   there	   are	   several	   ongoing	   clinical	   trials	   on	  both	  PCSK9	  and	  berberine,	  further	   highlighting	   the	   importance	   of	   understanding	   the	   extent	   of	   potential	   side	   effects	  associated	  with	  PCKS9	  modulation	  and	  berberine	  use.	  	  Studies	  I	  and	  III	  provide	  evidence	  that	  the	   lipoprotein	  receptors	  ApoER2	  and	  VLDLR	  hold	  differential	   roles	   in	   controlling	   neuronal	   viability.	   ApoER2	  modulates	   caspase-­‐dependent	  neuronal	  apoptosis	  (I),	  whereas	  VLDLR	  is	  upregulated	  upon	  neuronal	  stress	  (III).	  	  Study	   I	   describes	   the	   role	   of	   PCSK9	   in	   various	   models	   of	   neuronal	   apoptosis.	  Downregulation	   of	   endogenous	   PCSK9	   in	   primary	   neurons	   inhibited	   the	   activation	   of	  apoptosis-­‐mediators	   c-­‐Jun	   and	   caspase-­‐3	   and	   increased	   neuronal	   viability	   in	   an	  ApoER2-­‐dependent	  manner.	  	  Studies	  II	  and	  III	  describe	  the	  effects	  of	  berberine	  on	  neuronal	  viability	  and	  the	  expression	  of	  PCSK9	  and	  lipoprotein	  receptors	  in	  neurons.	  Berberine	  sensitizes	  neurons	  to	  glutamate	  and	  rotenone-­‐mediated	   injury	   in	  a	  NMDA	  receptor-­‐	  and	  mitochondria-­‐dependent	  manner	  (II).	  Subtoxic	  berberine	  concentrations	  cause	  a	  biphasic	  and	  opposite	  response	  on	  HIF-­‐1α	  and	  β-­‐catenin	  stabilization,	  which	  was	  associated	  with	  VLDLR	  upregulation	  (III).	  	  Novel	   treatments	   against	   aging-­‐related	   neurodegenerative	   diseases	   and	   metabolic	  disorders	   are	   sorely	   needed.	   Both	   PCSK9	   inhibitors	   and	   multifunctional	   nutraceuticals,	  such	  as	  berberine,	  are	  expected	  to	  increase	  in	  popularity	  as	  treatment	  options	  for	  metabolic	  diseases.	  However,	   the	  potential	  effects	  of	  PCSK9	  modulation	  and	  berberine	  treatment	  on	  neuronal	  function	  are	  currently	  poorly	  understood.	  This	  Thesis	  presents	  novel	  data	  on	  the	  effects	  of	  PCSK9	  inhibition	  and	  berberine	  on	  lipoprotein	  receptors	  and	  neuronal	  cell	  death,	  warranting	   further	   animal	   and	   human	   studies	   elucidating	   their	   effects	   on	   the	   nervous	  system.	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